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Abstract 
 
The management of patients with epithelial ovarian cancer (EOC) faces two major 
challenges which standard treatments fail to effectively address:  1) Diffuse metastasis as 
a consequence of late stage diagnosis and 2) intra-tumoral heterogeneity, which fuels tumor 
evolution and drives the acquisition of chemotherapeutic resistance.  In this thesis, we 
tested new therapeutic strategies using a 3-dimensional in vitro spheroid culture model that 
mimics key steps of epithelial ovarian cancer metastasis; and another model that mimics 
both temporal and cellular heterogeneity by establishing multiple cell lines from a single 
patient over the course of disease progression.  Using these models, we investigated the 
therapeutic efficacy of three oncolytic viruses for treatment of ovarian cancer: Myxoma 
virus (MYXV), a modified Vaccinia virus (vvDD), and Maraba virus (MRBV).  We 
determined that all three viruses were capable of inducing some level of oncolysis, but that 
spheroid formation limited the replication efficiency of poxviruses (MYXV and vvDD), 
which heavily rely on cell proliferation.  However, upon spheroid reattachment, poxvirus 
oncolysis was restored and prevented cell dispersion.  MRBV was least affected by 
spheroid formation, although there was a capacity for some cell lines to develop resistance 
to MRBV upon spheroid formation.  We discovered MRBV uses the low-density 
lipoprotein receptor (LDLR) to gain entry to host cells and that entry into spheroids was 
affected by dynamic changes in LDLR expression.  However, we observed that this was 
only a partial mediator of MRBV tropism.  In our in vitro assays of tumor heterogeneity, 
we observed temporal changes that directly impact MRBV oncolysis and we identified two 
major groups of subclones in our patient derived cell lines: one that was highly susceptible 
to MRBV, and another set which exhibited 1000-fold reduced susceptibility to MRBV-
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mediated oncolysis.  Differential susceptibility to MRBV virus oncolysis did not strictly 
depend on LDLR expression.  Furthermore, co-culture of virus-sensitive and virus-resistant 
cells conferred sensitization of virus-resistant cells to MRBV oncolysis.  We therefore 
sought other mechanisms which could impact MRBV tropism and found that oncolysis 
could be significantly increased through the induction of TGFβ signaling and epithelial-to-
mesenchymal transition, commonly activated pathways found during ovarian cancer 
metastasis.  Taken together, these findings not only define the differential therapeutic 
efficacies between oncolytic viruses for metastatic EOC, but also identify key trophic 
factors which impact MRBV oncolysis that can be exploited to enhance MRBV-mediated 
oncolysis for EOC in future therapeutic strategies. 
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CHAPTER 1: General Introduction 
1.1 Clinical presentation, frequency, and treatment of epithelial ovarian cancer   
Epithelial ovarian cancer (EOC) represents the 8th most commonly diagnosed 
cancer among women in Canada and ranks 7th globally [1, 2].  Approximately 2,800 
Canadian women (1 in 71 women) and 239,000 women worldwide will be diagnosed every 
year with EOC , which represents ~3.6% of all cancers diagnosed in females [1, 2].  Despite 
this relatively low rate of diagnosis, EOC represents the most lethal gynaecologic 
malignancy in industrialized countries, with approximately 1,750 deaths in Canada yearly 
or 1 in every 91 women [1].  This is largely due to its advanced stage presentation and 
limited therapeutic advances, despite extensive efforts over decades to identify more 
effective alternatives to conventional treatment regimens [3, 4].  
 EOC survival rates progressively decline with advanced staging of the disease.  
When the disease remains confined to the ovary, survival rates are particularly favorable 
with approximately 91% of women surviving beyond 5 years post diagnosis.  However, 
the majority of women are not diagnosed until widespread intraperitoneal metastasis has 
occurred and survival rates are dramatically reduced to 27% [3, 5].  Hence, there has been 
a tremendous effort to develop early detection methods for the diagnosis of EOC.  This is 
exceptionally difficult as the physical symptoms indicative of ovarian cancer are subtle and 
often overlap with more common disorders including dyspepsia, irritable bowel syndrome, 
menstruation, and menopause [6]. These symptoms include abdominal or pelvic pain, 
increased abdominal size or bloating, and feeling full or difficulty eating.  Although not 
one of these symptoms alone is sufficient, a combination of symptoms present are more 
effective for diagnosing EOC [6].  Symptom score systems have been developed to aid in 
the identification of specific individuals at risk of ovarian cancer based on the presentation 
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of single or combinations of symptoms, however the validation of such systems has not 
been effectively performed and the integration of other risk factors including menstrual or 
family history have not been incorporated into their design [6].  In general, although 
combinations of symptoms have higher sensitivity than individual symptoms, their 
specificity is still inadequate as an effective screening tool for diagnosis.  Based on the 
current systems criteria, in a population of 10,000 women, 3 out of 5 cancers may be 
detected, but 500 tests would result in false positives. This can result in patient anxiety, as 
well as unnecessary procedures such as ultrasound of the ovaries, and possibly a surgical 
biopsy. Thus, the positive predictive value would be only 3 of 503 or 0.6% [6]. Therefore, 
there is currently inadequate evidence to recommend the implementation of symptom 
scoring systems for general use.   
A subpopulation of EOC results from inherited mutations, most commonly in 
BRCA1 or 2.  Approximately 5-15% of ovarian cancers are associated with the inheritance 
of BRCA1 or 2 germline mutations.  Therefore, genetic screening can be useful to identify 
those at risk [7].  However, BRCA1 or 2 mutations have roughly only a 10-44% penetrance 
rate for ovarian cancer and the age at which the cancer occurs can be widely variable [8, 
9].  In short, the utility of predictive genetic testing can be limited and positive 
identification of BRCA1 or 2 mutations does not lead to straightforward measures that 
reduce risk.  This in combination with poorly defined symptomology make detection of 
early stage ovarian cancer very difficult.    
Since early detection is relatively uncommon, the treatment of ovarian cancer 
typically involves management of late stage advanced metastatic disease.  Standard 
treatment heavily relies on surgical intervention and optimal de-bulking of metastatic 
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tumors.  Optimal cyto-reduction is typically defined by the removal of tumors greater than 
1 cm in diameter with no or few amounts of residual disease apparent after surgery [10-
12].  This often requires radical resection procedures to remove metastatic lesions including 
intestinal resection, diaphragm stripping or resection, splenectomy and liver resection.  
However, complete cyto-reduction of disseminated tumors is possible in only 25% of cases 
[12, 13].  Therefore, a combination of surgery and platinum based chemotherapy 
(carboplatin and paclitaxel) is almost universally applied, although controversy remains 
over the timing of surgical and chemotherapeutic intervention.  Neoadjuvant 
chemotherapy, in which chemotherapy is applied prior to cyto-reductive surgery, is 
considered more favorable when patients present with comorbidities or with a priori non-
debulkable tumors.  Studies which have compared neoadjuvant chemotherapy vs. primary 
cyto-redutive surgery (surgery prior to chemotherapy) demonstrate decreased surgical 
morbidity and mortality with decreased estimated blood loss, shorter surgical times, less 
intensive-care-unit admissions, fewer bowel resections, and reduced overall lengths of stay 
with neoadjuvant treatment regimens.  Likewise, neoadjuvant therapy has been associated 
with a greater ability to achieve complete resection or optimal debulking and improved 
toxicity [14-19].  Likewise, it has been suggested that patients who initially present with 
large volumes of disease may fare better with neoadjuvant therapy [19]. However, many 
challenge this view by suggesting that although surgical morbidities may be decreased, 
both progression free survival and overall survival in neoadjuvant treatment groups are 
much poorer compared to primary cyto-reductive surgery [20-22].  Moreover, Chi et al. 
argue that patients undergoing primary de-bulking surgery fare much better than the 
neoadjuvant group and that the outcomes documented for neoadjuvant therapy in many of 
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the studies more closely resemble those of patients with large amounts of residual disease 
after debulking [23].  Thus, there is an ongoing debate between the application of 
neoadjuvant and primary cytoreductive surgery which remains unresolved [4]. 
1.2 Origin and pathogenesis of epithelial ovarian cancer 
There has been difficulty in identifying the origins of ovarian cancer from 
traditional epidemiological and pathologic observations due to the fact that these 
approaches assumed that EOC was one disease.  With greater advancement in the 
molecular techniques used to characterize cancer cells, it is now understood that EOC is a 
general term for a larger subset of tumors which may or may not manifest in the ovary and 
are varied in their clinical manifestation and behavior [24, 25].  Traditionally EOC is 
divided into two types based on cell phenotype and underlying genetic traits: type I (low-
grade) and type II (high-grade)[26].  These two larger groups can be further subdivided 
into a number of histologic subtypes: serous, mucinous, endometrioid, clear cell, 
transitional cell, or any combination of these (mixed) [27].  Type I tumors include low- 
grade serous, low-grade endometrioid, clear cell and mucinous carcinomas.  These tumors 
are typically slow growing or indolent and usually present at a lower stage [28].  Type II 
tumors however can present as high-grade serous, high-grade endometrioid and 
undifferentiated histologies and differ from that of Type I tumors in both their morphology, 
(type II typically exhibit papillary, glandular, and solid patterns) as well as their behavior 
[29].  Type II tumors are much more aggressive and typically diagnosed at an advanced 
stage and are unfortunately far more common, as they account for over 75% of ovarian 
carcinoma [24].  Perhaps the most distinguishing difference between the two types of 
ovarian cancer exist at the genetic level [30, 31].  The prototypical type II histotype, high-
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grade serous, which alone accounts for 70% of all ovarian cancers, almost always exhibits 
TP53 mutations, and in fact has the highest rate of TP53 mutations compared to all other 
solid tumors [32].  Type I tumors rarely have mutations in TP53, but do exhibit mutations 
in KRAS, BRAF, or ERBB2 in over two-thirds of low-grade cancers [33-38].  Due to their 
mutation profiles, high grade tumors display much higher degrees of genomic instability 
and cellular heterogeneity than low grade tumors which are typically more genomically 
stable [35, 39].   
There is much debate regarding the cell of origin from which EOC is derived.   To 
best understand the basis of these arguments, comprehension of the embryonic 
development of the reproductive system is required.  The ovary is derived from multiple 
embryonic structures, including the coelomic epithelium, the subcoelomic mesoderm, and 
the primordial germ cells from the yolk sac endoderm.  The rest of the female genital tract, 
including the fallopian tubes, uterus, cervix, and upper vagina, are derived from the 
Müllerian ducts [40].  However, the ovary itself does not contain epithelial cells.  Instead, 
a thin layer of ovarian surface epithelium (OSE) derived from the coelomic epithelium 
covers both the ovarian surface and the serosa of the fallopian tubes, uterus, and the 
peritoneal cavity [41].  Thus, it is difficult to know the origins of the epithelial nature of 
EOC when no truly differentiated epithelium actually exists in the ovary.  In fact, on 
pathological assessment of these tumors, many appear to be derived from the Müllerian 
ducts [42].  For example, serous tumors resemble the cells found in the fallopian tube 
epithelium and endometrioid tumors resemble the cells of the endometrium both of which 
are Müllerian in nature [42]. Thus, the debate over the origins of EOC exists as two major 
theories: 1) the original cancer cell arises from the ovarian surface epithelium (OSE) and 
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that metaplastic changes lead to the development of the cell types observed in the different 
EOC histotypes; and 2) tumors with a Müllerian phenotype (serous, endometrioid and clear 
cell) are derived from Müllerian-type tissue not the OSE (or mesothelium).   
Perhaps the strongest evidence that supports the cell of origin belonging to the OSE 
is the distinct association between number of ovulations and risk of EOC.  This relationship 
was first demonstrated in hens that were raised to produce excessive numbers of eggs 
without breaks in ovulation.  High rates of ovarian adenocarcinomas were documented in 
these hens due to incessant ovulation [43].  It was hypothesized that the OSE cells became 
damaged during ovulation and internalized into the ovary to form cortical inclusion cysts, 
which undergo metaplasia to become differentiated Müllerian-like epithelium and 
ultimately lead to ovarian carcinoma [44].  A similar correlation between number of 
ovulations and ovarian cancer has been observed in women [45].  Particularly, women who 
have decreased ovulatory cycles due to pregnancy, breast-feeding, or oral contraceptive 
use have a significantly reduced lifetime risk of developing ovarian cancer by almost 50% 
[46-48].  However, it must also be noted that this epidemiological evidence to support 
ovulations and risk of EOC is not entirely correlative.   Women with polycystic ovarian 
syndrome, characterized by infrequent ovulatory cycles, are at increased risk for EOC [49].  
Moreover, formulations of oral contraceptives which do not reduce the number of 
ovulations also have observed protective effects [50].  Although there are many theories 
about how the OSE can undergo metaplasia and dysplasia, perhaps the most difficult aspect 
of this theory to accept is that the identification of a true precursor lesion for EOC has not 
been found in the ovary [51, 52].   
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Due to the complex and heterogeneous nature of EOC, it is likely that not one single 
location or etiology can be used to explain all types of EOC.  The majority of mucinous 
tumors display intestinal differentiation or could be of appendiceal or other gastrointestinal 
origin [53].  Transitional cell tumors appear to be derived from urothelium of the urinary 
tract [53].  Endometriosis has also been more definitively linked to both endometrioid and 
clear cell EOCs [54].  For high-grade serous ovarian cancer, it is becoming more widely 
believed to originate from the fallopian tube.  Studies conducted of tubal segments derived 
from women with BRCA mutations or family history of EOC undergoing prophylactic 
bilateral salpingo-oopherectomy (removal of both fallopian tubes and ovaries) showed 
evidence of dysplasia or hyperplastic lesions histologically resembling high-grade serous 
ovarian cancer (HGSOC) at a frequency of 1–5% at the time of the surgery [55-58].  The 
majority of these malignancies were located in the distal fimbriated end of the fallopian 
tube.  It was hypothesized that these tubal epithelial cells then spill onto the surface of the 
ovary and therefore create the appearance of ovarian origin [59].  These regions of 
dysplasia within the fallopian tube have since been named “serous tubal intra-epithelial 
carcinoma” (STIC) and in most cases, these areas demonstrated high levels of p53 
accumulation, even in benign lesions which are now believed to be an even earlier 
precursor lesion than STICs [60].  The examination of fallopian tubes from advanced-stage 
HGSOC showed that 75% had evidence of STIC lesions.  Moreover, in a subset of these 
cases, the exact same TP53 mutation can be observed in both the fallopian tube and the 
cancer tissue, further supporting the site of origin and clonality of the STIC and the tumors 
[61].   
1.3 Genome instability, heterogeneity, and disease recurrence in EOC 
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The pathophysiology of EOC is diverse and can manifest as multiple histotypes with 
varied disease origins and differential behaviors and clinical outcomes.  Thus, it is clear 
that EOC is not a single disease, but a category of malignancies with a very heterogeneous 
nature.  Not only are the clinical manifestations of the disease diverse, EOC is highly 
heterogeneous, both spatially and temporally.  In high-grade EOCs, the overwhelming rate 
of TP53 mutations (>95%) bears a significant contribution to intratumoral heterogeneity 
observed (Fig. 1.1).   
 Genomic instability of EOC- the contribution of TP53 and BRCA1/2 
In HGSOC, mutations in prototypical oncogenes are relatively uncommon [62].  
However, mutations in TP53 and BRCA1 and 2 are the primary contributors of a significant 
level of genome structure variation and render HGSOC highly genomically unstable [63]. 
The tumor suppressor encoded by TP53, p53, has a central role in maintaining genome 
stability within normal cells.  Under stress-free conditions, p53 is monoubiquitinated 
predominantly through the RING-finger ubiquitin ligase, MDM2 and rapidly degraded [64, 
65]. In the event of genotoxic stress, p53 becomes stabilized through phosphorylation by 
many different kinases, the most commonly described being ATM [66].  Additionally, 
acetylation further promotes conformational changes in p53 structure to augment DNA 
binding capacity and induces the transcriptional upregulation of a number of genes 
involved in DNA damage repair, cell cycle arrest, and apoptosis [67-70].   
In normal cells, functioning p53 prevents the accumulation of DNA damage and 
mutation [71].  A loss of functioning p53, either through mutation or deletion, may result 
in the loss of G2/M checkpoint arrest, translocations, amplifications, and aneuploidy 
leading to genomic instability [69, 71-73].  Genomic instability is defined as a high  
9 
 
  
Intratumoral 
subclones 
 
Intratumoral 
Cell (spatial) 
heterogeneity 
Evolution during  
disease progression 
 
Interpatient 
variability 
 
1 
2 
3 
Figure 1.1 EOC tumor heterogeneity- 1) Genome instability drives intracellular 
heterogeneity within a tumor.  Each subpopulation of cells are characterized by their 
own set of mutations and aberrant signaling pathways.  Each subclonal population may 
respond differently to treatment. 2) Changes in the tumor over time due to changes in 
both tumor microenvironment, perhaps as a consequence of therapy, puts selective 
pressure on EOC tumors.  The fittest subclones are selected in a Darwinian fashion to 
repopulate tumors causing changes in behavior of tumors over the course of disease. 3) 
Differences in histotype and genetic mutations between patients create different degrees 
of genomic instability, affect degrees of spatial heterogeneity, and the rate of temporal 
changes, resulting in differences between patient responses to therapy. 
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frequency of DNA alterations within the genome resulting in mutations, chromosomal 
rearrangements or aneuploidy [74].  The majority of TP53 mutations in HGSOC are single 
nucleotide substitutions in the DNA binding domain of the protein resulting in hyper-
stabilization of the protein but inactivation of WT functions [75-79].  Approximately 92% 
of TP53 mutations in HGSOC render the protein non-functional [79].   
The consequence of such mutations and the loss of genomic stability is the development 
of a large number of small regions of copy number gain and loss, which often encompass 
genes that are involved in ovarian tumor progression, such as the small deletions found 
within the retinoblastoma 1, RB1, locus [73].  However, certain p53 mutations result not 
only in the loss of WT tumor suppressor functions, but in some instances can promote a 
gain of function change which results in p53 acting as an oncogene  (via a mechanism 
completely independent of its WT functions) [80].  Genome instability caused by mutations 
in p53 can promote further alterations in genes that contribute to invasion and metastasis 
by activating metastasis associated signaling pathways such as TGFβ and EGFR[81, 82].  
It is possible that up to 20% of TP53 mutations in EOC tumors may be oncogenic [80].  
Other mutations associated with EOC, such as BRCA1 and 2, which occur in approximately 
10% of EOC, further contribute to the high degree of genomic instability observed as both 
BRCA1 and 2 share vital roles in repairing DNA damage [7].  The prevalence of BRCA1 
and 2 mutations is 1/400 to 1/800 in the general population, which varies depending on 
ethnic background, and puts individuals at increased risk for both breast and ovarian cancer 
(and may be associated with prostate cancer) [83-85].  The penetrance rate for these 
heritable mutations in either of these two genes is between 6-65% for ovarian cancer, 
depending on the specific mutation [86].  Over 90% of ovarian cancer patients with a 
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BRCA1 mutation develop HGSOC, as opposed to 70% in EOC patients that do not have 
the mutation [87, 88].  Loss of functional BRCA1 and 2 result in defects in homologous 
recombination repair (HRR), a process involved in repairing double stranded breaks in the 
genome that occur during cellular replication [89].  It has been reported that in up to half 
of ovarian tumors HRR is defective through mutations or even methylation of BRCA1 or 
2 and other putative DNA repair genes, including ATM, RAD50, RAD51C, RAD51D and 
PALB2 [62, 90-93].  Thus, mutations in either BRCA1 or 2 result in further accumulation 
of DNA damage and genome instability within cells.  Furthermore, there is a significant 
amount of evidence to suggest that both p53 and BRCA1 physically interact in response to 
DNA damage and repair [94-99].  In fact, germline mutations in BRCA1 are often 
associated with the causal mutations in TP53 that lead to the accumulation of non-
functional P53 and may mark an important step in the malignant transformation of EOC 
cells [100].   
 Tumor heterogeneity in EOC 
Genetic diversity or heterogeneity within a tumor is the result of an accumulation of 
DNA damage and genomic instability accompanied by an escape from apoptosis in 
individual tumor cells.  These genetic differences result in a high degree of phenotypic 
variability between cells, some of which may be functionally significant and promote 
tumor development, while others represent random genetic mutations with little or no 
biological consequence.  These cell populations may be differentially affected and selected 
for by the tumor microenvironment.  Through this selection process, tumors evolve 
temporally in response to changes in the tumor microenvironment via the Darwinian 
process of natural selection [101].  Therefore, greater genomic instability promotes 
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increased intratumoral cellular heterogeneity, or spatial heterogeneity, resulting in greater 
fitness and survivability of a tumor.  Genetic studies using both microsatellite and single-
nucleotide polymorphism analysis in EOC have identified extensive intratumoral 
heterogeneity [102].  Phylogenetic investigation of the heterogeneous cell populations 
within different regions of EOC tumors shows that the origin of each clonal population is 
derived from a common ancestor, with subsequent evolutionary divergence to create 
genetically distinct cell populations within a tumor [102].  Similar phylogenetic screens of 
EOC metastases also show lineage tracing back to the primary tumor.  These data support 
a model in which EOC cells have a common clonal origin, but become polyclonal with 
both metastatic and primary tumours developing new clones, distinct from one another 
[103].  The extent of this clonal expansion between patients can vary significantly with a 
greater degree of clonal expansion correlating with poorer survival [104].  This is 
particularly true in the context of chemotherapeutic resistance.  Given the substantial 
degree of intratumoral heterogeneity, both intercellularly and temporally, that exists in 
EOC and that the rate of clonal expansion varies throughout the course of disease, not only 
is it likely that no two tumours within a patient are identical, but no two cancers between 
individuals are alike either.  This is a significant problem in designing effective treatment 
regimens in which a single therapy can be applied unilaterally across the patient spectrum. 
 The development of chemotherapeutic resistant EOC 
The majority of patients who undergo chemotherapy will almost inevitably develop 
chemotherapeutic resistance and succumb to recurrent disease.  The time between initial 
diagnosis and the development of resistance to platinum based chemotherapy is typically 
3 years [105, 106].  Recurrence with platinum resistant disease is almost always incurable 
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and death is eventual within 5 years after initial diagnosis [107, 108].  It is during this time 
between disease diagnosis and relapse that clonal expansion is most significant [104].  
Cancers with the greatest degree of genomic instability possess the greatest genetic 
diversity and this heightens the possibility of the emergence of drug resistant clones.  
Phylogenetic studies of patients with recurrent disease document the outgrowth and 
enrichment of cells with a mutation in NF1 after treatment, which has been associated with 
the development of chemotherapeutic resistance [109].  Histologic samples of matched 
fallopian tube and ovary tissue acquired prior to the start of treatment showed the same 
mutation in 1.2% of the primary invasive carcinoma of the fallopian tube and in 7.9% of 
the tumor biopsy, meaning that the resistant disease arose from the clonal expansion of a 
minor subclone that was present prior to treatment [104].  A larger cohort study of similarly 
matched primary tumour and recurrent disease samples demonstrated that only 6% of 
inactivating mutations in NF1 could be seen in primary samples, but the same inactivating 
NF1 mutations were observed in 20% of recurrent disease [109].  This is common example 
of temporal heterogeneity in EOC that is driven by high levels of genome instability and 
selective pressures from the tumour microenvironment.  Interestingly, this selective 
pressure can be so strikingly robust that BRCA2 reversion mutations can be observed post 
chemotherapy in BRCA2 mutated patients to yield functioning BRCA2 capable of repairing 
double stranded DNA breaks induced by treatment [110, 111].  Re-acquisition of BRCA2 
function decreases the effectiveness of chemotherapy and is a strong predictor of platinum 
resistant EOC [110, 111].  A deep sequencing study of primary tumour and metastases 
samples isolated during an autopsy of a patient with a BRCA2 germline mutation showcases 
this reversion phenomenon.  At the time of death, the patient no longer responded to 
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olaparib or carboplatin treatment after the recurrence of her disease.  Upon sequencing of 
the different tumor metastases, 12 different reversion events in BRCA2 could be 
documented contributing to her resistance to both treatments [109].  In the limited studies 
conducted on this phenomenon, reversion in mutated BRCA 1 or 2 occurs in 6% - 46% of 
patients with germline mutations [109, 110]. 
1.4 Biology of ovarian cancer metastasis 
The majority of ovarian cancer patients do not die from primary disease, and instead 
ultimately succumb to metastatic spread of tumors throughout the body. However, unlike 
many other cancers which disseminate to distal sites in the body via the circulatory system 
(which requires intravasation, migration, extravasation and invasion), EOC metastasis is 
not typically blood borne.  Rather, EOC cells detach from the primary tumour as either 
single cells or clusters and are passively carried by peritoneal fluid to seed secondary sites 
throughout the peritoneal cavity [112, 113].  Typical sites for metastases include the 
omentum (a large fold of fatty peritoneal tissue descending from the stomach connecting 
it to other organs), the bladder, large bowel, and colon [113].  Staging of ovarian cancer is 
directly related to the degree of dissemination of metastases through the peritoneum.  Stage 
I refers to cancers being restricted to one or both ovaries.  Stage II refers to cancer that has 
spread from the ovaries to the pelvis, including the uterus and fallopian tubes.  In stage III 
EOC, the cancer has spread from the ovaries microscopically (less than 2cm) to the 
abdominal area outside the pelvis or to pelvic lymph nodes.  Whereas in stage IV, tumors 
have spread to distal organs [114].  Approximately 85% of EOC patients are not diagnosed 
until stage III or IV [115].  It is therefore very important from a treatment standpoint to 
15 
 
understand the biological changes in both EOC cells and the tumor microenvironment that 
facilitate the migration of EOC tumors to distal sites (Fig. 1.2). 
 Exfoliation of EOC cells from the primary tumor and epithelial to mesenchymal 
transition 
One of the initial events triggering the exfoliation of EOC cells from the primary 
tumor into the peritoneum is an epithelial-to-mesenchymal transition (EMT) [116-118].  
During this process, cells lose their epithelial characteristics, including the loss of cell-cell 
junctions and apical-basal polarity, and acquire mesenchymal features, characterized by 
stress fiber formation and actin reorganization causing a spindle-shaped morphology [119].  
This process decreases cellular connection to the basement membrane and interaction with 
neighboring cells, which eases detachment from the primary tumor [120].  A loss of E-
cadherin (a glycoprotein present at adherens junctions between cells) is considered 
fundamental to the EMT process [121].  E-cadherin is a transmembrane protein with both 
an extracellular and cytoplasmic region.  Its cytoplasmic domain forms a complex with β-
catenin and αE-catenin, which together binds to actin cytoskeleton [122].  Its extracellular 
domain binds with other proteins related to cell-cell adhesion, including other cadherins 
and nectins, which thereby connect the cytoskeletons of neighbouring cells and facilitate 
the formation of different cell-cell junctions (including tight junctions, adherens junctions, 
and desmosomes) [123, 124].  Thus, the loss of E-cadherin has a significant role in the 
acquisition of a motile phenotype in cancer cells and helps facilitate metastasis.  In ovarian 
cancer, the absence of E-cadherin is associated with greater invasiveness and is a predictor 
of poor patient survival [125, 126]. 
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Figure 1.2. Mechanism of EOC metastasis – Malignant cells slough from the primary 
tumor due to decreased cell- cell adhesion.  While in suspension in the abdominal fluid/ 
ascites, EOC cells adhere to each other and undergo epithelial-to-mesenchymal 
transition to become spheroids.  Spheroids decrease cellular pathways associated with 
proliferation to conserve energy consumption and undergo dormancy to survive low-
nutrient conditions.  Autophagy is induced to promote survival by consuming 
unnecessary proteins and recycling amino acids for the synthesis of proteins necessary 
for survival during cell stress and starvation.  Spheroids are able to reattach and disperse 
to form secondary tumor metastases within the abdominal cavity via mesenchymal-to-
epithelial transition.  Omental metastases are common due to high levels of energy rich 
lipids which promote EOC cell survival.   
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The loss of E-cadherin can be triggered by the activation of a number of 
transcriptional repressors which suppress the transcription of E-cadherin’s encoding gene, 
CDH1 [127].  This may be initiated by different signaling events occurring in the tumor 
microenvironment or tumor-associated stroma.  Transforming growth factor β (TGFβ) has 
been shown to have dual functions in human cancers, acting as both a tumor suppressor 
and a promoter of metastasis [128, 129].  In normal cells and in early carcinogenesis, TGFβ 
acts as a growth inhibitor, inducer of apoptosis, and inhibitor of cell immortalization [130].  
In ovarian and other cancers, TGFβ is an important modulator of EMT.  TGFβ signaling is 
initiated when the ligand binds to a receptor complex that possess serine/threonine kinase 
activity.  TGFβ binds to the TGFβ type II receptor (TβRII), followed by the recruitment of 
the TGFβ type I receptor which is trans-phosphorylated by TβRII [131].  Activation of the 
TGFβ type I receptor is the main component of the TGFβ receptor complex and controls 
downstream signaling of various pathways, including the SMAD dependent pathway from 
which many EMT-mediated effects are driven (including the loss of E-cadherin) [128].  
Two receptor regulated SMADs (SMAD 2 and 3) are phosphorylated by the TGFβ type I 
receptor, causing their disassociation from the receptor complex and their interaction with 
SMAD4 in the cytoplasm [128, 132].  This SMAD complex then translocates into the 
nucleus where it associates with a number of DNA binding partners and acts as a 
transcriptional regulator of TGFβ target genes, including SNAIL, SLUG, and ZEB2 which 
act as a transcriptional repressors of CDH1 [127].  Furthermore, SNAIL repression of E-
cadherin expression allows for the dissociation of desmosomes and the dissolution of cell 
junction complexes [125, 133].   
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TGFβ induction of EMT is further exemplified by the loss of other epithelial 
markers including ZO-1, occludins, claudins, cytokeratins and the induction of more 
mesenchymal markers, including N-cadherin, vimentin, and fibronectin [134].  The 
transformed cells, which look more like fibroblasts upon undergoing EMT, acquire a more 
invasive phenotype [120].  The reorganization of the actin cytoskeleton leads to the 
formation of actin stress fibers, which are anchored to focal adhesion complexes and aid in 
the formation of filipodia which promotes cell migration [120].  After the cells have 
detached from the primary tumor as single cells or clusters, they spread to the peritoneum 
and are carried by the physiological movement of the peritoneal fluid [113].   
 Transit of ovarian cancer cells throughout the peritoneum 
A consequence of advanced metastasis is the formation of an exudative fluid within 
the peritoneum called ascites. This fluid accumulates and aids in the passive transit of 
ovarian cancer cells to distal sites within the abdomen [135].  More than one-third of 
patients present with ascites at the time of diagnosis and almost all have ascites with 
recurrent disease [136].  Clinically, the presentation and progression of ascites is correlated 
with poor survival [136, 137].  The presence of ascites strongly impacts the quality of life 
of patients as it causes debilitating symptoms such as abdominal swelling and pain, early 
satiety, and compromised gastrointestinal, urinary, and respiratory systems [138].  Under 
normal physiological conditions, capillary membranes of the peritoneum continuously 
produce lubricating fluid to cover serosal surfaces which allows the easy passage of solutes 
between the peritoneum and adjacent organs.  Two-thirds of this fluid is reabsorbed by the 
lymphatic channels of the diaphragm and is directed to the subclavian vein to allow 
drainage [139].  In advanced metastasis, these lymphatic channels often become obstructed 
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with tumor cells and heightened fluid production is induced by tumor cells due to the 
increased leakiness of tumor vasculature from angiogenesis [139-141].  Thus, there is an 
accumulation of abdominal fluid due to defects in drainage and increased fluid production.       
As single cells floating in suspension in the peritoneal fluid, EOC cells become 
susceptible to a process of cell death called anoikis.  Anoikis acts as a protective mechanism 
induced when epithelial cells detach from the extracellular matrix and helps prevent ectopic 
cell growth [142].  As a mechanism to avoid death due to detachment or as a consequence 
of clustered detachment from the primary tumor, EOC cells in suspension will form 
multicellular aggregates called spheroids [143].  It is believed that spheroids may survive 
anoikis through the upregulation of the anti-apoptotic protein Bcl-xL [144].  EMT plays an 
important role in the efficiency of spheroid formation by EOC cells.  Blocking SMAD 
dependent TGFβ signaling and EMT particularly through the Snail transcription factor, 
profoundly inhibits the ability of EOC cells to form spheroids and reduces their metastatic 
potential [145].   
Spheroids undergo a number of biological changes in their behavior to help 
promote EOC cell survival while in suspension.  As another mechanism of avoiding death 
due to starvation within the low-nutrient conditions of the ascites, spheroids have been 
shown to undergo a period of dormancy to support nutrient conservation. This occurs due 
to the downregulation of signaling pathways associated with metabolism and cell 
proliferation, such as the AKT pathway [146, 147].  Furthermore, spheroids can undergo 
autophagy, a cellular process initiated under periods of stress in which vesicles engulf 
cytoplasmic organelles and fuse with lysosomes to promote hydrolysis, thus utilizing 
intracellular proteins and lipids to temporarily sustain energy production [148, 149].  If 
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prolonged, autophagy of cells is lethal.  However acute induction of autophagy can not 
only promote survival in low nutrient conditions, but also permit cancer cell survival in 
response to cytotoxic drugs [150, 151].  For example, the mechanisms of action for 
platinum based chemotherapies is to target key components of the cell cycle and induce 
apoptosis in proliferating cell populations [152].  Thus, targeting dormant EOC cells in 
spheroids is considerably more challenging [148].  Furthermore, the expression of Bcl-xL 
in spheroids, which allows EOC cells to escape anoikis, contributes to their resistance to 
chemotherapy induced apoptosis [144].  Some studies suggest EOC spheroids are enriched 
for cells with stem-like properties marked by their gene expression profiles of Notch1, 
Nanog, Cdcp1, CD34, and Myc, which are upregulated by 10-2000 fold and have increased 
ALDH activity [153].  This may also contribute to chemotherapeutic resistance, increased 
invasion abilities, and resistance to hypoxic conditions.   
 Spheroid reattachment and secondary metastasis 
Although EOC spheroids are capable of reattaching throughout the peritoneum onto 
any mesothelial lined site, the location for reattachment is not entirely random.  The most 
common sites for distant metastases are the omentum, diaphragm, and small bowel [113].  
The first steps of invasion require an interaction between the EOC cells and the 
mesothelium.  Integrins exhibit a key functional role in this process.  β1-integrins on EOC 
cells can heterodimerize with a number of α-integrin subunits found on the mesothelium 
to promote adhesion [143, 154].  Similarly, blocking vascular cell adhesion molecule 1 
(VCAM-1) on mesothelial cells or α4β1-integrins on EOC cells can restrict adhesion and 
prevent metastasis in xenograft models [155].  The interaction of integrins between the 
mesothelium and EOC cells is aided by an upregulation of matrix metalloproteinase 2 
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(MMP-2), which cleaves the extracellular matrix proteins vitronectin and fibronectin into 
smaller pieces on the mesothelial cells.  Thus, binding to these smaller integrins on the 
mesothelium is enhanced [156, 157].  The CD44 cancer stem cell marker has also been 
shown to aid in adhesion to the peritoneal mesothelium, which could support the model 
that spheroids enriched for stem cells have enhanced metastatic abilities. This may be a 
possible mechanism for the observed selection of more highly aggressive cancer cells in 
secondary tumors [158].   
Interestingly, since EMT has been shown to be important in spheroid formation and 
migration, mesenchymal-to-epithelial transition (MET) has been demonstrated as a key 
morphological modification that promotes EOC spheroid invasion and adhesion [116, 
145].  Transcriptional changes in reattaching spheroids parallel those of cells undergoing 
MET [116, 145].  Likewise, metastasis and the dispersion of cells from reattaching 
spheroids was decreased when MET was restricted [145].   
After EOC spheroids attach to a secondary site and invade, effective growth of 
these newly seeded tumors must be supported by the transformation or modification of the 
secondary site.  For example, after reattachment and dispersion of EOC spheroids, EOC 
cells promote the production of vascular endothelial growth factors (VEGF) in both an 
autocrine and paracrine fashion to develop new vasculature to support their growth [159].  
High levels of VEGF within the ascites and in serum are associated with EOC tumor 
progression and poor prognosis [160].  Therefore, the microenvironment of disseminated 
tumors plays a significant role in the success of secondary tumor growth.  Implantation of 
EOC spheroid metastases to the omentum is enhanced through TGFβ production by EOC 
cells, which transforms normal fibroblasts in the omentum into cancer associated 
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fibroblasts (CAFs) that contribute to EOC adhesion and invasion [161].  The preferential 
cultivation of the omentum is supported by a microenvironment rich in adipocytes, which 
aid in homing, invasion, and growth of EOC cells [162].  Inhibition of the IL-8 receptor 
using a neutralizing antibody markedly reduced the amount of omental metastases in an in 
vivo mouse model of EOC metastasis, emphasizing the importance of IL-8 secretion by 
adipocytes to increase omental homing of EOC cells [162].  Furthermore, because 
adipocytes store triglycerides, the omentum provides energy-dense lipids to EOC cells to 
promote their growth.  Indeed, omental metastases display an increase in the expression of 
FABP4, which binds long chain fatty acids on adipocytes.  Inhibition of FABP4 in an in 
vitro co-culture of EOC cells with adipocytes strongly reduced lipid accumulation in cancer 
cells and invasion were dramatically reduced [162].  Likewise, in vivo metastasis models 
in FABP4 -/- mice showed significant reductions in tumor burden paralleled by a reduction 
in microvessel density and tumor cell proliferation [162].  These results further support the 
notion that adipocytes act as major mediators of ovarian cancer metastasis to the omentum 
as they fuel rapid tumor growth through fatty acid metabolism.   
1.5 Oncolytic virotherapy for the treatment of cancer 
The use of viruses as therapeutic agents against cancer has distinct advantages over 
current chemotherapeutic strategies and other conventional small molecule drugs.  The 
biological dysregulation often observed in cancer cells can provide a favorable 
environment for virus replication.  Viruses are often dependent on cell cycling of host cells 
to produce progeny.  Thus, uncontrolled cellular replication and resistance to apoptosis in 
cancer cells provides a suitable niche for virus amplification.  Moreover, the tumor 
microenvironment of many cancers is highly immunosuppressive, and is associated with 
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decreased immune surveillance from lymphocytes due to downregulation of antigen 
presentation and decreased immunostimulatory cytokine production.  These same features 
provide a concomitant loss in host cell defenses to pathogens, thereby making them more 
susceptible to viral infection.  Furthermore, virus efficacy can be augmented, either through 
genetic modifications that allow better targeting of cancer cells, or through combinations 
with specific adjuvants [163, 164].   
Before the concept of using viruses for cancer therapy, there had been a slow trickle of 
reports of cancer regression coinciding with virus infection [165-167].  The first clinical 
use of a virus for cancer treatment was in the early 20th century when rabies virus was used 
to vaccinate a woman with cervical cancer [168].  However, the dangers in using native 
wild-type (WT) viruses limited their use in a clinical setting.  With modern advances in 
genetic modification techniques, engineered viruses have been designed with cancer 
selective tropism and restricted replication, thus spawning a resurgence in the popularity 
of viral oncolytics over the past 20 years.  The following sections review both advances in 
basic research and the clinical application of viruses for the treatment of cancer and 
specifically EOC.    
 Basics of virology 
A virus is an obligate intracellular parasite with a genome consisting of either DNA 
or RNA that may be single stranded (ss) with either positive  or negative sense (+/ -) or it 
may be double stranded (ds) [169].   Virus genomes contain genes required for the infection 
and replication of a virus in a host cell.  The production of viral proteins promote the 
synthesis of viral components, assembly, maturation and packaging of virus particles or 
virions.  Viruses are acellular genetic parasites that hijack cellular machinery (eg. 
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polymerases, ribosomes) to provide the resources required for their own replication. The 
appropriation of host cell systems in the replication of viruses varies depending on the viral 
genome content, size, and proteins packaged with the virus [169].  A minimal virus consists 
of a virus genome and a proteinaceous coat called the capsid [170].  Virus infection begins 
with entry into a host cell.  This involves virus attachment to the cell, penetration into the 
cytoplasm, and uncoating of the virus to release its genome into the cell [171].  Enveloped 
viruses typically mediate attachment through the expression of virus glycoproteins that 
bind to cell surface receptors, whereas non-enveloped viruses may rely on a single protein 
or multiprotein structure to attach [170, 172].  Typically, non-enveloped viruses enter the 
cytoplasm through the endocytic pathway or disruption of cell membrane integrity [171, 
173, 174].  Enveloped viruses enter either through membrane fusion or through endocytic 
vesicles followed by the fusion of the virus envelope with the vesicle membrane, which 
can mediate the release of the capsid and genome into the cell [171, 172].  For other viruses, 
penetration sometimes triggers a change in the microenvironment, such as acidification of 
the endocytic compartment, to allow the uncoating of the virus which releases its genome 
and capsid into cytoplasm [171, 175].  The specific details in location of virus uncoating 
and the process varies depending on the virus.  Most DNA viruses are transported to the 
nucleus through a nuclear pore to allow transcription of virus genomes using cell 
replication machinery, such as RNA polymerase II [176].  For this reason, viruses are often 
dependent on the host cell cycle.  The mechanism for production of viral mRNA, 
translocation, and translation vary but for dsDNA viruses, it occurs in a similar fashion as 
in the host cell using host cell machinery [177].  ssDNA viruses may use cellular enzymes 
to generate dsDNA before proceeding.  For some RNA viruses (+ssRNA), their genome 
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can act as mRNA and interact directly with ribosomes to be translated with the subsequent 
polyprotein being cleaved to produce individual viral proteins.  -ssRNA or dsRNA require 
packaging of a viral polymerase to transcribe viral mRNA [177].  Due to their small 
genome sizes, viruses often maximize their coding potential by including overlapping 
genes and can be alternatively spliced to permit more than one protein to be produced from 
a single genome region [171]. 
 After the production of viral proteins, virus assembly usually occurs in the cellular 
compartment where genome replication takes place.  Virus components include the virus 
genome, any accessory proteins, capsid/structural proteins, and envelope proteins (if it is 
an enveloped virus).  Typically, assembly centers on capsid and structural proteins forming 
a scaffold for the virus genome to enter [178].  Viral glycoproteins may incorporate into 
cell membranes for viruses to acquire upon egress [179].  The specific mechanisms for 
viral protein packaging and assembly differ for each virus but generally rely on intricate 
localization signals and chance [180].  The release of non-enveloped viruses typically 
occurs during lysis of infected cells [181].  For enveloped viruses, budding occurs through 
a cell membrane after virus assembly leading to the acquisition of the envelope [182].  This 
may be the plasma membrane in which case this budding releases the mature infectious 
virus and may or may not induce lysis, or it may be a membrane acquired from an 
intracellular organelle membrane [183].  If it is the latter, the nascent virion is then 
transported in a vesicle to the plasma membrane for release by fusion of the vesicle to the 
plasma membrane [183]. 
 Inherent oncolytic virus selectivity for cancer cells 
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Cancer cells acquire a number of generally observed adaptations during the process 
of becoming malignant.  As reviewed above, this includes uncontrolled entry into S-phase, 
loss of functional apoptotic pathways, mutations in tumor suppressors including p53, 
suppression of tumor targeting cell-mediated immune surveillance, and decreased 
production of immunostimulatory effectors molecules [184].  These same features of 
cancer cells which may make them resistant to many conventional chemotherapeutics or 
small molecule inhibitors are in fact favorable characteristics for viral infection and 
production.  Viruses often require cycling host cells to replicate and benefit from immune 
evasion strategies to avoid systemic clearance [164].  Most if not all of these characteristics 
are capable of being modulated by viral proteins in order to replicate effectively in a host 
cell.  However, many viruses do not encode additional genes that modulate these systems 
and instead will preferentially infect host cells which possess such features; this endows 
them with inherent cancer cell selectivity.   
A list of naturally “cancer-specific” viruses includes reovirus, vesicular stomatitis 
virus (VSV), Newcastle disease virus, and parvovirus [164].  As these viruses do not 
encode genes which alter the host cell’s response to virus, they rely on the inherent defects 
in anti-viral immunity through tumor-specific inactivation of protein kinase R (PKR) and 
interferon (IFN) response pathways [185].  PKR is a highly conserved cytoplasmic RNA 
virus sensor which signals through the eIF2-α protein to terminate the translation of viral 
transcripts.  Furthermore its activation stimulates the production of a family of antiviral 
cytokines, IFNs, which trigger a cascade of antiviral responses within the cell and in 
neighboring cells to shut down replication or induce apoptosis to prevent virus spreading.  
In cancers with inactivating RAS mutations, PKR signaling is typically impaired, allowing 
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productive replication of reovirus, VSV, and Newcastle disease virus [185-189].  Impaired 
IFN signaling, either through inactivating mutations or epigenetic silencing, is found in a 
diverse range of cancers at both early and late stages of disease, meaning it is likely an 
early mechanism of immune dysfunction that persists through tumor progression and 
metastasis [190].  This defect renders cancer cells significantly more vulnerable to virus 
infection and can help oncolytic viruses selectively replicate in cancer cells, while 
safeguarding normal cells with intact IFN-signalling from virus infection.  This selective 
feature permits cancer specific oncolysis by a number of viruses including, Myxoma virus 
(MYXV) [191].   
Aside from direct infection and oncolysis of tumor cells, viruses have been 
strategically applied to target other aspects of tumor growth.  A secondary feature of some 
oncolytic viruses not only involves direct oncolysis of tumor cells but also targeting and 
inducing lysis of the tumor vasculature, thereby restricting nutrient supply to growing 
tumors.  This could be due to direct infection of tumor endothelial cells and the expression 
of viral proteins with antiangiogenic properties, although the mechanism is still unclear 
[192]. 
 Many malignancies also demonstrate an overexpression of virus receptors 
compared to normal cells, which increases permissiveness to virus infection.  For example, 
many melanoma tumors upregulate both I-CAM and DAF which are used by 
coxsackievirus to mediate virus infection of host cells [193, 194].  Furthermore, echovirus 
demonstrates specificity for ovarian cancer cells with upregulated expression of α2β1 
integrin, while poliovirus requires the overexpression of CD55 [195, 196].  Despite 
abundant expression of these receptors on normal cells, coxsackievirus, echovirus, and 
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poliovirus are likely limited in their ability to infect non-cancerous cells via additional 
factors, such as a functional IFN response.  
 Interestingly, some viruses also display anti-tumoral effects independent from 
direct infection and cell killing.  For instance, although the parvovirus NS1 protein can 
induce apoptosis of transformed cells, it also exhibits oncosuppressive behavior by 
preventing further transformation and tumorigenesis [197, 198].  Infection of BALB/c mice 
with parvovirus prior to engraftment with syngeneic sarcoma cells led to graft rejection 
despite the fact these sarcoma cells are resistant to parvovirus infection [199].  Similarly, 
replication defective cytomegalovirus was able to prevent tumor growth and metastasis in 
mice despite the absence of a productive virus infection [200].  The mechanisms by which 
these viruses are able to induce an anti-tumoral effect is most likely modulated by increased 
immune surveillance caused by virus infection acting as an adjuvant to stimulate anti-tumor 
immunity (Fig. 1.3).   
 Engineered viruses that improve tumor targeting and oncolytic efficacy 
Many virus genes necessary for replication in normal tissues are redundant (not 
necessary) for replication in cancer cells (due to the inherent changes in cancer cells, 
described in previous sections).  Therefore much effort has been placed into creating virus 
deletion mutants defective in these replication genes (essential for replication in normal 
cells) to improve their tumor cell selectivity.  Thymidine kinases (TKs; TK-1 and TK-2) 
are highly conserved enzymes which catalyze the phosphorylation of deoxythymidine into 
deoxythymidine monophosphate, a precursor to deoxythymidine triphosphate, which is 
incorporated into replicating DNA. [201].  TKs are therefore important for cell division, 
and in non-malignant cells, are expressed only during the cell cycle [202].  Thus, many 
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viruses encode their own TKs to provide nucleotides to promote the replication of their 
own genomes, even when the cells are not dividing and cellular TKs are not expressed.  
The creation of TK deletion mutants in various oncolytic viruses, including herpes simplex 
virus (HSV) and vaccinia virus (VACV), aids in restricting virus replication to cycling cells 
that have expression of cellular TK and have high phosphorylated deoxynucleotide pools 
for the virus to usurp [203, 204].  Furthermore, the overexpression of TK can be observed 
in many malignancies including bladder, breast, and colorectal cancers leading to 
significantly higher expression of TK compared to normal cycling cells.  This provides 
more favorable conditions for virus replication and subsequent oncolysis [205-207].   
The introduction of non-viral genes in an oncolytic virus is another strategy to help 
improve virus efficacy.  Typically, the addition of non-viral DNA (when not for improving 
tumor cell specificity) is done either to increase bystander cytotoxicity of the virus to 
neighboring tumor cells, enhance anti-tumor immunity, introduce pro-drug converting 
enzymes, or include safeguarding suicide genes that restrict uncontrolled virus infection 
and killing.  Perhaps the most common and rapidly expanding field in oncolytics research 
is the activation of the immune system to stimulate anti-tumor immunity and improve 
bystander cytotoxicity after virus infection.  A commonly introduced gene designed to 
stimulate enhanced anti-tumor immunity is CD40L, the ligand which binds to the CD40 
receptor found on many monocytes, dendritic cells, and B lymphocytes.  Viruses which 
have been engineered to express this ligand include adenovirus and VACV [208, 209].  
Oncolysis of tumor cells by these viruses induces a massive release in tumor associated 
antigens and provides co-stimulatory danger signals.  Moreover, arming oncolytics with 
CD40L further aids in inducing direct apoptosis of tumor cells and triggers a cascade of  
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Figure 1.3. Preferential viral replication in cancer cells- viral infection and 
replication in healthy tissues is normally restricted by highly conserved antiviral 
signaling through IFN.  Many tumor cells decrease IFN and other antiviral signaling 
molecules to help in immune evasion rendering them more susceptible to virus 
infection.  Selection of viruses with natural tropism for cancer associated signaling 
pathways and mutations, or engineering viruses to have improved cancer selective 
properties promotes virus replication that is more restricted to cancer cells.  Productive 
virus infection results in cell killing, virus release, and spread to neighboring cancer 
cells.  
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immunostimulatory signaling events to reduce the immunosuppressive environment of a 
tumor.  In vivo xenograft models of endometrial cancer using CD40L armed adenovirus 
showed increased potency over WT adenovirus infection via three mechanisms: 1) 
Increased recruitment and activation of antigen presenting cells (APCs) leading to the 
production of T-cell associated cytokines which stimulated robust cytotoxic T cell 
responses against tumors, 2) direct apoptosis of CD40L tumor cells by CD40 expressing 
cells caused by infection with CD40L expressing adenovirus; and 3) Direct oncolysis from 
adenovirus infection [208].  Thus, viruses can also be applied as a way to counteract tumor 
mediated immune evasion and immune suppression.   
 Clinical trials with oncolytic viruses 
The first engineered virus to enter clinical trials in humans was a strain of 
adenovirus with two deletion mutations called, ONYX-015 or Adenovirus dl1520.  This 
strain of adenovirus was engineered as a hybrid of adenovirus serotypes 2/5 and expressed 
mutations in the E1B-55K and E3B genome regions, thus rendering it only able to replicate 
in cancer cells with p53 mutations [210].  Over 10 clinical trials have been performed using 
the virus, leading all the way up to phase III which demonstrated that the virus was 
generally well-tolerated with patients experiencing flu like symptoms [211, 212].  
Importantly, the virus was shown to be tumor selective, but replication was fairly transient 
and typically lasted less than 10 days.  Moreover, replication was highly variable and was 
affected by tumor histology with a 0-14% tumor regression rate [211].  However, the 
clinical findings were important indicators of the strengths of oncolytics and of the hurdles 
that needed to be overcome.  A broad range of adenoviral serotype 5 vectors have been 
assessed clinically with no serious toxicity. However, strong antibody mediated 
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neutralization of the virus has repeatedly been observed with intravenous injections [213, 
214].  A majority of patients have pre-existing antibodies to adenovirus serotype 5 thus 
limiting its clinical utility [213, 215].   
Newer strategies with engineered viruses almost always contain an 
immunostimulatory component to augment the antitumor response.  The most clinically 
advanced construct of herpes simplex virus, OncoVexGM-CSF contains deletions in both the 
γ-34.5 gene, which renders the virus susceptible to PKR and eIF2α antiviral responses and 
also results in neuroattenuation, and ICP47 which re-enables MHC I presentation in host 
cells [216-221].  Furthermore, OncoVexGM-CSF also contains Granulocyte-macrophage 
colony-stimulating factor (GM-CSF), a glycoprotein secreted by macrophages, T cells, 
mast cells, and NK cells, and functions as a cytokine to stimulate stem cell differentiation 
into granulocytes and monocytes for greater immunogenicity [217].  Phase II studies with 
OncoVexGM-CSF in stage IIIc and IV melanoma showed that it was well tolerated with only 
transient flu like symptoms.   Importantly, 26% of the 50 patients enrolled showed either 
complete response (n=8) or partial response (n=5) [222].  OncoVexGM-CSF was rapidly 
inactivated in the blood as many people have pre-existing immunity to many strains of 
herpes viruses and this likely contributed to the relatively low success rate.  However, of 
patients who responded, regression of both intratumorally injected and distal lesions was 
observed and maintained for 7- 31 months with an additional 10 patients who exhibited 
stable disease for 3 months [222].  Overall, survival after 1 year was 58% and 51% after 
two years thus stimulating the progression of OncoVex GM-CSF to ongoing phase III trials 
with melanoma and squamous cell carcinoma of the head and neck [223].  
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 Improvements in vector delivery and design have propelled further advancement of 
oncolytics through clinical trials.  An oncolytic pox virus, JX-594, designed using a TK 
deletion mutant of vaccinia virus and armed with GM-CSF has demonstrated significant 
therapeutic utility in phase I-II dose escalation trials of hepatocellular carcinoma patients.  
Infection with this virus resulted in virus replication and successful expression of GM-CSF 
in tumors, which induced tumor necrosis, devascularisation, systemic dissemination of the 
virus and targeting of distant tumors [224].  Importantly, these studies also demonstrated 
an ability to treat patients with JX-594 despite having high neutralizing antibody titers.  
Phase I-II dose escalating trial in patients with advanced liver cancer showed significant 
improvement in overall survival of patients correlating with high doses of JX-594 [225].  
In this dose group, 35% of patients had a long-term survival benefit of greater than 2 years 
after 4 weeks of dosing suggesting a durable therapeutic benefit.  The mechanisms of action 
for these antitumor effects were direct oncolysis of tumor, acute vascular disruption, and 
immune stimulation through antibody generation and increased tumor-infiltrating 
lymphocytes [225].  Thus phase III clinical trials with JX-594 began in late 2015 and are 
ongoing with hepatocellular carcinoma patients actively being enrolled [226].    
The advent of oncolytic virotherapy as a new and viable therapeutic option for a 
breadth of malignancies has sparked tremendous enthusiasm among not only researchers 
but patients as well.  In 2005, China approved an oncolytic adenovirus called H101 for the 
treatment of head and neck cancers [227].  This brought with it a wave of medical tourism 
to the country after claims it could shrink tumors but never went so far as to say it could 
improve overall survival.  Late in 2015, the Food and Drug Administration approved its 
first oncolytic virus for use in the United States called, TVEC, an oncolytic herpes simplex 
34 
 
virus highly similar to OncoVexGM-CSF with an additional insertion of the US11 gene, 
encoding a tegument protein.  This alteration increases the efficiency of virus replication 
[228].  Phase III trials demonstrated clinical effectiveness through a significant reduction 
in tumor size and an increase in overall survival by 4.4 months although the result fell just 
short of being statistically significant [229].  However, therapeutic efficacy and survival 
may be improved with combinations with other cancer immunotherapies.  More than likely, 
these represent just two of many oncolytic viruses that are making their way down the 
pipeline for clinical approval. 
 Clinical trials of oncolytic viruses in ovarian cancer 
Adenovirus 
Due to the almost universal presence of TP53 mutations in HGSOC, it is logical to 
investigate the therapeutic efficacy of oncolytic viruses which selectively replicate in tumor 
cells harboring this mutation.  Among the first clinical trials in EOC patients using an 
oncolytic virus was a phase I clinical trial using the adenovirus construct ONYX-015, 
which was designed to preferentially replicate in p53-deficient tumor cells.  Repeated 
intraperitoneal injections of virus were delivered in 16 patients ranging from 1x109pfu-
1x1011pfu.  Although the treatment appeared safe (symptoms were generally mild, and a 
maximum tolerated dose was not reached), no clear therapeutic benefit was observed 
despite successful virus replication.  This may be due to the presence of neutralizing 
antibodies in 46% patients prior to the start of treatment, which increased significantly over 
the treatment, potentially limiting viral replication.  Moreover, 6/7 of the remaining patients 
without prior existence of neutralizing antibodies developed them over the course of 
treatment [230].  It is also possible that the minimal therapeutic benefit observed could be 
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due to variable expression of the coxsackie adenovirus receptor required by adenovirus to 
bind and enter cells.  To improve delivery and uptake of adenovirus to target EOC cells, 
other strains of adenovirus have been engineered with modified viral capsid proteins, 
including an integrin binding motif to target other overexpressed integrin receptors on EOC 
[231].  In a phase I clinical trial with the capsid protein modified adenovirus, Ad5-Δ24-
RGD, stable disease was observed in 15/21 patients.  However, no partial or complete 
responses were noted [232].   
Although little therapeutic efficacy was demonstrated in reducing tumor size or 
improving overall survival, other adenoviruses have demonstrated an ability to improve 
quality of life.  The clinically approved adenovirus construct, H101, which too is restricted 
to replicating in TP53-mutated cells, was shown in a phase I clinical trial to reduce ascites 
burden in EOC patients.  Outcomes were grouped as either complete response (no 
recurrence of ascites), partial response (recurrence of ascites <50% of volume), or no 
response (recurrence of ascites > 50%, requiring paracentesis).  Of 9 patients treated over 
a 30 day trial, 3 patients had complete responses, 2 had partial responses, and 4 had no 
response with no adverse effects.  The interval between paracenteses before and after H101 
treatment went from a mean of 12.4+/-3.4 days to 39.9 +/- 11.6 days thus demonstrating 
H101’s potential in improving patient quality of life [233].  
Measles virus 
Rather than engineering viruses to have increased tumor cell selectivity, other 
clinical trials have focussed on viruses with innate tropism for tumor associated proteins.  
Measles virus requires expression of CD46 cell surface receptor to bind and enter target 
cells and this is highly overexpressed in many carcinomas, including EOC [234, 235].  To 
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examine virus replication in real time, a measles virus strain with an engineered carcino-
embryonic antigen (MV-CEA) was generated such that CEA levels could be used as a 
surrogate for virus replication.  Intraperitoneal injection of MV-CEA was performed in 6 
cycles over 4 weeks at 7 different doses in 21 patients with platinum resistant ovarian 
cancer.  Although 13 of 15 tumors which were immunohistologically positive for CD46 
showed overexpression of the receptor, the best objective response was disease 
stabilization in 14/21 patients with effects lasting from 54-277 days.  Although no 
statistically significant assessments could be made on the effects on overall survival, the 
median survival rate was 12 months (ranging between 1.3- 38.4 months) and is relatively 
favorable compared to historic averages of 6 months in this patient population.  With no 
dose limiting toxicities or treatment-induced immunosuppression, no increase in anti-CEA 
antibodies, no increase in anti-MV antibody titers, or virus shedding in urine or saliva, 
these findings are promising for the continued development of measles virus as an 
oncolytic for EOC [236]. 
Additional phase I studies have been conducted with other strains of measles that 
were modified to facilitate in vivo imaging of virus infection and replication. In particular, 
a specific measles virus strain has been altered to express a sodium-iodide importer (MV-
NIS).  Unlike MV-CEA, which was engineered to allow for assessment of viral replication 
using CEA protein levels as a surrogate marker, the MV-NIS strain permits the 
visualization of virus replication in tissues in vivo.  In a similar treatment regimen as 
described for MV-CEA, 16 patients with platinum and taxol resistant EOC were treated for 
4 weeks with 6 cycles of high dose virus treatment (1x108-1x109 vpu).  Median survival 
was 26.5 months, and 2/3 patients treated with 1x108 vpu and 11/13 patients treated with 
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1x109 vpu exhibited stable disease. This was in agreement with patients from the previous 
MV-CEA trial treated with the same doses, and improvement in overall survival correlated 
with higher dosing of both MV-CEA and MV-NIS.  NIS uptake was observed for 3/13 
patients treated with the higher dose of MV-NIS and the intratumoral expression of NIS 
correlated with longer progression free survival.   
Interestingly, although no measles virus specific antibodies were developed over 
the course of treatment, tumor specific T cell activation and IFNγ production was induced 
to two EOC antigens, FRα and IGBP2, and continued even after treatment stopped.  Thus, 
not only is measles potentially a highly effective oncolytic for EOC based on its direct 
targeting and oncolysis of tumor cells, it may also possess immunotherapeutic advantages 
to augment virus oncolysis.  Thus phase II trials comparing MV-NIS intraperitoneal 
administration to chemotherapy in patients with recurrent EOC and low disease burden 
have been designed and other phase I/II trials which test MV-NIS infected mesenchymal 
cell carrier delivery systems are being assessed [237, 238].     
Reovirus 
One of the earliest oncolytics to be used to treat ovarian cancer in clinical trials was 
reovirus serotype 3 also knowns as, Reolysin.  This relatively small and quickly replicating 
virus preferentially infects cells with activated RAS.  There are two ongoing clinical trials 
with Reolysin in EOC.  A randomized phase II clinical study with Reolysin in combination 
with paclitaxel vs paclitaxel alone in patients with recurrent EOC, fallopian tube, or 
primary peritoneal cancers.  Although the study is ongoing, it is no longer recruiting 
patients and results have not been published [239].  The second clinical trial with Reolysin 
is a phase I/II trial in patients with metastatic ovarian, peritoneal, or fallopian tube cancers 
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using intravenous and intraperitoneal injection [240].  As of 2010, viral replication in 
peritoneal and ovarian cancer cells could be observed after IV injection and is the first 
observation of reovirus to penetrate and replicate within the peritoneum and ascites [241].  
However, official conclusions from the study have not been published.  Recently the FDA 
gave orphan drug designation to Reolysin for the treatment of ovarian cancer [242]  
Vaccinia Virus 
The phase I clinical trial with JX-594 previously described in Section 1.5.3 included 
2 patients with recurrent ovarian cancer.  One of the two patients received a low dose of 
JX-594 and did not have observable virus present in tumors but did exhibit stable disease 
for more than 4 weeks after treatment. The other patient received the second-highest dose 
and had replicating virus present in her tumors and exhibited stable disease for more than 
16 weeks [243].  A phase II clinical study was designed to specifically investigate the 
potential therapeutic efficacy of JX-594 for ovarian cancer patients, but was withdrawn 
prior to the enrollment of patients [244].    
 Other vaccinia virus vectors have been engineered to induce the expression of 
tumor associated antigen NY-ESO1 (vaccinia-NY-ESO1) in infected tumor cells and have 
been used in phase II clinical trials as a vaccination strategy against both melanoma and 
ovarian cancer followed by booster vaccinations with fowl pox-NY-ESO1.  In melanoma 
and ovarian cancer patients, both cytotoxic T cells and T helper cells were induced in a 
high proportion of patients (20/22).  Patients who were seronegative for viral antibodies 
and remained seronegative, but developed T cell responses, and/or patients who 
seroconverted and developed T cell responses showed improved overall survival of 52.4 
months and 48.4 months respectively compared to those that elicited no response (median 
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survival of 14.5 months).  Furthermore, cytotoxic T cells extracted from EOC patients were 
able to induce lysis of NY-ESO1 positive tumor cells, thus providing clinical evidence and 
promising efficacy for the application of poxvirus oncolytics as immunotherapeutic 
vaccines against EOC [245].  Similar vaccination strategies with other modified vaccinia 
viruses are currently undergoing clinical trials.  One example includes the p53 expressing 
P53MVA strain, which induces the expression of p53 in vaccinia virus infected tumors.  
Used in combination with gemcitabine, P53MVA was designed to help build more 
effective immune responses to tumor cells expressing mutated P53.  This phase I clinical 
trial is ongoing and actively recruiting patients [246]. (Table 1.1). 
 Pre-clinical development of novel oncolytic viruses for the treatment of metastatic 
heterogeneous EOC 
Although progress is being made in the development of viruses for the treatment of 
ovarian cancer, few agents have been evaluated in metastatic disease models, and none to 
our knowledge have been investigated in the context of both spatial and temporal 
heterogeneity.  It is clear that both tumor heterogeneity and metastasis act as major hurdles 
in the development of clinically efficacious therapies to treat EOC. Therefore we sought to 
investigate the therapeutic potential of three oncolytic viruses, Myxoma virus, a strain of 
vaccinia virus (vvDD), and Maraba virus (MRBV), to overcome the most commonly 
neglected and lethal aspects of EOC. 
Myxoma virus 
Myxoma virus (MYXV) is a dsDNA enveloped virus and a member of the 
Poxviridae family.  The Lausanne strain of MYXV contains a large 161.8 kbp genome and 
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encodes 171 genes, a large proportion of which produce immunomodulatory and host-
interactive factors, which aid in its subversion of the host immune system and other anti-
viral responses [247-249].  Unlike other poxviruses such as VACV, which is capable of 
infecting a broad range of hosts, MYXV replication is restricted to lagomorphs and only 
causes pathogenesis in European rabbits [250-252].  MYXV virus co-evolved with the 
Sylvilagus genus (cottontail rabbit) which can be found endemically in Brazil.  Although it 
replicates robustly and may be transferred efficiently from host to host, it causes no serious 
disease in its normal host [253].  The virus is passively transmitted through mosquitoes and 
other biting arthropods [254-257].  In its natural host, the cotton tail rabbit, MYXV causes 
a cutaneous fibroma at the site of inoculation.  However in European rabbits, MYXV 
infection is lethal, causing disseminated disease called, myxomatosis [258].  In the 1950s, 
MYXV was introduced into Australia as a pesticide against encroaching European rabbits.  
With lethality rates as high as 99.8% huge declines in the rabbit population were observed 
making MYXV one of the most successful examples of a biological agent as a pesticide 
[253].  Lethality from myxomatosis is typically observed between 8-12 days after infection 
with virus shedding from ocular and nasal discharge and multiple cutaneous swellings and 
lesions which can be transmitted through contact or biting insects [259, 260].  MYXV’s 
success in rabbits derives from its ability to effectively circumvent a wide range of host 
innate and adaptive immune responses.  MYXV encodes many mimetics of host immune 
receptors (also known as viroceptors) which sequester immune responses to infection. This 
includes the viroceptor M-T7, which antagonizes the effects of rabbit IFN-γ [261].  
Moreover, M-T7 can promiscuously bind to the heparin-binding domain of a broad range 
of chemokines to significantly reduce macrophage and other immune cell influx to the site  
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SD- stable disease, CR- Complete response, PR- partial, response, NR- no response, OS 
overall survival 
Table 1.1 Oncolytic viruses used in clinical trials with ovarian cancer patients 
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of infection [261, 262].  However, the MYXV host range is extremely narrow.  It is 
virtually non-pathogenic for any host outside the lagomorph family and fails to replicate 
efficiently in any non-rabbit host, even severely immunodeficient mice [263, 264].   
Despite its narrow host range, MYXV is able to broadly infect human cancer cells.  
This is primarily due to two factors: 1) many cancer cells are unable to produce a potent 
anti-viral response through the synergistic interaction between IFN and tumor necrosis 
factor α (TNFα), which normally blocks MYXV virus replication and transmission in non-
cancerous human cells [265, 266]; and 2) malignant transformation of many cancers 
induces constitutive activation of a number of intracellular pathways including the 
activation of AKT [267].  Pharmacological manipulation of AKT phosphorylation directly 
impacts MYXV tropism for human cancer cells [268].  It is thought that because MYXV 
has such broad cancer cell specificity that these two factors are the main determinants of 
MYXV tropism for cancer cells, rather than the expression of any particular cell surface 
receptor [269, 270].  For these reasons, and its otherwise highly restricted species 
specificity, MYXV can act as a highly specific oncolytic virus for cancer cells with a 
promising safety profile.  MYXV demonstrates cancer cell-specific viral replication in a 
number of cancer types, including glioma, medulloblastoma, melanoma, pancreatic cancer, 
acute myeloid leukemia (AML), and ovarian cancer [271-276].  In AML, MYXV has been 
shown to effectively kill primary leukemic hematopoietic stem and progenitor cells derived 
from patients without inducing lysis or altering the behavior of normal hematopoetic stem 
cells [271].  Furthermore, MYXV has been shown to work synergistically with 
chemotherapeutic agents in models of pancreatic cancer that have acquired resistance to 
gemcitabine [277].  Resistance to gemcitabine is associated with increased levels of pAKT, 
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thereby selecting for cells with greater MYXV permissivity.  Combination treatment 
regimens of MYXV and gemcitabine demonstrate enhanced survival in disseminated 
pancreatic cancer models than either treatment alone and may suggest novel therapeutic 
alternatives for this disease [277].   
The activation of PI3K/AKT pathway can be found in up to 70% of ovarian cancers 
and is associated with poor overall survival and progression free survival [278-282].  Thus, 
we postulate that MYXV may act as a potent oncolytic in the most aggressive EOC cells 
which harbor activating mutations or dysregulated signaling of AKT.  Our lab has 
demonstrated that MYXV can effectively replicate and kill EOC cell lines and has varying 
oncolytic efficacy for cells isolated directly from EOC-patient ascites [275].  Furthermore, 
infection of spheroids formed from EOC cell lines demonstrate decreased reattachment and 
dispersion in our in vitro models of EOC metastasis [275].  These oncolytic effects were 
correlated with changes in activation of AKT between adherent and spheroid EOC cells 
[275].  MYXV replication is also directly modulated by the mutational status of TP53 and 
preferentially replicates in cancers with dysfunctional or deleted TP53 (which is found in 
>95% of HGSOC cases) [283].  These findings suggest that MYXV may work as a targeted 
therapeutic for the treatment of metastatic EOC and possibly for type II EOCs in which 
pAKT is most highly induced and TP53 mutations are ubiquitous.   
Double deleted vaccinia virus (vvDD) 
 Similar to MYXV, VACV belongs to the poxviridae family, is enveloped, and is 
also has a genome composed of dsDNA.  However, unlike MYXV, VACV is capable of 
replicating in a diverse range of mammalian hosts including humans, allowing for abundant 
preclinical research to be conducted in many different animal systems [269].  Much of its 
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genome encodes for enzymes required for its replication, such that it can replicate with 
little dependence on host cell machinery.  This includes a DNA dependent RNA 
polymerase, numerous transcription factors, a number of capping and methylating 
enzymes, a poly(A) polymerase, and many immunomodulatory proteins [269, 284].  To 
encode all these proteins, VACV has a very large genome with over 190kbp needed for 
approximately 270 genes [285].  Moreover, by encoding most of the genes required for its 
replication, VACV does not need to enter the nucleus and its replication is entirely 
cytoplasmic, thereby eliminating any risk of viral gene integration in the host genome 
[286].  It is this large genome that makes poxviruses effective gene therapy vehicles for the 
delivery and expression of up to 25kb foreign DNA without significantly compromising 
virus particle integrity [287].  However, despite its large genome, VACV completes its 
replication cycle within 24hrs of infection and produces relatively high titers of virus [288].  
Furthermore, its historical use as the vaccination agent in the eradication of smallpox has 
allowed for extensive characterisation of clinical effects in human (compared to any other 
virus) [289].  Thus, VACV pathogenesis in both preclinical and clinical settings is well 
defined, with clear symptomology and safety profiles outlined.   
 VACV is capable of inducing robust immune responses mediated through both T 
cell activation and antibody responses, which can induce potent bystander effects to 
augment anti-tumor immunity [290].  For this reason, VACV is considered a promising 
oncolytic for the treatment of cancer.  VACV has typically been applied in cancer therapy 
as either a gene therapy vehicle to deliver tumor specific therapeutic genes, a direct 
oncolytic that can replicate and kill within cancer cells specifically, or as a cancer vaccine 
which expresses tumor antigens or immunostimulatory agents.  
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VACV entry into target cells occurs via the expression of a multi-protein fusion 
complex carried by the virion and may be dependent on interaction with cell surface 
glycosaminoglycans or other undefined cell moieties that promote direct virus membrane 
fusion with the plasma membrane [291].  Alternatively, some strains of VACV can also 
use the endocytic pathway under low pH conditions, however inhibition of endosomal 
acidification prevents virus entry [292].  Upon entry and initial rounds of viral mRNA 
translation and protein production, vaccinia growth factor (VGF) is produced, which binds 
the EGF receptor and signals through the ERK1/2 pathway to stimulate the production of 
thymidine kinase (TK) in the host cell and increase nucleotide pools to provide sufficient 
availability of nucleotides for the production of new virions [293-295].  In addition, VACV 
encodes its own TK (vTK) to further promote phosphorylation of deoxythymidine, 
contributing to higher nucleotide pools for the incorporation into replicating VACV 
genomes [296].  In replicating cancer cells, available nucleotides for genome incorporation 
are abundant, thus the need for vTK and VGF are considered dispensable for VACV 
replication [297].  Therefore, to promote cancer specific viral replication, a construct of 
VACV with a double deletions of vTK and VGF was created, called vvDD.  This created 
enhanced cell tropism for cells with constitutive EGFR or ERK1/2 activation [298].  By 
this same logic, cancers with activating mutations in KRAS downstream of EGFR also 
promote vvDD replication [299].  Infections of both resting and dividing NIH-3T3 cells 
demonstrated restricted vvDD replication compared to WT in resting cells but equivalent 
virus production in actively dividing cells [298].  Currently, strains with additional 
modifications to the vvDD backbone have gone on to clinical trials in patients with 
superficial injectable tumors [300].  
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General poxvirus replication lifecycle  
Poxviruses encode the necessary enzymes and proteins to allow replication within 
the host cytoplasm.  The binding of poxvirus virions is mediated by the expression of 
surface glycosaminoglycans on target cells or by components of the extracellular matrix 
[301-305].  The full replicative cycle depends on three waves of viral mRNA and protein 
synthesis known as early, intermediate, and late [284, 306].  After cell surface binding, 
poxvirus membranes fuse with cell membranes to release the virus core into the cytoplasm 
[307].  Along with the virus, packaged viral RNA polymerase and transcription factors 
initiate the first wave of viral gene expression (including the production of vTK in VACV).  
Approximately half of the 200+ genes encoded by VACV are transcribed during early 
infection [284]. These genes include intracellular modulators that inhibit apoptosis and 
block IFN signaling and prevent anti-viral responses [308].  Through a poorly understood 
mechanism, core uncoating is initiated causing dissolution of the core structure, releasing 
viral DNA into the cytoplasm which can be used as a template for DNA replication and the 
subsequent intermediate and late stages of virus lifecycle.  Unlike the early stage, the 
subsequent intermediate and late stages require host transcription factors to contribute to 
the efficiency of viral gene expression [299, 309-312].  Late genes are required for the 
assembly of virus particles.  The assembly of virions occurs in compartmentalized regions 
of the cytoplasm known as viral factories, which largely exclude cell organelles [286]. The 
process of forming infectious progeny is known as morphogenesis. The first visible 
structures are crescent shaped and made from lipid and protein, which subsequently 
elongates to form an oval or spherical structure that encloses the virus core components, 
creating an immature virion [313].  The viral DNA genome becomes packaged within the 
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immature virion, and as the core proteins are cleaved the virus acquires a characteristic 
brick-shaped structure which is fully infectious.  These are known as intracellular mature 
virions (IMV). For the majority of progeny virions, morphogenesis ends here and IMV are 
released after cell lysis [313].  However, a subset of IMV will be transported away from 
the viral factories via microtubule trafficking to acquire an envelope, typically from golgi-
derived membranes forming intracellular enveloped viruses (IEV) [314-319].  During 
egress of the virus from the cell, the IEV loses one of its outer membranes and fuses to the 
cell membrane to form cell-associated enveloped virus [320-323].  This articulated form 
of the virus can either help aid spread of the virus through direct cell-cell contact, or it may 
be released freely as extracellular enveloped virus [324].  For both MYXV and VACV 
based oncolytics, the IMV and IEV are used, since the majority of virions remain in these 
forms.   
Maraba Virus 
Maraba virus (MRBV) is an insect virus originally derived from female Brazilian 
sand flies in 1983.  Following the initial characterization of MRBV in 1984, MRBV was 
believed to be a strain of vesicular stomatitis virus (VSV), belonging to the Rhabdoviridae 
family, based on a number of complement fixation assays.  It is antigenically related to the 
New Jersey, Indiana, Cocal, Alagoas, and Carajas strains of VSV [325].  Rhabdoviruses 
are a family of bullet-shaped, enveloped viruses whose genomes consist of negative sense 
single stranded RNA and encode only 5 genes.  The prototypical Rhabdovirus, VSV, is 
made up of 11,161 nucleotides.  The outer most layer consists of a lipid envelope with 
incorporated glycoproteins (G), which allows virus binding and entry into the host cell 
[326, 327].  Currently, it is unknown what cell surface receptor the MRBV G protein binds 
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to mediate virus entry.  However, due to the diverse species tropism, it is believed that the 
receptor is ubiquitously expressed.  The middle layer consists of a matrix (M) protein which 
forms a bridge between the viral envelope and its genome [328].  The inner core is made 
up of the virus RNA genome tightly coiled around nucleocapsid protein (N) [329].  This 
core associates with both the large polymerase protein (L) and the phosphoprotein (P) 
[330]. (Fig. 1.4)  
Interestingly, MRBV, Indiana, Alagoas, and Cocal are so antigenically similar that 
they were indistinguishable from one another based on the laboratory methods used at the 
time [331].  Isolations from human sera revealed high neutralizing antibody titers 
indicating that human infection with these viruses was common, but this only manifested 
in 3-4 day illness with fever, headache, myalgia, and malaise [332].  With improvements 
in genome sequencing over many years, stratification of VSV strains became more feasible 
with VSV becoming divided into two serotypes, New Jersey and Indiana.  Based on the 
sequences of its glycoprotein and phosphoprotein genes, MRBV was later classified as a 
vesiculovirus with a distinct lineage within the Indiana serotype [333].  In the burgeoning 
field of oncolytic virotherapy, VSV demonstrated potent oncolytic activity and specificity 
for cancer cells in both in vitro and in vivo models [334-336].  However, the concern of 
pre-existing neutralizing antibodies against VSV raises the possibility of diminished 
systemic therapy for human cancer.  Serological studies with VSV in both human and non-
human animal models demonstrates differential serum neutralization of VSV between 
cancer patients and those of healthy subjects.  Interestingly, both MRBV and pseudotyped 
VSV with MRBV glycoprotein were able to evade both non-immune and immune 
mediated serum neutralization and retained parental virus growth kinetics and tropism.   
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Figure 1.4. Rhabdovirus structure and genome organization- Rhabdoviruses 
are transcribed in a sequential manner with genes at the 3’ end being transcribed in 
higher numbers than those at the 5’ end.  Nucleocapsid proteins are transcribed at 
the highest level to maintain RNA genome stability and viral packaging.  
Phosphoproteins play an important role in initiating and stabilizing L and N during 
transcription, translation, and genome replication during virus replication.  Matrix 
protein maintains structural integrity of the virus and acts as an anchor for G protein 
incorporation in the virus membrane.  Glycoprotein expression at the virus surface 
is required for virus binding and entry into the host cell.  Packaged polymerases are 
important for transcription and replication of virus genomes.   
M G L 
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Therefore, although there is high genetic sequence similarity between these two viruses, it 
is clear that MRBV is a serologically distinct member of the Rhabdoviridae family [337].   
VSV replication lifecycle 
Rhabdovirus binding to the host membrane is pH dependent as G protein folding is 
influenced by pH [327].  Entry is facilitated by clatharin-dependent endocytosis of virions 
and trafficked through the cytoplasm via microtubule transport [338, 339].  Through an 
undefined mechanism, the endosome becomes multi-vesicular, causing fusion of the virus 
envelope with the internal vesicles in a pH dependent fashion [340, 341].  These internal 
vesicles then fuse back with the membrane of the endosome releasing the virus core into 
the cytoplasm of the cell [342].  The genome serves as both a template for genome 
replication and for transcription of virus genes.  Upon entry into the cytoplasm, the virus 
is uncoated and the M protein dissociates from the virus core leaving the N-RNA complex 
associated with both L and P proteins [343, 344].  The P protein is post translationally 
modified to promote homodimer formation, which is important for the interaction with the 
N and L proteins [330, 345].  Interaction of the L protein with the N-RNA is mediated 
through the P protein to initiate transcription [330, 346].  The L protein acts as the catalytic 
subunit of the viral polymerase and with the P protein forms an RNA dependent RNA 
polymerase (RdRp).  Together with host cell elongation factor 1α, guanylyl transferase, 
and heat shock protein 60, this complex facilitates transcription of viral genes [347, 348].  
As the RNA genome is non-segmented, transcription is sequential with genes at the 3’ end 
being transcribed in greater abundance than those at the 5’ end [349, 350].   
The fundamental difference for genome replication is the requirement of newly 
synthesized L, N and P protein complexes, whereas transcription requires predominantly 
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just L and P complexes [351].  During replication, the full genome is duplicated to produce 
an anti-genome, which subsequently acts as a template for the production of the full-length 
genome [352].  Because the promoter region of the anti-genome is more efficient than that 
of the genome promoter, more genomic copies of the RNA are made than anti-genome 
[352].  It is thought that the P protein maintains the N protein in a soluble encapsidated 
form [353, 354].  Both the genome and anti-genome contain localization signals to promote 
their replication and incorporation into new virions [355].  Virus assembly occurs at the 
cell membrane, where viral proteins are transported through different mechanisms.  G 
protein is transported to the plasma membrane through the secretory route, however the 
mechanism for M protein transport remains undefined [356, 357].  The core comprised of 
N-RNA, P, and L proteins is transported in a microtubule dependent manner to the plasma 
membrane, where it associates with M proteins [339, 358].  Finally, the M protein recruits 
a number of cellular proteins which help facilitate M protein ubiquitination and virus 
budding from the membrane [359, 360]. 
MRBV cancer cell tropism 
Maraba virus was first discovered to possess cancer cell specific tropism in a screen 
of a number of Rhabdoviruses in a panel of cancer cell lines. Maraba was discovered to be 
the most potent of these viruses, even more so than VSV.  Further modifications of the 
virus were introduced through point mutations in both the M (L123W) and G (Q242R) 
proteins, which rendered the virus more virulent but also more vulnerable to IFN responses.  
With a 100x greater maximum tolerated dose than WT MRBV, the MG1 construct of 
MRBV showed durable curative responses in syngeneic murine models of colon carcinoma 
and ovarian xenograft models [361].  Additional modifications to MRBV MG1 have been 
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engineered to produce an IFN decoy receptor (MG1IDE) upon successful replication of the 
virus, thereby reducing the capacity for IFN mediated resistance to MRBV in IFN-
responsive cancer cells.  Furthermore, normal cells were protected against MG1IDE 
oncolysis as only a small subpopulation were capable of being infected.  Thus, without 
productive virus replication, insufficient levels of the IFN decoy receptor could be 
produced to render the uninfected cells sensitive to virus infection [362].  Based on its 
broad acting cancer cell specificity and the relatively cell independent nature of replication, 
it is unclear whether additional trophic factors exist which may affect MRBV replication 
other than IFN response.   
It is abundantly clear that effective MRBV based oncolysis is not strictly due to its 
direct infection and oncolysis of cancer cells, but also because of its immunostimulatory 
activity.  In syngeneic murine models of metastatic melanoma, MG1-induced dendritic cell 
(DC) and natural killer (NK) cell activation was vital to effective oncolysis of cancer cells 
and reducing lung metastases.  Infection and replication of MG1 in DCs induced DC 
maturation, which allowed for priming of NK cells to mediate NK cell cytotoxicity of 
tumor metastases [363].  However, MRBV alone is a relatively weak inducer of anti-
tumoral adaptive T cell immune responses.  Therefore MRBV application has since 
evolved to be utilized as a vaccine vector.  Other syngeneic melanoma models have applied 
adenovirus vector based delivery of melanoma tumor associated antigens (Ad-hDCT) to 
prime CD8+T cell responses prior to MRBV administration.  Although no hDCT-specific 
T cells could be observed 10 days after Ad-hDCT was administered, administration of 
MG1-hDCT 12 days after Ad-hDCT elicited a strong recall response from CD8+ T cells.  
Optimal administration of secondary MG1-hDCT 9 days after Ad-hDCT showed reduction 
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of melanoma metastases and tumor burden, which significantly improved survival and 20% 
of mice were cured [364].  Thus, current phase I/II clinical trials being carried out have 
adopted a similar prime boost vaccine strategy with adenovirus vectors engineered to 
express the MAGE A3 tumor associated antigen (AdMA3) followed by MG1MA3 
administration [365].   
1.6 Experimental objectives and hypothesis 
 Oncolytic virotherapy represents a burgeoning field in cancer therapy.  The 
development of engineered viruses with improved cancer cell tropism, specificity, and 
efficacy represent the most recent advances in virotherapy.  Furthermore, many different 
pre-clinical and clinical trials have made it evident that viruses have central roles in 
immunostimulatory functions aside from strictly inducing oncolysis of tumors.  However, 
important questions remain unresolved in establishing the clinical utility of viruses for 
cancer therapy, specifically ovarian cancer therapy.  Few studies have investigated the 
therapeutic effect of viruses in intraperitoneally disseminated EOC metastases.  EOC 
spheroids undergo substantial morphological and signaling changes in pathways which are 
known to directly impact virus replication.  Thus it remains to be determined what impact 
spheroid mediated metastasis has on viral oncolysis.  Currently, only one study conducted 
by our research program has attempted to investigate how these factors impact MYXV 
oncolysis, and it remains unclear whether or not MYXV represents the best virotherapy for 
the treatment of metastatic EOC or whether more effective virotherapies exist.  Previous 
trials with MYXV, vvDD, and MRBV have demonstrated that all three viruses have 
significant oncolytic activity and potential clinical benefit.  However, the trophic factors 
which dictate their specificity are differentially represented within EOC tumors during 
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metastasis and across the patient population.  Therefore we sought to determine how 
dynamic changes in EOC biology during metastasis and between EOC cell lines impact 
their viral kinetics in an in vitro metastasis model.   
 Additionally, we sought to investigate cell mediators of MRBV infection and 
replication as they have yet to be elucidated. Published research on VSV has shown that 
few host cell dependent factors are required for virus replication.  This suggests that VSV 
and other highly similar viruses (such as MRBV) may be less susceptible to the various 
biological changes that occur in EOC cells.  Studies with MRBV have shown diverse cell 
tropism for a number of homogenous cancer cell lines, but it is unclear whether or not 
MRBV oncolysis will be impacted by intercellular differences within a heterogeneous 
tumor.  Thus, we sought to discover potential cell mediators that may impact MRBV and 
whether modulation of those factors could improve MRBV oncolysis.  Based on the 
complex and transforming nature of EOC cells during spheroid formation and metastasis 
as well as the high degree of intratumoral heterogeneity between cells within a tumor and 
over time, we hypothesize that these biological differences will directly impact oncolytic 
virus killing by MYXV, vvDD, and MRBV MG1 in EOC cells.   
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CHAPTER 2: Evidence for differential viral oncolytic efficacy in an in vitro model of 
epithelial ovarian cancer metastasis 
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2.1 Introduction 
Epithelial ovarian cancer (EOC) is the most lethal gynaecologic malignancy and 
represents the sixth most commonly diagnosed cancer amongst women in the developed 
world [1].  A lack of effective therapeutic options, coupled with the highly heterogeneous 
nature of EOC, and being typically diagnosed at an advanced metastatic stage, contribute 
to the lethality of EOC [2, 3].  Current therapeutic strategies involve exhaustive 
cytoreductive surgery and post- operative platinum- and taxane-based chemotherapy [4-6].  
However, effective treatment is complicated by the manifestation of EOC as multiple 
histotypes, which are differentially responsive to platinum- and taxane-based combination 
chemotherapy treatments [7].  Furthermore, patients that initially respond well to platinum 
therapy almost inevitably relapse with chemo-resistant disease resulting in reduced overall 
survival.  Thus, there is a critical need for targeted and durable therapeutic alternatives 
beyond the standard first-line chemotherapeutic agents [8-10].  
Oncolytic virotherapy promotes viral infection and lysing of cancer cells.  The specific 
nature of oncolytic virus therapy stems from the selection of non- or lowpathogenic non-
human viruses that display tropism for cancer-associated genetic mutations or aberrant 
signaling [11].  Myxoma virus (MYXV) is a European rabbit-specific poxvirus that has not 
been shown to cause disease in humans and is used as a pesticide to control Australian 
rabbit populations [12].  MYXV displays tropism for cancer cells with up-regulation in 
active AKT signaling and dysfunctional p53, which is found in essentially all high-grade 
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EOC [13].  Conversely, vvDD is an engineered poxvirus with deleted vaccinia growth 
factor and viral thymidine kinase genes, which limit its infection to cells harbouring 
upregulated EGFR/RAS signaling commonly observed in low-grade EOCs [14].  Point 
mutations in the strain of MRBV used in this study modify the matrix protein (M) and 
glycoprotein (G) effectively boosting its replicative capacity in cancer cells while 
rendering it unable to counteract an antiviral type I interferon response in healthy cells.  
Though its specific tropism for cancer cells is relatively undefined, MRBV has been shown 
to have potent oncolytic effects in a broad range of cancer cells, including EOC [15].  
The mode of EOC metastasis is unique among most solid malignancies, and therefore 
it likely possesses distinct and novel mechanisms. EOC metastasis occurs via the shedding 
of malignant cells from the primary tumor into the peritoneal cavity; this can occur in the 
context of ascites, an exudative fluid commonly associated with advanced-stage disease. 
Single cells in suspension within the ascites are susceptible to death through anoikis; thus 
aggregation of single cells into multicellular spheroids facilitates escape from cell death 
[16, 17].  Furthermore, EOC spheroid survival is maintained in the low-nutrient 
environment of the ascites by undergoing cellular quiescence and autophagy [18, 19].  This 
tumour cell dormancy phenotype within spheroids is thought to allow persistence of 
microscopic EOC secondary deposits after treatment with first-line chemotherapeutics and 
support growth under more favorable conditions [20]. In addition, spheroids have an 
enhanced capacity to attach and invade mesothelial-lined surfaces in the peritoneal space 
promoting the formation of secondary tumor nodules [16].  
In our current study, we hypothesize that in the context of metastatic ovarian cancer, 
the ability to kill dormant tumour cells is essential to eradicate the potential for disease 
recurrence. In this study, we compare three oncolytic viruses, MYXV, vvDD and MRBV, 
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in an in vitro spheroid culture model of ovarian cancer metastasis to determine whether 
they have the potential to kill dormant tumour cells residing in spheroids.   
2.2 Results 
Oncolytic effects of MYXV, vvDD and MRBV in ovarian cancer cell lines.  
To begin to define the optimal oncolytic viral approach to the eradication of dormant 
EOC cells in spheroids, we applied three different viruses in an in vitro three-dimensional 
spheroid culture system, which we have established to model metastatic EOC (Fig. 2.1). 
Distinct molecular characteristics typify the lifecycle of metastatic ovarian cancer cells as 
they move from a proliferative state in the solid tumour to the resting state in ascites-
suspended spheroids and finally when these structures attach to a secondary site and cells 
proliferate to form a metastatic lesion. Herein, we performed oncolytic infections using 
proliferating adherent EOC cell lines, spheroids cultured in suspension, and spheroid 
reattachment to tissue culture substratum to determine whether molecular and cellular 
changes at these specific steps would affect oncolytic virus cell killing efficacy. We 
selected the established HEYA8, SKOV3 and OVCAR8 cell lines since they have been 
well-characterized genomically (Suppl. Fig. A1) and have been predicted to represent 
different EOC subtypes based on this data [21].  
First, we performed parallel viral infections of adherent EOC cell lines with 
established spheroids in suspension (Fig. 2.2a). Even in proliferating adherent cultures, we 
found that MYXV, vvDD, and MRBV were capable of inducing oncolysis of EOC lines 
with differential killing capacities among the three viruses and across cell lines (Fig 2.2).  
MYXV displayed the least potent killing and was unable to induce significant oncolysis at 
less than an MOI 1 in all cell lines (Fig 2.2b).  vvDD exhibited oncolysis at similar  
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Spheroids in patient 
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implants 
Figure 2.1 In vitro three-dimensional spheroid model system of ovarian cancer 
metastasis.  (a) Ovarian cancer cells are grown as adherent proliferating monolayer 
cultures, and are transferred to Ultra-Low Attachment tissue culture plastic-ware where 
they naturally form multicellular aggregates, or spheroids, when in suspension culture. 
Spheroids are subsequently transferred back to standard tissue culture plastic to 
facilitate adhesion and growth of cells out of viable spheroids. (b) Phase contrast 
images of ovarian cancer cells in each of the culture conditions outlined in panel a. (c) 
Left: Phase contrast microscopic image of freshly-collected ovarian cancer patient 
ascites indicating the presence of spheroids in suspension. Right: Image representing 
ovarian tumour nodules implanted on the peritoneal wall of an ovarian cancer patient 
at the time of laparoscopic surgery.  
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concentrations as MYXV, but was able to induce greater loss of viability in comparison.  
Among the three EOC cell lines, OVCAR8 cells displayed greatest sensitivity to vvDD 
and MYXV infection whereas SKOV3 cells were most resistant in adherent culture 
infections.  In a similar fashion, when tested using ovarian cancer patient ascites-derived 
primary cultures, vvDD yielded better oncolytic activity than MYXV in the majority of 
clinical samples (Suppl. Fig. A2.1).  Although both MYXV and vvDD were able to induce 
modest oncolysis of EOC cell lines in adherent culture, infection-mediated cell killing was 
dramatically reduced in EOC spheroids for all cell lines tested (Fig. 2.2c).  vvDD was 
completely ineffective at inducing oncolysis of SKOV3 spheroids, but it did maintain some 
oncolytic activity in HEYA8 and OVCAR8 spheroids.  
These findings using MYXV and vvDD were in stark contrast to results of MRBV 
infection, which induced robust oncolysis-mediated cell killing across all EOC cell lines 
in adherent culture even at an MOI of 0.001 (Fig. 2.2b).  In contrast, MRBV infection of 
heterogeneous patient-derived cells yielded highly variable oncolytic effects with one 
sample exhibiting robust MRBV-mediated loss in cell viability similar to established EOC 
cell lines (Suppl. Fig. A1). However, a potent oncolytic effect was observed in MRBV-
infected HEYA8 and SKOV3 spheroids where dramatic loss of cellular viability was 
evident with as little as MOI 0.01 at three days post-infection. Interestingly, we observed 
a significant reduction in MRBV oncolytic effects in OVCAR8 spheroids compared with 
adherent cells suggesting that EOC cells may have the capacity to acquire resistance against 
MRBV infection in three-dimensional spheroid form (Fig. 2.2c).  
MRBV is faster at inducing oncolysis of EOC cells than MYXV and vvDD.    
We hypothesized that the potent oncolysis of EOC cells by MRBV may be due to 
a rapid ability to replicate its small RNA-based genome, allowing it to complete multiple   
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Infect Infect a 
Adherent culture Spheroid culture 
Figure 2.2 Analysis of MYXV, vvDD, and MRBV oncolytic-mediated killing of 
EOC cell lines in adherent and spheroid culture. (a) Schematic representation of 
viral infection of ovarian cancer cells in adherent and spheroid culture. (b) HEYA8, 
SKOV3, and OVCAR8 cells were infected at increasing concentrations to a maximum 
of multiplicity of infection (MOI) 10, as indicated; UV-inactivated virus was used at a 
MOI of 10. Cell viability was measured after 72 hours using CellTiter-Glo. (c) HEYA8, 
SKOV3, and OVCAR8 cells were seeded to Ultra-Low Attachment dishes to form 
spheroids over 3 days, then infected at the indicated doses; spheroid cell viability was 
assayed as in panel b (*P < 0.05). EOC, epithelial ovarian cancer; MYXV, Myxoma 
virus. 
b c 
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rounds of infection within the experimental time frame of 72 hours.   MRBV contrasts the 
large poxviruses, MYXV and vvDD, which have been shown to take up to several days to 
complete their life cycle, thus they may only complete a single round of infection within 
72 hours.    
To assess this directly in our system, we sought to compare viral infection kinetics 
among MYXV, vvDD, and MRBV in both adherent and spheroid cultures.   Cells were 
infected with an MOI 10 to maximize infection of all cells at the initial time point.   We 
then assayed cell viability as an initial surrogate to observe virus infection over five days.  
In adherent culture, we found that MRBV was able to induce oncolysis in both HEYA8 
and OVCAR8 cells within 24 hours of infection (Fig. 2.3a).   In support of our previous 
findings (Fig. 2.2b), MRBV exhibited a significant delay of infection in adherent SKOV3 
cells taking over 48 hours to die from MRBV infection.   In contrast, complete oncolysis 
of adherent EOC cells by MYXV and vvDD  
required up to five days.  
We have previously shown that MYXV replication is attenuated in EOC spheroids 
compared to infection of adherent monolayer cells [22].  Therefore, we tested the kinetics 
of MYXV, vvDD, and MRBV infection in spheroids to compare directly with our results 
using proliferating adherent cell lines.   We found that MYXV was largely ineffective at 
inducing detectable oncolysis in EOC spheroids by three days, but cell viability was 
reduced in HEYA8 and OVCAR8 spheroids by five days post-infection (Fig. 2.3b). 
Although a 72-hour infection of EOC spheroids with vvDD yielded little oncolysis, 
extending the time course to five days was sufficient for marked loss of HEYA8 and 
OVCAR8 spheroid cell viability.   Time course infections with MRBV resulted in cell 
death between 48 and 72 hours for both HEYA8 and SKOV3 spheroids.  Interestingly,  
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Figure 2.3 Rapid kinetics of MRBV-mediated killing of EOC cells and spheroids 
compared with MYXV and vvDD. (a) MRBV-mediated cell killing is observed 
within 24 h in adherent EOC cells, but requires longer incubation in SKOV3 cells. 
Oncolysis of adherent cells by MYXV and vvDD is considerably slower. (b) MRBV 
produces rapid cell killing in spheroids, but there is an incomplete oncolytic effect in 
SKOV3 and OVCAR8 spheroids. EOC spheroids have reduced viability due to vvDD 
infection by 5 d, yet remain relatively resistant to MYXV infection. (* p<0.05)  
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OVCAR8 spheroids were relatively resistant to MRBV mediated cell killing with a limited 
extent of cell death similar to what we observed for vvDD.  This significantly contrasts 
MRBV infections of adherent EOC cell lines, including OVCAR8 cells, which displayed 
significant cell death within 24 hours. These unexpected results reinforce the idea that the 
potential underlying mechanisms governing oncolytic efficacy in EOC cells may be quite 
dynamic, and stress the importance of preclinical testing in complementary in vitro model 
systems.  
MRBV produces significantly more virus progeny than MYXV and vvDD.   
We postulated that the observed differences in oncolytic effect among the three 
viruses in our spheroid culture system were also impacted by the efficiency of total virus 
production.  To assess this directly, we infected adherent cells and spheroids and titrated 
total infectious virus particles. MRBV infection of adherent EOC cell lines yielded 
significantly more infectious viral progeny compared to both vvDD (7- to 17-fold increase) 
and MYXV (90- to 400-fold increase) (Table 2.1).  Moreover, the number of viral progeny 
produced from MRBV infection in adherent culture was relatively similar among the three 
EOC cell lines.  In spheroids, however, infectious progeny produced by MRBV infection 
was more variable among cell lines. MRBV infection of SKOV3 spheroids yielded 16-fold 
less virus and OVCAR8 spheroids yielded 69-fold less than HEYA8 spheroids (Table 2.1).  
These MRBV titers were congruent with our results of cell viability demonstrating reduced 
MRBV oncolysis of OVCAR8 spheroids (Fig. 2.2c).  The number of viral progeny 
produced from vvDD infections was similarly reduced in spheroids among cell lines tested.  
In fact, both MYXV and vvDD were able to produce only a 0.2- to 3.2-fold increase in 
viral progeny than what was used to initiate infection.  Again, this result suggests that EOC 
spheroids possess physical or molecular changes in cells that significantly impact the  
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Table 2.1. Quantification of oncolytic virus production in infected adherent ovarian 
cancer cells and spheroids.  
  
  
 Adherent culturea   
HEYA8  SKOV3  OVCAR8  
MYXV  1.38±0.08 x105  5.37±0.21 x105  1.30±0.13 x105  
vvDD  7.78±1.22 x106  2.78±0.35 x106  2.83±0.59 x106  
MRBV  5.52±1.55 x107  4.82±1.11 x107  2.38±0.43 x107  
      
  
  
 Spheroid cultureb   
HEYA8  SKOV3  OVCAR8  
MYXV  8.54±2.07 x105  1.75±0.33 x105  1.12±0.34 x105  
vvDD  1.60±0.21 x106  3.12±1.58 x105  6.04±1.39 x105  
MRBV  1.09±0.15 x108  6.80±0.78 x106  1.58±0.41 x106  
a- In adherent culture, 2.5 x 104 cells were infected in 24-well dishes at MOI 10 
(2.5 x 105 pfu). b- In spheroid culture, 5 x 104 cells were infected in 24-well ULA 
cluster plates at MOI 10 (5 x 105 pfu).   
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replicative life cycle or amplification for both MYXV and vvDD in these dynamic 
structures.  
Activation of MYXV and vvDD oncolysis upon spheroid reattachment.    
 
We use spheroid reattachment as a general method to assess cell viability within 
these structures, as well as to model metastasis formation due to adhesion of spheroids to 
secondary sites. To this end, EOC spheroids were infected for 72 hours prior to transfer to 
adherent culture for spheroid reattachment (Fig. 2.4a).  Spheroid cells are allowed to 
reattach and disperse for another 72 hours, after which the dispersion area of cells from 
infected spheroids was quantified (Fig. 2.4b).   Despite lacking a significant oncolytic cell-
killing effect in spheroids while in suspension, oncolysis mediated by both MYXV and 
vvDD was activated upon spheroid reattachment and significantly reduced the ability of 
cells to disperse from spheroids and form a viable monolayer (Fig. 2.4c and 2.4d).  Reduced 
dispersion was apparent within 24 hours after reattachment and sustained for up to 4 days 
(Supplementary Fig A2.2).  Due to its dramatic impact on spheroid cell viability, MRBV 
infection completely prevented reattachment of HEYA8 and SKOV3 spheroids (Fig. 2.4c 
and Supplementary Fig. A2.2).   Although our previous results of cell viability indicated a 
marginal effect of vvDD infection on OVCAR8 spheroids (Fig. 2.2c), vvDD completely 
prevented OVCAR8 spheroid reattachment suggesting a significant reduction of cell 
viability in these structures.  Interestingly, and in marked contrast to vvDD, MRBV-
infected OVCAR8 spheroid cells were still capable of reattaching and dispersing, but to a 
lesser extent than mock-infected controls (Fig. 2.4c and 2.4d, and Supplementary Fig. A1).     
We next sought to examine the direct oncolytic effect of all three viruses on 
established reattached spheroids (Fig. 2.5a).  This facilitates our ability to evaluate their 
potential to target metastases, as well as determine whether insensitivity to oncolytic virus 
infection observed in suspension spheroids also existed in reattached spheroid nodules.  
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Figure 2.4 MYXV and vvDD oncolysis is reactivated after spheroid reattachment. (a) 
Schematic representation of spheroid infection followed by reattachment to standard tissue 
culture-treated plastic. (b) Representative image of dispersion area quantification as denoted 
by dashed outline. (c) HEYA8, SKOV3 and OVCAR8 cells were seeded to form spheroids 
then infected with MYXV, vvDD, or MRBV for 72 h. Infected spheroids were transferred 
to adherent culture to allow reattachment for 72 h, then fixed and stained. Spheroid 
reattachment was either completely absent (indicating lack of viable cells), or dispersion of 
cells from the attached spheroid was significantly reduced (indicating re-activation of 
oncolytic activity upon reattachment to adherent culture). Scale bar: 1mm. (d) 
Quantification of mean dispersion area was performed using ImageJ software. (* p<0.05).   
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We observed virus infection of attached spheroids with treatment of MYXV, vvDD, and 
MRBV within 24 hours using green fluorescent protein (GFP) expression as a marker (Fig. 
2.5b); this resulted in cytopathic effect in the dispersing adherent cells emanating from 
attached spheroids while leaving the spheroid cores relatively intact (Fig. 2.5c).  These 
findings further emphasize the requirement of cells to be adherent to promote MYXV and 
vvDD induced oncolysis. Similar to reduced cytopathic efficacy observed in MRBV 
infection of OVCAR8 spheroids, we observed reduced GFP expression in MRBV-infected 
OVCAR8 attached spheroids when compared with MRBV-infected HEYA8 and SKOV3 
attached spheroids, suggesting decreased viral entry or replicative potential in  
OVCAR8 spheroids.     
MRBV entry into EOC spheroid cells is significantly reduced.   
Since we had observed an appreciable difference for MYXV and vvDD to induce 
oncolysis of spheroids, and slower infection kinetics of spheroids by MRBV particularly 
in OVCAR8 spheroids, we sought to determine the efficiency of virus entry into adherent 
cells and spheroids.  To achieve this end, we titrated both the amount of virus remaining 
in the supernatant and that which had entered the cell. Although we had observed a 
significant reduction in oncolytic efficacy in EOC spheroids for MYXV and vvDD (Fig. 
2.2b and 2.2c), there was no significant difference for either MYXV or vvDD to enter 
adherent or spheroids cells (Fig. 2.6a).  In contrast, we observed a significant reduction in 
the ability of MRBV to enter spheroids for all three EOC cell lines when compared with 
adherent cells.      
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Figure 2.5 Reattached EOC spheroids are susceptible to MRBV infection. (a) Schematic representation of the 
infection of reattached spheroids. (b) HEYA8, SKOV3 and OVCAR8 cells were seeded to form spheroids, 
transferred to adherent culture to attach and disperse for 72 h, and then infected with MYXV, vvDD, or MRBV. 
Bright field and fluorescence images were captured at 24 h post-infection and images were merged using Adobe 
Photoshop software. (c) After 72 h of infection, SKOV3 and HEYA8 spheroids and dispersing cells are completely 
eradicated by MRBV infection, yet OVCAR8 spheroids and dispersing cells exhibit less oncolytic-mediated cell 
death. Infection by vvDD is more effective to reduce viable cells than MYXV for all reattached spheroids. Scale 
bar: 1 mm.  
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MRBV binding and infection of EOC spheroids requires low density lipoprotein 
receptor (LDLR) expression.    
To investigate the acquired mechanism determining the enhanced ability of MRBV 
to enter adherent EOC cells compared with spheroids, we postulated this was due to 
changes in the expression of a cell surface receptor required for MRBV entry.  Previous 
studies have identified the LDLR as a cell surface receptor that is used by the closely-
related vesicular stomatitis virus (VSV). Since the glycoprotein responsible for binding 
and entry of host cells by VSV shares 80% amino acid sequence homology with MRBV 
glycoprotein, we sought to determine if the mechanism of MRBV entry in EOC cells was 
LDLR mediated.  Indeed, we observed a consistent decrease in the expression of LDLR 
protein expression in day-3 spheroids when compared with adherent cells among multiple 
EOC cell lines (Fig. 2.6b).  To test this mechanism further, we performed siRNA 
knockdown of LDLR to validate whether LDLR is required by MRBV to gain entry to host 
cells.  LDLR knockdown in SKOV3 cells (Fig. 2.6c) resulted in a significant decrease in 
MRBV entry (Fig. 2.6d), and a resultant increase in cell viability in MRBV infected cells 
as compared with knockdown control SKOV3 cells (Fig. 2.6e). In contrast, knockdown of 
LDLR had no effect on cell viability due to infection with MYXV or vvDD.    
2.3 Discussion 
  
Most ovarian cancer patients are diagnosed with late-stage metastatic disease, are 
subjected to multiple successive recurrences, and will eventually succumb to 
chemotherapy-resistant disease.  Thus, the first objective of this study was to test the 
potential of MYXV, vvDD, and MRBV as therapeutic alternatives to conventional 
chemotherapeutics for the treatment of metastatic EOC. A second important objective was 
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Figure 2.6 Efficient MRBV entry into ovarian cancer cells requires LDLR 
expression. (a) HEYA8, SKOV3 and OVCAR8 cells were seeded to adherent and 
spheroid culture, and infected with MRBV, vvDD and MYXV for 1 h at 4ºC to allow 
adsorption. Virus titers from cell lysates are shown relative to total virus collected (i.e., 
supernatant + cells). MRBV titers were determined using supernatant only.  Virus 
treatment in the absence of cells were used as controls.  MRBV binding was 
significantly reduced in EOC spheroids for all three cell lines tested when compared 
with MYXV and vvDD. (b) LDLR protein expression is reduced in ovarian cancer day-
3 spheroids as compared with proliferating adherent cells; this results was also observed 
in the HEY and OVCAR3 cell lines. (c) Western blot demonstrating siRNAmediated 
LDLR knockdown performed by transient transfection of SKOV3 cells. (d) MRBV 
binding is reduced in SKOV3 cells with LDLR knockdown as compared with siNT 
control transfected cells. (e) LDLR knockdown significantly decreases MRBV-
mediated oncolytic SKOV3 cell death as determined by CellTiter-Glo after 24 h, 
whereas there is no effect on viability after MYXV and vvDD infection. (* p<0.05; ** 
p<0.01)  
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to demonstrate that testing viral oncolytics in a uniquely different culture-based model 
system, i.e. three-dimensional spheroids, can elicit unforeseen results and uncover 
important mechanisms controlling virus infection and efficacy. MRBV is clearly the most 
potent oncolytic virus among the EOC cell lines that we tested in both proliferating 
adherent cells and quiescent 3D spheroids. In addition, we are the first to discover that 
endogenous down-regulation of LDLR protein expression in spheroids has the potential to 
reduce MRBV oncolytic efficacy. Although the larger and slower poxviruses MYXV and 
vvDD were less infectious and produced less virus progeny in ovarian cancer cell lines and 
spheroids, virus-infected spheroids displayed reduced capacity to reattach and grow due to 
reactivation of virus infection. Given our results, we propose that early in vitro testing of 
viral oncolytic agents should consider using an experimentally-tractable cell culture system 
such as ours that mimics unique mechanisms of disease metastasis.   
We observed significant differential effects of the three viruses among the three cell 
lines and when assessing the different steps of metastasis as modeled in our culture system, 
particularly when comparing adherent to spheroid cells (summarized in Table 2.2). In 
adherent culture, MRBV clearly exhibited the highest oncolytic activity. Adherent 
monolayer cultures represent proliferating ovarian cancer cells with intact growth factor 
signaling. In contrast, overall efficacy was reduced among the three viruses in spheroids. 
In particular, the almost universal MRBV oncolytic efficacy was dramatically reduced in 
OVCAR8 spheroids. We demonstrate that one of the key receptors MRBV utilizes to bind 
and enter ovarian cancer cells is LDLR; surprisingly, we also show that the LDLR receptor 
is down-regulated in spheroids compared with adherent proliferating ovarian cancer cells. 
This could be related to the dormant phenotype and the fact that the overall anabolic 
metabolism is reduced in spheroids [18, 19, 23]. It has been reported previously that  
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Table 2.2 Summary of overall results for MYXV, vvDD and MRBV oncolytic efficacy in ovarian 
cancer adherent cells and spheroids.  
  
  
HEYA8  SKOV3  OVCAR8  
ADH  SPH  ADH  SPH  ADH  SPH  
MYXV  +  -  +  -  +  -  
vvDD  ++  +  +    - ++  ++  
MRBV  +++++ ++++  +++++  ++++  +++++  +  
- No killing 
+     EC50 MOI 10 
++  EC50 MOI 1 
+++  EC50 MOI 0.1 
++++ EC50 MOI 0.01 
+++++ EC50 MOI 0.001 
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densely-packed cells down-regulate LDLR resulting in decreased cholesterol metabolism 
in gynaecologic cancer cell lines [24, 25].   It is possible that this same effect of LDLR 
down-regulation is occurring in densely-packed cells comprising EOC spheroids thereby 
reducing initial virus entry. It is important to note, however, that after this initial delay in 
virus entry, MRBV is capable to infecting spheroid cells and producing infectious viral 
progeny albeit with slower kinetics compared with adherent proliferating cells. We 
postulate that the dormant phenotype observed in cultured spheroids is analogous to 
microregions of tumours that are avascular or lack essential growth factor and nutrient 
availability. To that end, it would be important to address LDLR expression level in ovarian 
tumours directly, and assess whether modifications can be made to increase MRBV 
binding and entry to the potentially resistant subpopulations due to altered metabolism.  
MRBV is the most potent of the three oncolytic viruses tested. It exhibited the 
greatest killing in the three cell lines. It had the fastest kinetics and generated the most 
infectious progeny. This is most likely supported by the fact that MRBV is a rhabdovirus 
with a short life cycle and small genome. This has also been observed for MRBV in other 
cancer cell systems, and its related family members, such as the most widely-studied 
rhabdovirus, VSV [15, 26]. MRBV was originally identified from a large biorepository of 
rhabdoviruses as having potent activity in several different cancer cell lines [15]. This 
group also developed the double point mutant MRBV MG1, which exhibited enhanced 
growth in cancer cells and reduced effects in normal cells. MRBV is rapidly entering 
clinical trials with engineered vectors expressing tumour-associated antigens (TAAs), such 
as MAGE A3 [27]. We postulate that identifying similar TAAs specific for ovarian cancer, 
perhaps other MAGE proteins [28], could be rapidly applied to develop clinically-useful 
MRBV oncolytic viral vectors. It has become increasingly evident that oncolytic virus 
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efficacy in vivo relies on eliciting an active immune response, which may lead to more 
durable anti-tumour effects in the long-term [29].  We recognize that the cell culture-based 
system used in this report is unable to assess the contribution of the immune system; 
however, we argue that our in vitro ovarian cancer spheroid metastasis model is a useful, 
rapid and widely-amenable experimental tool for initial testing of novel oncolytic vectors 
across histologic and molecularly-defined cancer subtypes, particularly using patient-
derived malignant tumour cells.  
Generally speaking, ovarian cancer spheroids are more restrictive to viral oncolysis. 
One argument could be made regarding the general physical structure of spheroid that may 
make them less readily infected by viruses. Interestingly, we found that for MYXV and 
vvDD viruses there was no difference in binding of these viruses to adherent monolayer 
cultured cells compared with 3D spheroids in suspension. However, the ability of these 
two different viruses to complete their lifecycle was dramatically restricted in spheroids. 
In this case, this is most likely due to the inherent phenotype of ovarian cancer cells in 
spheroids, namely down-regulation of AKT signaling, induction of autophagy, and a 
cellular quiescent phenotype [18, 19, 23]. Oncolytic viruses typically rely on overactive or 
mutant growth factor signaling to promote their life cycle and this constitutes a critical 
cancer-specific tropism [30]. We have shown in other reports that the AKT signaling 
pathway is markedly down-regulated in ovarian cancer cell spheroids, and this directly 
affected MYXV oncolytic efficacy [22]. Soares and colleagues have shown that increased 
levels of phosphorylated AKT are required for late-stage vvDD morphogenesis and 
production of virus progeny [31].  Likewise, phosphorylated AKT is also required for 
permissive infection of MYXV; however, the specific stage of the requirement is currently 
undefined [32].   In our previous study we demonstrated that activated AKT levels are 
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significantly reduced within spheroids as compared with adherent EOC cells, but this 
activity is re-instated upon spheroid reattachment [19]. Our present results are in agreement 
with this phenomenon, since reattachment of spheroids triggered the re-activation of 
MYXV and vvDD-mediated oncolytic killing of dispersing cells.  
MYXV and vvDD reach late-stage virus production in spheroids yet are restricted 
to cause cell death. This restriction is quickly relieved upon spheroid reattachment when 
the dormant-to-proliferative switch occurs [19] and cells are again susceptible to viral-
mediated oncolytic cell death. This result is consistent with our previous study using 
MYXV in patient-derived spheroids [22]. We use spheroid reattachment as a model of 
intraperitoneal metastatic seeding of malignant cells akin to what is observed in patients 
[16, 17, 33, 34]. In fact, OVCAR8-generated spheroids were dramatically susceptible to 
vvDD-induced cell death when using spheroid re-attachment as an assay. It would be 
interesting to determine what mechanisms are utilized by vvDD to affect OVCAR8 
spheroid cells compared with MRBV, an agent that was largely ineffective only in 
OVCAR8 spheroids. This knowledge may uncover novel strategies to engineer MRBV to 
make it more widely applicable to ovarian tumours of different histologies and 
pathobiologies across the ovarian cancer patient spectrum. Given our results, we propose 
that tumour-homing oncolytic viruses could be potent therapeutic agents with particularly 
high tropism and efficacy to seek and destroy these persistent microscopic structures in a 
patient after surgical debulking of macroscopic disease.  
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2.4 Materials and methods 
Cell culture  
HEYA8, SKOV3, HEY, Vero, HeLa, and BGMK cell lines were cultured in DMEM 
(Wisent) supplemented with 5% fetal bovine serum (FBS; Wisent). OVCAR8 and 
OVCAR3 cells were cultured DMEM/F12 (Wisent) containing 10% FBS. All cell lines 
were cultured in a humidified environment at 37ºC with 5% CO2.  
Ascites fluid obtained from ovarian cancer patients at the time of debulking surgery or 
paracentesis was used to generate primary cell cultures as described previously [22]. Cells 
were cultured in DMEM/F12 media supplemented with 10% FBS and grown in a 37°C 
humidified atmosphere of 95% air and 5% CO2. Since these represent primary cell cultures, 
all experiments were performed between passages 3 and 5. All patient-derived cells were 
used in accordance with institutional human research ethics board approval (UWO HSREB 
12668E).  
  
Virus production   
MYXV, vvDD, MRBV were amplified in BGMK, HeLa, and Vero cell lines, respectively.  
BGMK cells were infected with MYXV at MOI 10 for 1 h.  After 48 h of infection, cells 
were harvested and lysed, cell debris was pelleted by centrifugation and supernatant with 
MYXV were purified [35].  HeLa cells were infected with vvDD at MOI 0.1 and 60 h after 
infection cells and virus were harvested and purified similar to MYXV.  Vero cells were 
infected with MRBV at MOI 0.01.  After 20 h of infection, supernatant was collected and 
virus was purified using a 0.2 μM filter.  All virus constructs have been engineered 
previously to express green fluorescent protein (GFP) from endogenous viral promoters: 
MYXV [36, 37], vvDD[14], MRBV [26]. The MRBV MG1 mutant strain used in these 
experiments has been described previously [26].  
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Viral titer quantification 
Quantification of MYXV, vvDD, and MRBV titers were performed using BGMK, HeLa, 
and Vero cells, respectively.  Virus titers were determined through limiting dilutions of 
virus on BGMK, HeLa, or Vero.  Agarose overlays and plaque assays were performed to 
determine virus concentration.   
Adherent culture   HEYA8, SKOV3, and OVCAR8 cells were seeded at 25 000 cells/well 
of a 24-well plate and infected with MYXV, vvDD, or MRBV at MOI 10.  After 48 h 
MRBV infection, and 4 d after MYXV and vvDD infection, cells and supernatant were 
harvested together for virus content.   MYXV, vvDD, and MRBV were titrated on BGMK, 
HeLa, and Vero cell lines, respectively.  
Spheroid culture   HEYA8, SKOV3, and OVCAR8 cells were seeded at 50 000 cells/well 
of a 24-well ultra-low attachment (ULA) cluster plate and allowed to form spheroids for 3 
d. Spheroids were then infected while in suspension with MYXV, vvDD, or MRBV at 
MOI 10. Seventy-two hours after MRBV infection, and 5 d after MYXV and vvDD 
infection, spheroids and supernatant were harvested together for virus content.   Spheroids 
were triturated using a 26-gauge needle and titered as described above.  
Virus infection of EOC cells  
HEYA8, SKOV3, and OVCAR8 were seeded at 5 000 cells/well of a 96-well plate and 
were infected the following day with MYXV, vvDD, or MRBV at a multiplicity of 
infection (MOI) 0.001, 0.01, 0.1, 1, and 10.  The appropriate UV-inactivated virus at MOI 
10 or no virus (mock infected) was used as controls.  Seventy-two hours post infection, 
viability was assayed using CellTiter-Glo® Luminescent Cell Viability Assay (Promega).    
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For infection of EOC spheroids, cells were seeded at 50 000 cells/well of a 24-well 
ULA cluster plate (Corning) and spheroids were allowed to form over 72 h. Spheroids were 
then infected at MOI 0.01, 0.1, 1, and 10, using the same controls as described for adherent 
cell infections.  
For infection of reattached spheroids, spheroids were formed as previously 
described, in the absence of virus, and transferred to 6-well tissue culture-treated plates for 
reattachment.   Forty-eight hours after reattachment, spheroids were then infected at MOI 
10 based on the initial seeding of 50 000 cells/well of a 24-well ULA plate.   Spheroids 
were imaged 24 h after infection then fixed and stained at 72 h post-infection using 
HEMA3 (Fisher HealthCare™).  Phase contrast and fluorescence images of infected cells 
and spheroids were captured during each experiment using a Leica DMI 4000B inverted 
microscope.  Fluorescence and phase contrast overlays were generated using Adobe 
Photoshop.  
Kinetics of infection and cell viability  
HEYA8, SKOV3, and OVCAR8 cells were seeded as described above for both adherent 
and spheroid cultures.  Cells were then infected with an MOI 10 to allow for maximum 
virus infection and achieve synchronous virus lifecycle among all cells within the culture.  
Viability was then assayed using CellTiter-Glo® at 12, 24, 36, 48, 72 h, and 4 and 5 d after 
infection for adherent cultures and at 24 h intervals for up to 6 d with spheroids. To assay 
cell viability in spheroids, spheroids were collected and pelleted, followed by resuspension 
in CellTiter-Glo® and trituration with a 26-gauge needle. Luminescence was measured 
using a Wallac Plate Reader (PerkinElmer).  
Spheroid reattachment quantification  
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Cells were seeded at 50 000 cells/well of a 24-well ULA cluster plate to form spheroids 
over 72 h. Spheroids were infected with MYXV, vvDD, or MRBV at MOI 10.  Spheroids 
were reattached by transferring to 6-well tissue culture plates.   Spheroids were permitted 
to attach and disperse for an additional 72 h prior to fixing and staining using HEMA3™.   
Dispersion areas were calculated using ImageJ 1.48 software (NIH) by subtracting the area 
of the core spheroid from the total area of the dispersion zone.  
Virus entry quantification  
Adherent cells and spheroids were infected with MOI 10 MYXV, vvDD, and MRBV for 
1 h at 4ºC to allow virus infection of cells, but to prevent virus uncoating that would affect 
subsequent quantification of infectious virus titers.  After 1 h of virus adsorption, 
supernatant and cells were separated and cell pellets were washed twice with PBS.  
Spheroids and adherent cells were triturated as described above to ensure that all non-
adsorbed virus was released.  Virus content from supernatants and cell pellets were titrated 
separately to quantify the proportion of virus that had entered adherent cells and spheroids.  
Immunoblotting  
Cell lysates were generated using a modified radioimmunoprecipitation assay (RIPA) 
buffer [50 mM HEPES pH7.4, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl2, 1 nM EGTA, 
1 nM sodium orthovanadate, 10 mM sodium pyrophosphate, 10 mM NaF, 1% Triton X 
100, 1% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 1× protease inhibitor cocktail 
(Roche, Laval, QC)] as described previously [38].  Lysates were incubated on ice for 20 
minutes and vortexed to ensure complete lysis.  Lysates from day-3 spheroids were 
triturated using a 26-gauge needle to help facilitate lysis.  Protein concentrations were then 
determined by Bradford assay using Protein Assay Dye Reagent (BioRad, Mississauga, 
ON). Thirty micrograms of each lysate was run on an 8% SDS PAGE gel and transferred 
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to a polyvinylidene difluoride membrane (PVDF; Roche).  Blots were blocked with 5% 
skim milk in Tris-buffered saline with Tween 20 (TBST; 10 mM Tris-HCl, pH 8.0, 150 
mM NaCl, 0.1% Tween 20).  After 1 h of blocking, blots were incubated on a rocking 
platform shaker at 4ºC overnight with specific antibodies at 1:1000 dilution in bovine 
serum albumin (BSA)/TBST [anti-LDLR (Abcam, ab14056; Cambridge, MA); anti-actin  
(Sigma)].  Blots were washed using TBST and incubated with peroxidase-conjugated anti-
rabbit IgG (GE Healthcare) at 1:10 000 dilution, 5% skim milk/TBST (LDLR) or 5% 
BSA/TBST (actin), for 1 h at room temperature.  Blots were washed again using TBST 
followed by incubation with Luminata™ Forte Western HRP Substrate (Millipore) and 
visualization of bands with the ChemiDoc™ MP System (BioRad).   
LDL Receptor Knockdown  
SKOV3 cells were seeded in 48-well dishes and transfected the next day with siLDLR 
SMARTPool RNA or the siNT non-targeting control RNA using DharmaFECT 1 
transfection reagent (Dharmacon).  At 48 h post-transfection, cells were used for infection 
experiments [virus entry (MRBV at MOI 0.1) and cell viability (MYXV and vvDD at MOI 
1; MRBV at MOI 0.1)] as described above.   
Statistical Analysis  
Statistical significance was determined by unpaired two-tailed Student’s t-test or one-way 
analysis of variance (ANOVA) using GraphPad Prism 6.  Statistical significance was set 
at p<0.05.   
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2.5 Supplementary information  
 
Supplementary Table A2.1. Summary of gene mutations identified in the three cell lines 
used in this study.  
  TP53  KRAS  BRAF  PIK3CA  ERBB2  ARID1A  CTNNB1  
HeyA8    G12D; AMP  G464E  AMP        
SkOV3    AMP    H1047R  AMP  Q586*    
OVCAR8  Y126 splice  P121H      G776V    Q26R  
Data from Domcke et al. (2013) Ranking ovarian cancer cell lines by suitability as HGSOC 
models. Nat Commun 4: 212   
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Supplementary Figure A2.1. Differential oncolytic efficacy in ovarian cancer patient ascites-
derived primary cells. Primary cultures of four independent ascites samples (EOC56, EOC63, 
EOC118 and EOC105) were infected with MYXV, vvDD and MRBV in adherent culture at increasing 
concentrations to a maximum of MOI 10, as indicated. UV-inactivated virus was used at an MOI of 10.  
Cell viability was measured after 72 h of infection using CellTiter-Glo®.  
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Supplementary Figure A2.2. Time course of infected spheroid reattachment. Spheroids were formed 
using HEYA8 (a), SKOV3 (b) and OVCAR8 (c) cells for three days, infected, then followed by 
reattachment to adherent culture as described in Figure 4. Spheroids were fixed and stained every 24 h 
for up to 4 d. Spheroid attachment and cell dispersion area was significantly reduced by all virus 
infections, however OVCAR8 spheroids exhibited reduced oncolytic efficacy by MYXV and MRBV 
infection. Scale bar: 1 mm. 
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CHAPTER 3: Spatial and temporal epithelial ovarian cancer cell heterogeneity  
can impact Maraba virus oncolytic potential 
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3.1 Introduction 
Diagnosis of high grade serous epithelial ovarian cancer, the most common ovarian cancer, 
late in metastasis and the inevitable acquisition of chemotherapeutic resistance are the 
major contributors to the lethality of this disease [1, 2].  This chemoresistance is fueled by 
profound genomic instability caused by DNA repair pathway deficiencies and universal 
loss of TP53 which also results in a high degree of intratumoral cellular heterogeneity [3, 
4].   As seen in many cancers, intratumoural heterogeneity results in a high degree of 
phenotypic variability which can manifest as differential responses to different therapies.  
Debulking surgery either before or after adjuvant chemotherapy is the standard treatment 
for ovarian cancer patients with metastatic disease.  Under this treatment regimen, 
epithelial ovarian cancer (EOC) is still the most lethal gynaecologic malignancy in the 
developed world with a 5-year survival rate of less than a 30% [5-7]. Following 
chemotherapy, the selection and expansion of platinum-resistant EOC cells results in the 
recurrence of aggressive disease that is largely incurable with second-line treatment options 
[8-10].  Thus, there is significant clinical need for more effective therapeutics that target 
disease heterogeneity more effectively, thereby increasing progression-free survival for 
these patients. 
Cancer cells not only gain survival- and growth-enhancing properties through the 
selection and expansion of specific clones within a tumour, they also lose many 
intracellular pathogen defense mechanisms and induce immunosuppressive mechanisms.  
113 
 
Oncolytic virotherapy (OV) exploits these defects in intracellular defense to selectively 
replicate in malignant cells.  Additional changes in the tumour microenvironment, such as 
decreased immune surveillance, also enhance virus targeting of cancers.  For example, 
mutations in interferon (IFN) and in other proteins in this signaling pathway are frequently 
seen in cancer cells as they are major drivers of antitumor immunity [11-13].  However, 
type I IFNs are also key antiviral signaling molecules found in all somatic cells, thereby 
allowing cancer cells to be selectively infected and killed by OVs [14].  Many 
rhadbdoviruses, including Maraba virus (MRBV), represent promising OV vectors because 
of their susceptibility to IFN signaling, as well as other innate and adaptive immune 
responses, making these viruses relatively non-pathogenic in humans.  Thus, the 
immunological deficits in cancer cells deficient confer increased susceptibility to these 
viruses.  Currently, a construct of MRBV armed with the MAGE A3 tumor associated 
antigen, is being evaluated in a phase I/II clinical trial in conjunction with a similarly armed 
adenovirus to investigate their immunostimulatory activity and oncolytic potential.   
In a previous cross-comparison of several OVs, we observed potent oncolytic 
effects of MRBV in several EOC cell lines [15].  Infections of EOC cell lines cultured as 
either adherent cells or three-dimensional spheroids in suspension revealed that MRBV 
was the most potent of the viruses tested at inducing oncolysis.  Furthermore, we identified 
the low-density lipoprotein receptor (LDLR) and its family members as partial mediators 
of MRBV entry, which may be used to predetermine MRBV oncolysis of cancer cells.  
However, the potential for resistance to MRBV treatment has yet to be determined in a 
heterogeneous tumor model. 
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Our previous analyses described the variability of virus oncolysis of EOC cells 
derived from independent patients. Herein, our objective was to examine the efficacy of 
MRBV infection and oncolytic killing in the context of the temporal and spatial 
heterogeneity of malignant EOC cells present in a patient with metastatic disease. Direct 
analysis of multiple isolates from an individual patient with metastatic high-grade serous 
ovarian cancer (HGSOC) of the ovary may provide evidence for intratumoral heterogeneity 
impacting MRBV oncolytic efficacy. Moreover, it is unclear whether temporal changes in 
a tumour cell population, particularly after chemotherapy, may cause molecular and 
cellular changes that affect MRBV infection and oncolysis. Thus, we hypothesized that the 
high degree of tumour cell heterogeneity in HGSOC of the ovary would yield differential 
MRBV oncolytic efficacy.   
3.2 Results 
MRBV oncolysis can be impacted by HGSOC tumour cell heterogeneity 
We commonly isolate cancer cells from the ascites of patients with metastatic EOC to 
perform in vitro cell culture experimentation [16]. In one case, we received four 
independent isolates from a single patient over 14 months of disease progression and 
treatment (Fig. 3.1a). To investigate the effects of temporal heterogeneity on EOC cell 
susceptibility to MRBV, we used these newly-derived continuous HGSOC cell lines to 
assess oncolytic infection and cell killing. Using a range of MOI from 0.001 to 10, we 
observed that iOvCa105 and iOvCa147 cell lines, which were the first and last isolates 
received, were highly sensitive to MRBV with complete oncolysis achieved by an MOI 
0.01 after 3 d post-infection.  This result was in stark contrast to iOvCa131 and iOvCa142 
cell lines isolated from the same patient, where complete oncolysis was not achieved at any 
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virus concentration and partial oncolysis was observed only at MRBV concentrations as 
high as MOI of 1 after 3 d (Fig. 3.1b).  
These results indicated that the HGSOC metastatic cell population in this patient 
was dynamic and heterogeneous with respect to MRBV sensitivity. We had generated 
several subclones from the iOvCa147 cell line by limiting-dilution subculturing. Using a 
set of seven different subcloned cell lines, we performed MRBV infections as described 
above and viability was measured 3 d post-infection.  We observed two distinct responses 
to MRBV infection from the clones: one group of four subclones exhibited complete 
oncolysis at less than or equal to an MOI of 0.1, and another group of three subclones 
(iOvCa 147-B3, G4, G7) exhibiting 1000-fold reduced sensitivity to MRBV, where 
complete oncolysis was not achieved even at an MOI of 10 (Fig 3.2a).  Indeed, we readily 
observed a widespread cytopathic effect (CPE) and readily detectable green fluorescent 
protein (GFP) expression from MRBV infected cells, signifying productive MRBV 
replication in iOvCa147-F8 sensitive cells. However, we observed only modest CPE and 
GFP-positivity in the resistant iOvCa147-G4 cell line (Fig. 3.2b). Taken together, these 
results represent an important example of both temporal and spatial heterogeneity in 
metastatic HGSOC of the ovary and its impact on MRBV oncolytic efficacy. 
Low-density lipoprotein receptor (LDLR) is required for efficient MRBV entry of 
sensitive HGSOC cells 
As a first step to determine factors affecting differential MRBV oncolysis in 
HGSOC cell subpopulations, we sought to determine whether MRBV entry was altered 
between sensitive and resistant subclone cell lines.  Since we have previously established  
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a link between the expression of LDLR and MRBV entry [15], we also sought to determine 
if differences in the levels of LDLR expression between the iOvCa147-F8 and iOvCa147-
G4 subclones could affect MRBV entry and cell susceptibility to MRBV.  We infected 
iOvCa147-F8 and -G4 cell lines with MRBV for one hour after which we quantified the 
remaining virus in the media.  We observed that nearly 25% of MRBV entered iOvCa147-
F8 cells, yet only 5% of MRBV entered iOvCa147-G4 cells (Fig. 3.3a).   
We previously reported reduced LDLR expression in EOC cell lines during 
spheroid formation which correlated which decreased MRBV entry into spheroid cells, and 
this was confirmed by siRNA-mediated knockdown of LDLR expression in adherent cells 
[15].   In fact, analysis of gene copy-number alterations in serous ovarian adenocarcinoma 
using The Cancer Genome Atlas data revealed that approximately 14% of HGSOC tumours 
show LDLR gene amplification with elevated mRNA expression levels (Suppl. Fig. A3.1). 
Therefore, we determined whether LDLR was differentially expressed between sensitive 
and resistant clonal lines.  We examined LDLR expression in iOvCa147-F8 and iOvCa147-
G4 cells with and without MRBV infection.  Indeed, iOvCa147-F8 cells expressed two-
fold higher LDLR as compared with iOvCa147-G4 cells.  In response to both UV-
inactivated MRBV (binds and enters cells, but does not replicate) and replication-
competent MRBV, LDLR expression was decreased in iOvCa147-F8 cells. This may 
indicate virus-binding to the LDLR, followed by endocytosis and lysosomal degradation 
of the internalized receptor [17].  This result was distinct from iOvCa147-G4 cells as the 
lower LDLR expression in this line did not change in response to virus (Fig 3.3b).   
After observing similar correlative data linking LDLR expression with virus 
infectivity in iOvCa147-F8 and -G4 cells, we sought to determine if decreased LDLR 
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would impact the susceptibility of sensitive HGSOC cells to virus infection.  As expected, 
siRNA-mediated LDLR knockdown in two MRBV-sensitive subclone cell lines, 
iOvCa147-F8 and -E2 (Fig. 3.3c), was sufficient to significantly decrease MRBV entry 
(Fig. 3.3d, Suppl. Fig. 3.2).  An inhibitor of LDL-related receptors, RAP, was sufficient to 
impact MRBV entry in iOvCa147-E2 clones but not F8 (Fig. 3.3d).  Thus, we suspect that 
LDLR is the primary mediator controlling virus entry over its related family members.  
Given that EOC cells require sufficient LDLR expression to mediate efficient 
MRBV entry, we sought to determine whether endogenous LDLR expression was 
sufficient to predict HGSOC cell susceptibility to MRBV oncolysis.  We assessed LDLR 
expression in the four independent isolates, iOvCa105, iOvCa131, iOvCa142, and 
iOvCa147, and all seven subclone cell lines generated from iOvCa147, yet failed to observe 
a correlation between LDLR expression and sensitivity or resistance (Suppl. Fig. A3.3).  
This suggests that although LDLR regulates MRBV entry into HGSOC cells, its expression 
alone is not sufficient to predict sensitivity to MRBV oncolytic infection.   
Secreted factors do not impact MRBV infection of sensitive or resistant HGSOC cells.   
We next sought to determine whether MRBV-resistant HGSOC produce secreted 
factors that would reduce infection of sensitive cells. Since type I IFN response to MRBV 
infection can elicit a robust anti-viral response in normal cells, we investigated whether 
MRBV-resistant HGSOC cells possessed an intact IFN response. We performed 
quantitative RT-PCR analysis of IFNB1 mRNA expression in sensitive iOvCa147-F8 cells, 
and two resistant subclones, iOvCa147-G4 and -B3, in response to MRBV infection.  
Neither MRBV-sensitive nor -resistant HGSOC subclone cell lines elicited a potent IFN 
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antiviral signaling response after MRBV infection, whereas the positive control A549 
human lung adenocarcinoma cell line responded with a robust increase in IFNB1 
expression (Fig 3.4a).  Thus we sought to determine if any other secreted factors elicited 
an effect on cell sensitivity to MRBV.  We performed treatments of iOvCa147-F8 and -G4 
cell lines with conditioned media (reciprocal media swap; media change or no media 
change served as controls) immediately prior to MRBV infection.  Forty-eight hours after 
infection, we observed that none of the conditions altered sensitivity or resistance to 
MRBV oncolytic infection (Fig 3.4b).  Since extracellular factors other than IFNB1 may 
affect HGSOC cell sensitivity to MRBV infection, we performed conditioned media 
experiments as described above, but after MRBV infection.  Again, we detected no 
differences in cell viability that would indicate transfer of resistance factors between 
iOvCa147-F8 and -G4 subclone cell lines (Fig 3.4c).   
Direct contact in MRBV-sensitive and -resistant cell co-cultures can restore efficient 
oncolysis.   
Lastly, we sought to determine whether or not direct interaction of MRBV-sensitive 
and –resistant cells within a heterogeneous tumour cell population might impact oncolytic 
efficacy. We predicted that efficient MRBV infection and oncolysis would be restored 
since the original iOvCa147 cell line was quite sensitive to MRBV oncolytic infection (Fig. 
3.1b).  To recapitulate various iterations of a heterogeneous tumour population, we co-
cultured iOvCa147-F8 and iOvCa147-G4 cells at different ratios. Indeed, we observed 
increased sensitization to MRBV-mediated cell death at each co-culture ratio compared 
with the expected cell viability for each individual subclone cell line (Fig. 3.5a).  In fact, 
where co-cultures consisted of an equal ratio of sensitive and resistant cells the viability  
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 Figure 3.3. Differences in sensitivity between subclones are partially due to differences LDLR expression 
and MRBV entry. a) F8 and G4 cells were seeded at 75,000 cells/ well of a 24 well plate. 24 h after seeding, 
cells were infected with MOI 1 MRBV.  1 h after infection, supernatants were collected and uninfected virus 
was titered on vero cells.  Supernatants from a no-cell infection were titered as a control for total inoculated 
virus. b) Cells were seeded at 300,000 cells/well of a 6-well plate. Cells were infected with MRBV at MOI 1 
and cells were harvested for protein at 20 h after infection. c) Cells were seeded at 20,000 cells/well of a 48-
well plate. Cells were transfected for with siNT or siLDLR.  48hrs after transfection, wells were harvested for 
lysates; and unharvested cells were d) treated with 100nM of RAP for 1hr then infected with MRBV for 1hr. 
Media was collected for titering of uninfected virus. No-cell infections were performed as controls.  Virus was 
titered on vero cells via plaque assay. 
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was reduced to the level routinely achieved with the MRBV-sensitive iOvCa147-F8 cells 
alone.  Individual fluorescence labeling of iOvCa147-F8 cells (DiI) and iOvCa147-G4 cells 
(CMAC) prior to co-culture and infection (MRBV expressing GFP) confirmed the 
increased presence of MRBV-infected iOvCa147-G4 cells (both CMAC and GFP positive) 
when cultured with infected iOvCa147-F8 cells (DiI and GFP positive) (Fig. 3.5b).  Indeed, 
quantification of co-stained GFP and CMAC cells revealed a 9 fold increase in the number 
of infected iOvCa147-G4 cells when co-cultured at an equal ratio with iOvCa147-F8 cells 
when compared to MRBV infection of iOvCa1470G4 cells alone (Fig. 3.5c).  These 
observations were further validated when iOvCa147-F8 cells were co-cultured with 
iOvCa147-G4 cells, but physically separated by a porous Transwell membrane to allow 
transfer of secreted factors and virus during active infection (Fig. 3.4b and c). We observed 
no enhanced sensitivity of iOvCa147-G4 cells when cells were cultured separately from 
the iOvCa14-F8 cells confirming the need for physical contact between sensitive and 
resistant cells to mediate sensitization (Fig. 3.5d).  These findings support MRBV as an 
effective therapeutic agent to infect and kill HGSOC cells throughout a heterogeneous 
tumour, as long as sufficient subpopulations of sensitive cells are present to support 
oncolytic replicative infection.   
3.3 Discussion 
There is currently a dire and unmet need for therapeutic alternatives for the 
treatment of metastatic EOC due to the high rate of therapeutic resistance.  This is largely 
a result of genomic instability driving disease heterogeneity.  We previously showed 
MRBV to be a potent oncolytic in EOC cells in both adherent and spheroid culture, thus 
we sought to evaluate the impact of disease heterogeneity on MRBV oncolysis.  Using 4  
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  Figure 3.5.  MRBV sensitivity can be conferred to resistant cells through co-culture 
and cell-cell contact. a) F8 and G4 cells were seeded to a total of 100,000 cells/well of 
a 24well plate.  No virus controls of each cell mixture were used as controls to determine 
relative viability.  Viability was assessed 48hrs after infection using CellTiter-Glo®.  
b) Fluorescence images of co-cultured cells F8 (red) and G4 (blue) were taken 16 h 
after infection with MRBV MOI 0.1.  Infected F8 cells appear yellow.  Infected G4 
cells appear turquoise.  c) Infected G4 cells were counted for each co-culture 
concentration and normalized to the total number of G4 cells to determine percent 
infectivity.  d) Physical separation of cells was achieved through culturing cells in 
0.4uM pore transwell plates.  Media was shared between both top and bottom chambers. 
100,000 cells total were seeded in a 24-well transwell plate.  25,000 cells were seeded 
in the top chamber while 75,000 cells were seeded in the bottom chambers.  24 h after 
seeding, media was changed and cells were cultured and infected with 2.5ml media 
containing 50,000 vpu (MOI 0.5) of MRBV. 48 h after infection, viability of cells in 
the bottom chamber was measured using CellTiter-Glo®. 
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ascites-derived primary EOC cell lines, which were isolated directly from the same patient, 
we observed differential oncolytic efficacies for MRBV in EOC from a temporal 
perspective.  Likewise, clones generated from one of these heterogeneous samples were 
differentially sensitive to MRBV oncolysis despite having been cloned from a sample that 
is largely sensitive to MRBV.  These findings highlight the potential impact that disease 
heterogeneity can have on therapeutic efficacy particularly in disease models in which 
genomic instability is an outstanding feature.  Our data represent the first evidence to 
highlight the impact of both temporal and spatially heterogeneity in EOC on oncolytic virus 
therapy.  Given our results, we propose that in vitro testing of therapeutics should consider 
using cell culture systems which recapitulate the disease heterogeneity found in EOC from 
a temporal and spatial perspective.  These findings not only imply that disease 
heterogeneity can impact MRBV, but also show that in a largely sensitive heterogeneous 
tumour, there can exist resistant cells which could potentially be selected for to give rise to 
MRBV resistant tumours after treatment.   
Previously, we have reported that expression of LDLR could mediate the entry of 
MRBV in target cells [15].  Although we further validated that this receptor is in fact 
important for mediating MRBV entry, we found that LDLR expression across a 
heterogeneous tumour did not solely dictate cell sensitivity to MRBV.  We found that we 
could sensitize G4 cells to MRBV mediated oncolysis when co-cultured with as little as 
10% F8 cells and achieve oncolytic effects of 100% infected F8 cells when as little as 25% 
of the co-culture is made up of sensitive F8 cells.  As physical contact between these cell 
populations is needed to facilitate this sensitization, we speculate that perhaps the 
formation of a virological synapse to allow direct cell-cell transmission could permit 
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MRBV infection of resistant cell populations.  Extensive studies with HIV have shown 
more efficient virus transmission through direct cell-cell contact than cell-free virus spread 
[18].  This occurs when virus assembly components polarize at the site of the synaptic 
junction allowing for direct transfer of mature virus to an adjacent cell rather than having 
large excesses of cell-free virus [19, 20].  This is true for other viruses including vesicular 
stomatitis virus (VSV) which can spread directly between cells [21].  In fact, intravenously 
injected VSV is rarely observed as cell-free particles in vivo and are normally rapidly 
sequestered by cells (either by infection or adhesion) [22].  Surface attachment of VSV has 
been shown to modulate infectivity by augmenting viral passage between cells.  VSV-G 
(glycoprotein) pseudotyped HIV-derived particles exhibit prolonged retention on the cell 
surface which mediate direct cell-cell transfer of virus and increase infectivity by 20-130 
fold [23].  Therefore we speculate that MRBV, which has greater than 80% sequence 
homology with the VSV glycoprotein and was initially thought to be a vesiculovirus may 
be transmitted in a similar fashion between sensitive and resistant clones [24, 25].  These 
findings imply that perhaps only a subpopulation of cells need to be initially infected to 
obtain oncolysis of an entire heterogeneous tumour.   
Moreover, our findings support the notion that MRBV may be more effective and 
broad acting than other precision therapies since its infectivity is not entirely dependent on 
the expression of a single tropic factor, such as LDLR expression.  Likewise, the capacity 
for resistance to MRBV treatment in heterogeneous cell populations can arise 
independently of LDLR expression as observed in the iOvCa 131 and 142 patient samples.  
This suggests that these heterogeneous populations initially have too few sensitive cells 
permissive to infection to facilitate sensitization of resistance cells and that the resistance 
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of the overall tumour may be insurmountable.  Alternatively, it could be that other 
undefined intracellular factors affect productive virus replication.  Ilkow et al. recently 
reported that fibroblasts could be sensitized to VSV killing through pretreatment with 
TGFβ.  This led to production of fibroblast growth factor 2 (FGF2) and subsequent 
reduction in retinoic acid-inducible gene I (RIG-I) which is responsible for virus detection, 
IFN production, and induction of innate antiviral responses against RNA viruses [26].  It 
is possible that upregulated signaling within the TGFβ pathway, which is commonly 
observed in ovarian cancer, may promote or sensitize certain EOC clones to MRBV 
oncolysis.  It would be interesting to determine what, if any, impact endogenous TGFβ 
signaling during EMT in ovarian cancer metastasis would have on MRBV oncolysis.  This 
approach could uncover novel strategies to better exploit MRBV for broader therapeutic 
use in treating EOC over the course of disease progression and in preventing disease 
resistance to MRBV therapy.  Given our results, we propose that perhaps the use of cell 
carrier systems for MRBV may be more efficient in transmitting MRBV to resistant cells 
in heterogeneous populations via direct cell-cell contact rather than cell-free spread [22].    
3.4 Materials and methods 
Cell Culture 
Ascites fluid obtained from ovarian cancer patients at the time of debulking surgery or 
paracentesis was used to generate primary cell cultures as described previously [27]. 
iOvCa-105, 131, 142, and iOvCa147 lines were isolated after removal of non-cancer cells 
by differential trypsinization from the mixed ascites-derived cultures from the same 
patient. Histopathological assessment concluded that this patient’s ovaries displayed a 
mixed morphology tumour consisting of 70% serous and 30% clear cell adenocarcinoma. 
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She presented with metastasized stage IIIC disease. The iOvCa147 line was used in a 
limiting dilution series with each well of two 96-well cluster dishes seeded with 0.3 
cells/well. Clonal lines isolated in this manner were subjected to STR analysis, which 
verified that they originated from the iOvCa147 line. STR analysis confirmed that all four 
lines were derived from the same patient. The resulting lines were cultured in Dulbecco’s 
Modified Eagle medium/ F12 (Wisent) supplemented with 10% FBS (Wisent).  Cells were 
grown in a 37ᵒC humidified atmosphere of 95% air and 5% CO2.  Adherent cells were 
maintained on tissue culture treated polystyrene (Sarstedt, Newton, NC). Non adherent 
cells and spheroids were maintained on Ultra-Low Attachment (ULA®) cultureware 
(Corning, Corning, NY), which is coated with a hydrophilic, neutrally charged hydrogel to 
prevent cell attachment. All patient-derived cells were used in accordance with institutional 
human research ethics board of approval (UWO HSREB 12668E).  
Generation of clones 
Clones were generated through limiting dilution of iOvCa147 cells in a 96-well plate.  Cells 
were seeded at 1 cell/well and cultured in DMEM/F12 (Wisent) supplemented with 10% 
FBS.   Cells were expanded to generate all 7 clones used, which included - B3, C8, E2, 
F5, F8, G4, and G7. 
Virus production 
Vero cells were infected with MRBV at MOI 0.01.  Twenty hours after infection, 
supernatant was collected and virus was purified using a 0.2 micron filter.  The MRBV 
MG1 mutant strain used in these experiments has been described previously.   
Virus infection of EOC cells 
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Primary EOC cells were seeded at 10,000 cells/well of a 96-well plate and were infected 
the following day at MOIs of 0.001, 0.01, 0.1, 1, or 10.  The appropriate UV-inactivated 
virus at an MOI of 10 or no virus (mock infected) was used as controls.  Seventy-two hours 
after infection, viability was assayed using the CellTiter-Glo® Luminescent Cell Viability 
Assay, which is based on quantitation of ATP levels (Promega, Madison, WI).  For 
infection of EOC spheroids, cells were seeded at 50,000 cells/well of a 24-well ULA cluster 
plate (Corning, Corning, NY) and spheroids were allowed to form over 72 h. Spheroids 
were then infected at MOIs of 0.01, 0.1, 1, or 10 using the same controls as described for 
adherent cell infections.  Phase contrast and fluorescent images of infected cells and 
spheroids were captured during each experiment using a Leica DMI 4000B inverted 
microscope. 
Virus entry quantitation 
iOvCa147-F8 and iOvCa147- G4 cells were infected with MRBV at an MOI 1 at 4ᵒC to 
allow virus infection of cells.   1hr after infection, supernatants containing uninfected virus 
was removed and titrated on vero cells. Virus titers were determined through limiting 
dilutions of virus.  Agarose overlay and plaque assay was performed to determine virus 
concentration.  A no cell infection was performed as a negative control to determine virus 
concentration at 0% infection.  
LDL receptor knockdown  
iOvCa147-F8 and E2 cells were seeded in 48-well dishes and transfected 16 h after seeding 
with siLDLR sMARTPool RNA or with siNT nontargeting control RNA using 
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DharmaFECT1 transfection reagent (Dharmacon). At 48 h post-transfection, cells were 
used for infection experiments (virus entry and cell viability) as described above.   
Media swapping experiments 
Media swap after infection 
Cells were seeded at 10,000 cells/well of a 96-well plate.  Sixteen hours post seeding, cells 
were infected with MRBV at an MOI of 0.1 for 1 h followed by media change. At 12 h, 
fresh media was either replaced, swapped between iOvCa147- F8 and iOvCa147- G4 
subclone cells, or were unchanged.  CellTiter-Glo® assays were performed for cell 
viability 48 h after infection. 
Media Swap before infection 
Cells were seeded at 10,000 cells/well of a 96-well plate.  Sixteen hours after seeding, 
conditioned media from both iOvCa147- F8 and iOvCa147- G4 was either replaced with 
fresh medium, swapped between the two clones, or remained unchanged.  Cells were then 
infected at MOI 0.1 and viability was assessed 48 h after infection.  
Quantitative RT-PCR 
iOvCa147- F8, G4, and B3 clones were seeded at 500,000 cells / well of a 6-well plate.  
Sixteen hours post seeding, cells were infected with MRBV at an MOI of 1 or UV 
inactivated MRBV at an MOI of 1 for 6 h.  The A549 lung cancer epithelial cell line was 
used as a positive control for an IFN response.  Total RNA was isolated from both non-
infected and infected clones and A549 cells using Qiagen RNeasy Mini Kit (Qiagen, 
Valencia, CA). Purified RNA was quantified using an ND-1000 spectrophotometer 
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(NanoDrop technologies, Wilmington, DE). Reverse transcription was performed using 
total RNA isolated and Superscript II reverse transcriptase (Invitrogen) as per 
manufacturer’s instructions. PCR reactions were carried out using Brilliant SYBR Green 
QPCR Master Mix (Agilent Technologies/Stratagene) and a Stratagene Mx3000P machine 
with data exported to Microsoft Excel for analysis.  IFNβ1 and GAPDH primers were used 
and were previously described [28].  GAPDH served as an internal control for RNA input 
and quantification was performed using the ∆∆Ct method (Livak and Schmittgen 2001).   
Co-culture experiments 
Co-cultures of iOvCa147-F8 and G4 cells were seeded in 24-well plates at a total of 
100,000 cells/ well.  Wells of 100% iOvCa147- F8 and G4 cells were used as positive 
controls for MRBV effects on viability.  An increasing proportion of iOvCa147- F8 cells 
were titrated into the G4 co-culture (G4:F8 ratio: 98:2, 90:10, 75:25, 50:50, and 25:75).  
Sixteen hours post seeding, cells were infected with MRBV at an MOI of 0.05 and viability 
was measured 48 h after infection using CellTiter-glo.   
Stained co-culture images 
Confluent 10cm plates of iOvCa147-F8 cells were stained with Molecular ProbesTM 
Lipophilic Tracer DiI at 1:500 (ThermoFisher Scientific, Waltham, MA).  Confluent 10cm 
plates of iOvCa147-G4 cells were stained with CellTrackerTM Blue CMAC Dye 1:500 
(ThermoFisher Scientific, Waltham, MA).  Cells were stained for 1 h.  Subsequent seeding 
and infection of cells was performed as described above.  Images were captured at 24hrs 
post infection using a Leica DMI 4000B inverted microscope.  
Immunoblotting 
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Cell lysates were generated using a modified radioimmunoprecipitation assay (RIPA) 
buffer ((50mM HEPES pH 7.4, 150mM NaCl, 10% glycerol, 1.5mM MgCl2, 1nM ethylene 
glycol tetraacetic acid, 1nM sodium orthovanadate, 10mM sodium pyrophosphate, 10mM 
sodium fluoride, 1% triton X 100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 
1mM phenylmethylsulfonyl fluoride, 1x protease inhibitor cocktail (Roche, Laval, QC)) as 
described previously [15]. Lysates were incubated on ice for 20 minutes and vortexed to 
ensure complete lysis.  Protein concentrations were determined by Bradford assay using 
Protein Assay Dye Reagent (BioRad, Mississauga, ON).  Thirty micrograms of lysates 
were run on an 8% sodium dodecyl sulphate-polyacrylamide electrophoresis gel and 
transferred to a polyvinylidene difluoride membrane (Roche, Mississauga, ON).  Blots 
were blocked with 5% skim milk in Tris-bffered saline with Tween 20 (TBST; 10mM Tris-
HCl, pH 8.0, 150mM NaCl, 0.1% Tween 20).  After 1 hr of blocking, blots were incubated 
overnight on a rocking platform shaker at 4ᵒC with specific antibodies at 1:1000 dilution 
in BSA/ TBST (anti-LDLR (Abcam, ab14056; Cambridge, MA); anti-actin (Sigma)).  
Blots were washed using TBST and incubated with peroxidase- conjugated anti-rabbit IgG 
(GE Healthcare) for 1hr at 1:10,000 dilution, in 5% skim milk/TBST for the LDLR 
antibody, or 5% BSA/TBST for actin at room temperature.  Blots were washed again using 
TBST followed by incubation with Luminata Forte Western horseradish peroxidase 
substrate (Millipore, Etobicoke, ON) and visualized with the ChemiDoc MP System 
(BioRad, Mississauga, ON).   
Statistical Analysis Statistical significance was determined by either unpaired two-tailed 
Student’s t-test or one-way analysis of variance using GraphPad Prism 6 (GraphPad 
Software, San Diego, CA).  Statistical Significance was set at p<0.05. 
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3.5 Supplementary Information  
  
Supplementary Figure A3.1 The LDLR gene is altered in a significant fraction of ovarian serous cancers. 
(A) Mutation and gene copy-number status for LDLR across human cancers as determined used The Cancer 
Genome Atlas (TCGA) Provisional datasets accessed from cBioPortal as of November 12, 2015. Ovarian cancer 
(serous adenocarcinoma) has the highest rate of LDLR gene mutation and copy-number changes as compared 
with all other malignancies characterized to date. (B) Oncoprint of serous ovarian tumours harbouring LDLR 
mutations, copy-number changes, and gene expression changes (z-score > 2) from the TCGA Provisional 
dataset. Only tumour samples with alterations (13%; 78/599 samples) are displayed for clarity. (C) LDLR gene 
expression as compared with copy-number status among all serous ovarian tumours from the TCGA Provisional 
dataset. 
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Supplementary Figure A3.2 siLDLR smart pool knockdown and impact on clone 
viability- a)Individual siLDLR siRNA from the siLDLR smartPool. Cells were seeded at 
20,000 cells/well of a 48 well dish.  Cells were transfected with each siLDLR siRNA for 
48 h. 4 wells were harvested for each protein lysate b) and remaining wells were infected 
with F8 MRBV MOI 0.05 for 48 h then viability was measured using CellTiter-Glo®.  c) 
Cells were seeded and transfected as described in a).  48 h after transfection, 100nM of 
RAP was added for 30 minutes followed by infection with MRBV for 1h.  Media was then 
removed.  48 h after infection, viability was measured by CellTiter-Glo®. 
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Supplementary Figure A3.3-LDLR expression does not consistently correlate with 
MRBV sensitivity across heterogeneous ascites cells or its subclonal populations.   
Cells were seeded at 500,000 cells/ well of a 6 well plate.  Lysates were generated 24hrs 
after seeding.  Parallel wells were used for infection to verify MRBV sensitivity.    
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Supplementary Figure A3.4- LDLR expression in adherent and spheroid iOvCa147 
parental line and F8 and G4 clones. A) Cells were seeded at 500,000 cells/ well of 6-
well plate and harvested for lysate 24 h after seeding.  B) cells were seeded at 50,000 cells/ 
well of a 24-well ULA plate and spheroids were formed over 72 h. Spheroids were then 
infected with MRBV MOI 0.1 for 48 h and viability was assessed using CellTiter-Glo®  
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CHAPTER 4: Transforming growth factor-beta signaling mediated induction of 
epithelial-to-mesenchymal transition in ovarian cancer ascites-derived spheroid cells 
augments Maraba virus-mediated oncolysis  
In preparation for submission to Cancer Biology & Therapy 
Tong, J.G., Rafehi, S., Valdes, Y.R., Bertrand, M., McGee, J., Prefontaine, M., Sugimoto, A., Bell, J.C, 
Stojdl, D., DiMattia, G.E., Shepherd, T.G. 
 
4.1 Introduction  
Epithelial ovarian cancer (EOC) metastasis is unique amongst carcinomas in that 
its primary route is not via the bloodstream or lymphatics.  Rather it occurs through the 
direct shedding of malignant cells from a primary tumour on the ovary into the peritoneal 
fluid (ascites) and subsequent dissemination of these cells throughout the peritoneum [1, 
2].  During this process, shed cells are capable of forming multicellular aggregates, or 
spheroids, with the concurrent induction of epithelial-to-mesenchymal transition (EMT) 
[3].  EMT in ovarian cancer enhances metastasis by a general decrease in cell adhesion 
within the primary tumour yet promotes cell migration and invasion during secondary 
tumour formation.  EMT is characterized by reduced epithelial features, including the loss 
of cell-cell junctions and apical-basal polarity, and acquired mesenchymal features, such 
as stress fiber formation and actin reorganization causing a spindle-shaped morphology [4, 
5].  Loss of E-cadherin is considered fundamental to this process and can occur through 
the activation of a number of transcriptional repressor proteins, such as Snail, that actively 
repress expression from the CDH1 gene encoding E-cadherin [1, 6-8].  Snail expression is 
robustly induced through endogenous transforming growth factor-beta (TGFβ) signalling 
activation in ascites-derived cells to promote EMT during EOC spheroid formation [3, 9]. 
The activation of an EMT-like phenotype has been associated with greater chemotherapy 
resistance, cell motility, and cancer stem-cell characteristics; thus, EMT is considered to 
be reflective of more aggressive tumour behaviour[10].  Therefore, the development of 
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therapies which can better target EOC tumour cells which undergo EMT during tumour 
progression and metastasis is essential to improving clinical outcomes.   
 We have previously demonstrated that a derivative of Maraba virus (MG1, herein 
referred to as MRBV), is a potent inducer of oncolysis in EOC lines and that the low-
density lipoprotein receptor (LDLR) can mediate efficient MRBV infection [11].  Thus, 
MRBV oncolysis is delayed and in some cases completely abrogated due to the down-
regulation of LDLR expression in EOC spheroids [11].  However, LDLR expression was 
not the sole determining factor for susceptibility to MRBV infection since we failed to 
observe any correlation between LDLR expression and MRBV oncolysis (Tong et al, in 
preparation).  Furthermore, we were able to increase sensitivity to MRBV independently 
from LDLR expression through co-culturing of sensitive and resistant cells.  Therefore we 
speculate that intracellular signaling events downstream of virus entry could also influence 
MRBV replication.  Ilkow et al., recently demonstrated that cancer associated fibroblasts 
could have enhanced sensitivity to a number of oncolytic viruses, including VSV, when 
pre-treated with TGFβ [12].  This is due to an observable decrease in antiviral transcripts, 
including RIG-I, rendering cancer associated fibroblasts more susceptible to virus 
oncolysis.  Since induction of EMT is a canonical response of epithelium-derived cells to 
TGFβ, we sought to determine whether MRBV oncolytic activity is modulated by 
endogenous TGFβ signalling in ovarian cancer ascites-derived spheroids during this robust 
EMT response.   
4.2 Results  
Spheroid formation of EOC ascites-derived cells promotes robust MRBV-mediated 
oncolysis 
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We have demonstrated previously that by treating several ovarian cancer cell lines 
with three different oncolytic viruses—Myxoma virus, double-deleted vaccinia and 
Maraba virus (MRBV)— the greatest oncolytic effect was observed using MRBV, yet it 
yielded less cancer cell killing in cells cultured as three-dimensional spheroids [11]. This 
finding was similar to our results using MYXV infection of primary cells isolated directly 
from the malignant ascites of ovarian cancer patients, where MYXV had impaired 
oncolytic efficacy in cultured spheroids [13]. To extend these studies, we sought to 
determine whether MRBV oncolytic potential would also be hindered in ovarian cancer 
ascites-derived spheroids. The MG1 strain of MRBV [14] was used to infect (MOI of 0.1) 
ascites cells isolated from nine independent ovarian cancer patients that were cultured as 
both adherent cells and spheroids.   Surprisingly, we observed a significant reduction in 
cell viability in all nine ascites-derived cells due to MRBV-mediated oncolysis, but only 
when cultured as spheroids (Fig. 4.1a).  This effect was in stark contrast to MRBV infection 
of adherent cells where minimal or no oncolysis was observed.  Collectively, spheroids 
generated using EOC ascites-derived cells exhibited a nearly 4-fold greater degree of 
MRBV-mediated oncolysis in comparison with matched cells in monolayer culture (79.2% 
vs. 21.5% cell killing, respectively) (Fig. 4.1b).  This MRBV oncolytic effect was readily 
evident with a decrease in overall spheroid integrity (Fig. 4.1c), which corresponded 
directly with our observed decrease in cell viability in these structures.  This indicates that 
the majority of cells present in the malignant ascites of ovarian cancer patients can be 
infected effectively by MRBV, but may require one or more acquired properties of 
spheroids to render them susceptible to MRBV-mediated oncolysis. 
143 
 
  
M
o
n
o
la
y
e
r  
S
p
h
e
ro
id
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
E O C  2 0 9
M R B V  M O I 0 .1
R
e
la
t
iv
e
 V
ia
b
il
it
y
M
o
n
o
la
y
e
r  
S
p
h
e
ro
id
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
E O C  2 3 7
M R B V  M O I 0 .1
R
e
la
t
iv
e
 V
ia
b
il
it
y
M
o
n
o
la
y
e
r  
S
p
h
e
ro
id
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
E O C  2 4 5
M R B V  M O I 0 .1
R
e
la
t
iv
e
 V
ia
b
il
it
y
M
o
n
o
la
y
e
r  
S
p
h
e
ro
id
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
1 .2
E O C  2 9 4
M R B V  M O I 0 .1
R
e
la
t
iv
e
 V
ia
b
il
it
y
M
o
n
o
la
y
e
r  
S
p
h
e
ro
id
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
E O C  2 9 9
M R B V  M O I 0 .1
R
e
la
t
iv
e
 V
ia
b
il
it
y
M
o
n
o
la
y
e
r  
S
p
h
e
ro
id
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
E O C  2 0 6
M R B V  M O I 0 .1
R
e
la
t
iv
e
 V
ia
b
il
it
y
M
o
n
o
la
y
e
r
S
p
h
e
ro
id
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
P o o le d
M R B V  M O I 0 .1
R
e
la
ti
v
e
 V
ia
b
il
it
y
M
o
n
o
la
y
e
r  
S
p
h
e
ro
id
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
E O C  1 9 5
M R B V  M O I 0 .1
R
e
la
t
iv
e
 V
ia
b
il
it
y
M
o
n
o
la
y
e
r
S
p
h
e
ro
id
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
E O C  2 9 5
M R B V  M O I 0 .1
R
e
la
t
iv
e
 V
ia
b
il
it
y
M
o
n
o
la
y
e
r
S
p
h
e
ro
id
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
E O C  2 8 7
M R B V  M O I 0 .1
R
e
la
t
iv
e
 V
ia
b
il
it
y
a b 
c 
 
UV-inactive MRBV 
MRBV 
Figure 4.1. Spheroid formation sensitizes ascites-derived cells to MRBV oncolysis. 
a) Ascites-derived cells were used at passage 3.  Cells were seeded at 50,000 cells/ well 
of a 24 well adherent plate or in ULA plate to form spheroids.  Adherent cells were 
infected with either UV inactivated or MRBV at an MOI of 0.1 24 h after seeding.  
Spheroids were infected at the same concentrations 72 h after seeding.  48 h after 
infection, adherent and spheroid cells were assayed for viability using CellTiter-Glo® 
reagent.  Relative viability was determined by normalizing MRBV infected cells to their 
own UV infected adherent or spheroid control. b) Individual patient samples assayed 
were pooled as biological replicates and t-test was performed to determine statistical 
significance between adherent and spheroid MRBV infected cells. c) Images of 
spheroids were taken 48 h after infection when viability was being assayed. 
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TGFβ treatment sensitizes adherent ascites-derived cells to MRBV-induced oncolysis. 
There are numerous alterations that can occur in ovarian cancer ascites-derived 
spheroids as compared with cells in monolayer culture, including the induction of 
epithelial-to-mesenchymal transition (EMT) due to endogenous activation of transforming 
growth factor-beta (TGFβ) signaling in these structures [3]. The presence of TGFβ 
signalling in ovarian cancer primary cell spheroids may directly impact MRBV infectivity 
since the presence of this pathway in tumour stroma has been recently implicated in 
modulating MRBV oncolysis in animal models [12]. To directly test whether TGFβ 
signaling could sensitize ascites-derived monolayer cells to MRBV oncolysis, we pre-
treated the cells with 5 ng/mL of TGFβ for 48 h prior to infecting with MRBV at an MOI 
of 0.1. This is a time point at which we have observed robust transcriptional and 
translational changes in EMT-associated proteins and the resultant morphological changes 
characteriztic of EMT [3].  In almost every patient-derived sample (9 out of 10), we 
observed enhanced MRBV-mediated oncolysis in TGFβ-treated cells (Fig. 4.2a), with a 
significant reduction in overall cell viability (Fig. 4.2b).  We verified TGFβ induction of 
EMT cell morphological changes, and readily observed a robust cytopathic effect due to 
MRBV infection in these co-treated cell samples (Fig. 4.2c). 
TGFβ signaling inhibition prevents MRBV oncolysis of EOC ascites-derived 
spheroids.   
Inhibition of TGFβ receptor signalling using small molecule inhibitors is an 
effective approach to block its downstream effects, including EMT [15]. Indeed, we have 
demonstrated that treatment of ascites-derived spheroid cells with the type I receptor 
inhibitor SB-431542 effectively blocks endogenous TGFβ signalling and the induced EMT  
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Figure 4.2. TGFβ treatment sensitizes adherent ascites-derived cells to MRBV 
oncolysis. a) Ascites-derived cells were seeded at 50,000 cells/ well of a 24 well plate. 24 h 
after seeding, cell were Treated with 10nM of TGFβ or DMSO as a control.  Forty-eight 
hours after treatment, cells were then infected with MRBV or UV inactivated MRBV at an 
MOI of 0.1 for 48 h after which cell viability was assayed using CellTiter-Glo®.  Relative 
viability was determined by normalizing TGFβ treated cells to the DMSO control. b) 
Individual assays from different patient samples were pooled as biological replicates and 
statistical significance was determined by student’s t-test.  C) Images were  captured at 48h 
after infection when cell viability was being performed.   
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phenotype in these structures [3]. To determine whether the sensitization of EOC ascites-
derived spheroids to MRBV oncolysis is due to endogenous TGFβ signalling, we treated 
with 5 μM SB-431542 at the time of seeding cells to form spheroids followed by MRBV 
infection (MOI of 0.1) at 72 h.  In all four patient samples tested, we observed a complete 
blockade in the ability of MRBV to achieve effective killing of EOC ascites-derived 
spheroids, as compared with infections of untreated cells (Fig. 4.3a).  In line with previous 
findings, we observed significant effects on  spheroid formation due to SB-431542 
treatment alone with smaller and less dense clusters (Fig. 4.3b), but this has little effect on 
overall spheroid cell viability on its own (data not shown, and [3]).  Thus, the enhanced 
oncolytic effect due to MRBV infection that we observed in EOC ascites-derived spheroids 
is largely controlled by endogenous TGFβ receptor signalling.   
Enhanced MRBV oncolysis is not a result of enhanced virus entry, changes in LDL 
receptor expression, or changes in IFN-β1 antiviral responses.   
Since MRBV is highly related to vesicular stomatitis virus [16-19], it utilizes the 
low density lipoprotein receptor as its primary means for binding and entering host cells 
[11].  In fact, we have evidence that this is at least one mechanism by which MRBV may 
have differential ability to gain access to ovarian cancer cells for efficient oncolysis [11] 
(and Tong et al, in preparation).  To address this further in the current study, we first 
determined whether activated TGFβ signalling influences MRBV entry of ascites-derived 
cells.  Direct MRBV entry assays were performed in which we infected adherent cells pre-
treated with 5 ng/mL TGFβ1 ligand and compared them to untreated controls.  After only 
1 h of MRBV infection, we removed culture supernatant and titrated virus that remained 
unbound and available for infection using Vero cells.  We observed no significant  
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Figure 4.3. Inhibition of signaling through TGF-β type I receptor in spheroids prevents sensitization 
to MRBV oncolysis.  a) EOC ascites-derived cells were seeded at 50,000 cells/well ULA plate.  At the 
time of seeding, 5nM of the TGFβ inhibitor, SB-431542, was used to treat cells or DMSO as control.  
Seventy-two hours after seeding, spheroids were infected with MRBV or UV inactivated MRBV at MOI 
0.1 for 48 h after which viability was assayed using CellTiter-Glo®. b) Images of treated spheroids were 
taken 48 h after infection at the time viability was being assessed.   
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differences between TGFβ-treated and untreated samples (Fig. 4.4a), thus strongly 
suggesting that activated TGFβ signaling did not increase MRBV oncolytic efficacy via 
enhanced virus entry. In addition, we did not observe either increased LDLR expression in 
TGFβ-treated monolayer cells or decreased LDLR expression in SB-431542-treated 
spheroids (Fig. 4.4b).  
A common mechanism by which cells can potently block MRBV infection is by 
the induction of a robust type I interferon response, a hallmark of which is the rapid 
expression of IFNβ1 from infected cells [14]. However, we observed no significant 
differences in IFNB1 mRNA expression among TGFβ-treated monolayer cells and SB-
431542-treated spheroids and their respective controls after 8 h of MRBV infection (Fig. 
4.4c); we confirmed a robust induction of  IFNB1 expression in A549 cells, which are 
known to elicit a type I interferon response to virus infection [20].  Although anti-viral 
responses may be regulated by TGFβ signalling in some tumour contexts to affect MRBV 
infectivity [12], our results imply that this is not likely to be the mechanism utilized by 
ovarian cancer ascites-derived spheroids.   
TGFβ-induced EMT via Snail is required for efficient MRBV oncolysis of ovarian 
cancer ascites-derived spheroids.   
Both the endogenous TGFβ signalling during spheroid formation and TGFβ-
treatment of monolayer ascites-derived cells induced an EMT response as defined by 
decreased E-cadherin and increased Snail expression (Fig. 4.5a), in line with our previous 
report [3].  Since Snail is the most consistently upregulated EMT product in both spheroids 
and TGFβ-treated monolayer cells and is a key regulator of EMT induction in these cells  
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Figure 4.4. Sensitization to MRBV by TGFβ treatment and spheroid formation is not due to 
increased virus entry, changes in LDLR expression, or IFNβ signaling. a) Ascites-derived cells were 
seeded at 50,000 cells/well of a 24 well plate.  Twenty-four hours later, cells were then treated with 10nM 
of TGFβ or DMSO.  Forty-eight hours after treatment, cells were then infected with MRBV at an MOI 
of 0.1 for 1 h.  After 1 h, supernatant was collected with uninfected virus.  No cell control infection was 
also performed as a negative control to mimic 0% infection.  Unadsorbed virus was titrated via plaque 
assay on Vero cells.  b) Cells were seeded at 50,000 cells/well of a 24 well ULA plate to form spheroids 
or in adherent culture to harvest for protein and RNA.  SB treated spheroids were treated at the time of 
seeding.  TGFβ treated cells were treated 24 h after seeding.  Forty-eight hours after treatment wells were 
harvested for protein.  c) Unharvested wells were then infected with MRBV at an MOI of 0.1 or a no 
virus control. Eight hours after infection, cells were harvested for RNA and qPCR was performed for 
human IFNβ1.  Infection of A549 cells in monolayer were used as a positive control for IFNβ1 response 
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(Rafehi & Shepherd, unpublished), we performed siRNA-mediated knockdown 
experiments of SNAI1 in EOC ascites-derived spheroids.  In three out of the four patient 
samples tested, we observed significant reduction of MRBV-mediated oncolysis as a result 
of SNAI1 knockdown in spheroids (Fig. 4.5b). In fact, the sample that failed to elicit a 
Snail-dependent response via knockdown (EOC287) did not respond to TGFβ1 to induce 
Snail in monolayer cells, nor did it decrease Snail expression upon SB-431542 treatment 
of spheroids (Fig. 4.5a), perhaps indicating that this sample has uncoupled TGFβ signalling 
regulation of Snail and EMT.   Taken together, it is likely that the EMT phenotype as 
regulated by TGFβ signalling in ovarian cancer ascites-derived spheroid cells is a chief 
regulator of MRBV oncolysis of cells found in these structures.  
4.3 Discussion 
The process of spheroid formation in EOC has been postulated to create important 
reservoirs for malignant EOC cells associated with increased metastasis in advanced stages 
of the disease [21-23].  We have previously shown that the induction of EMT through 
endogenous activation of TGFβ signaling can increase spheroid migration and invasiveness 
and confer greater resistance to standard chemotherapies such as carboplatin [3].  We have 
identified a novel tropic factor of MRBV that promotes the oncolysis of cells which are 
upregulated in the specific factors that make EOC spheroids more aggressive, invasive, 
and chemoresistant.   
Similarly to what has previously been observed, we found that endogenous TGFβ 
signaling in EOC ascites-derived spheroids could dramatically sensitize EOC cells to  
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Figure 4.5 Sensitivity to MRBV correlates with markers of EMT and knockdown of Snail 
prevents ascites derived spheroid sensitization. a) Adherent and spheroid cells were seeded as 
previously described.  Lysates were generated and probed with human E-cadherin, Snail, and Actin 
antibodies.  b) Cells were seeded at 300,000 cells/ well of a 6 well plate and transfected with siSnail or 
non-targeting control. Seventy-two hours after transfection, cells were trypsinized and re-seeded at  
50,000 cells/well of a 24 well ULA plate to form spheroids.  Seventy-two hours later, cells were infected 
with MRBV at an MOI of 0.1 and viability was assessed 48 h after infection using CellTiter-Glo® 
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MRBV induced oncolysis [12].  However, unlike what was described by Ilkow et al., we 
did not observe significant differences in antiviral responses of ascites-derived cells to 
MRBV infection upon TGFβ treatment or spheroid formation.  Instead, we specifically 
identified that through TGFβ type I receptor activation, the subsequent EMT response 
induced through SNAIL upregulation is capable of sensitizing EOC ascites cells to MRBV.   
  It is important to note that enhanced viral oncolysis of EOC spheroids is context 
dependent as previously we have documented that MRBV oncolysis is delayed or even 
abrogated in spheroids form from EOC cell lines [11].  Likewise, TGFβ treatment of EOC 
cell lines does not result in sensitization to MRBV.  It remains to be determined the precise 
biological differences between ascites-derived EOC cells and that of established cell lines 
which may be important in determining their sensitivity to MRBV.  It is likely that the 
restricted ability for EOC cell lines to induce a complete EMT response with corresponding 
morphological changes and transcriptional activation of EMT associated genes prevents 
EOC cell lines from being sensitized to MRBV when cultured as spheroids or when treated 
with TGFβ [24-26].  Decreased expression of SMAD4, which is an essential factor in EMT, 
has been described in several ovarian cancer cell lines which results in a loss of sensitivity 
to TGFβ treatment and corresponding growth inhibition [27].  Furthermore, it is unlikely 
that the heterogeneous population of cells from the ascites are entirely cancerous, but 
instead likely represents a combination of cancerous cells, cancer associated fibroblasts, 
and normal cells and therefore may have differential responses to TGFβ [28-30].  However, 
QPCR of IFNβ1 transcripts from MRBV infected EOC ascites derived cells shows little 
upregulation in IFNβ1 in response to infection suggesting a defect in initiating an antiviral 
response which is characteristic of abnormal cells.  Aside from the direct oncolysis of 
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cancer cells, targeting cancer associated fibroblasts in the ascites would also be vital in 
limiting the aggressive metastatic behavior of EOC tumours [31].  Specifically, TGFβ’s 
contributions to ovarian tumour invasiveness and motility are largely controlled by 
affecting the transcriptional profile of cancer associated fibroblasts in the tumour 
microenvironment [32].   
Although previous studies have shown an association of EMT with greater 
sensitization of cancer cells, including ovarian, to oncolytic virus induced cell death by 
adenovirus and herpes virus, the mechanisms by which the viruses sensitize cancer cells 
are distinctly different.  Both adenovirus and herpes virus show decreases in virus entry in 
epithelial cells due to virus receptors required for entry being trapped in tight-junctions.  
During EMT however, the mesenchymal phenotype promoted a loss of tight and adherens 
junctions, allowing more freely accessible receptors to increase virus entry [34, 35].  We 
observed no difference in entry of MRBV in patient samples which had been treated with 
TGFβ in monolayer or SB-431542 in spheroids, nor increases in LDLR expression from 
adherent to spheroid culture conditions.  Therefore we believe the sensitization to MRBV 
occurs intracellularly and is imparted by active TGFβ signaling and EMT rather than 
increased entry to mesenchymal-like cells.  TGFβ ligands are present and active in 
malignant ascites from ovarian cancer patients [26]. We have demonstrated that active 
maintenance of endogenous TGFβ signaling promotes EMT in spheroids and is required 
for efficient re-attachment and dispersion [8].  Furthermore, spheroids that have undergone 
EMT have been found to be enriched for cells with stem-like characteristics with increased 
resistance to apoptosis and contribute to more aggressive secondary tumour growth [10, 
33].  Therefore, a heightened mesenchymal and stem-like phenotype of EOC tumors and 
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metastases could serve as important predictive biomarkers for MRBV to act as a potent 
therapeutic against the invasive and chemo-resistant cells.  
 The use of MRBV in combination with current therapeutic approaches may be 
advisable to best tackle advanced metastatic disease.  Current therapeutic strategies 
centered on surgery and platinum based chemotherapy could be applied to enrich for cell 
populations which may have chemoresistant disease due to elevated TGFβ signaling.  This 
process could select for cell populations which may be best suited and better targeted by 
MRBV to promote oncolysis of the most aggressive tumour cell types which contribute to 
therapy resistant and recurrent disease.   
4.4 Materials and methods 
Cell Culture  
Vero and A549 cells were cultured in Dulbecco’s Modified Eagle Medium (Wisent) 
and supplemented with 5% fetal bovine serum (Wisent).  Cell lines were cultured in a 
humidified environment at 37ᵒC with 5%CO2.  Both cell lines were generously donated by 
Dr. Joseph Myrmyk. 
Ascites fluid obtained from ovarian cancer patients at the time of debulking surgery 
or paracentesis was used to generate primary cell cultures as described previously [13].  All 
patient samples were cultured in Dulbecco’s Modified Eagle medium/ F12 (Wisent) 
supplemented with 10% FBS (Wisent).  Cells were grown in a 37ᵒC humidified atmosphere 
of 95% air and 5% CO2.  Adherent cells were maintained on tissue culture treated 
polystyrene (Sarstedt, Newton, NC). Non-adherent cells and spheroids were maintained on 
Ultra-Low Attachment (ULA®) cultureware (Corning, Corning, NY), which is coated with 
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a hydrophilic, neutrally charged hydrogel to prevent cell attachment. All patient-derived 
cells were used in accordance with institutional human research ethics board of approval 
(UWO HSREB 12668E).   
Virus production 
MRBV MG1 was generated as previously described [14].  Vero cells were infected at MOI 
0.01.  Twenty hours after infection, supernatant was collected and virus was purified using 
a 0.2micron filter.  MRBV MG1 mutant strain used in these experiments has been 
described previously [14].   
Virus infection of EOC cells 
Primary EOC cells were seeded at 50,000 cells/well of a 24-well plate and were infected 
the following day at MOI 0.1.  Spheroids were formed using 50,000 cells/ well in a 24-
well ULA plate (Corning, Corning, NY) over 72 h prior to infection.  The appropriate UV-
inactivated virus at MOI 0.1 or no virus (mock infected) was used as controls.  Forty-eight 
hours after infection, viability was assayed using CellTiter-Glo Luminescent Cell Viability 
Assay (Promega, Madison, WI).  Phase contrast images of cells and spheroids were 
captured during each experiment using a Leica DMI 4000B inverted microscope. 
TGFβ signaling modulation  
Recombinant TGFβ1 was purchased from Millipore (Temecula, CA), prepared in distilled 
water, and used at a concentration of 5 ng/mL [38].  Adherent cells were treated with 
recombinant human TGFβ1 24 h after seeding for 48 h to induce and EMT response.  
Images were captured using a Leica DMI 4000B inverted microscope prior to cells being 
harvested for analysis.  The TGFβ type I receptor small molecular inhibitor, SB-431542 
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(Sigma) was prepared in DMSO and used at a concentration of 5 μM [39].  Spheroids were 
treated with SB-431542 or DMSO vehicle control at the time of seeding to ULA plates.  
Seventy-two hours after seeding and treatment, spheroids were imaged and harvested for 
analysis.    
Cell Viability 
Adherent culture  
Cells were kept in their original 24-well plates and 75ul of CellTiter-Glo® reagent 
(Promega, Madison, WI) was added to each well and diluted at a 1:1 ratio with media as 
per manufacturer’s instructions.  Ten minutes after the addition of the diluted reagent, cell 
lysates were harvested and placed in white walled 96-well microplates and luminescence 
signal was detected using a Wallac 1420 Victor 2 Spectrophotometer (Perkin-Elmer, 
Waltham, MA).  Results were normalized to vehicle treated adherent controls.   
Spheroid culture 
Spheroids were collected, pelleted, and left in 100ul of media.  CellTiter-Glo® reagent was 
added at a 1:1 ratio with media as previously described and as per manufacturer’s 
instructions.  Samples were triturated using a 26 ½ guage needle until spheroids were no 
longer visible.  Samples were then added to a white-walled 96 well microplate and 
luminescence was detected as described above and normalized to vehicle-treated contorl 
spheroids.   
Quantitative RT-PCR 
EOC ascites-derived cells cultured as both adherent and spheroids were harvested from 24-
well plates seeded at 50,000 cells/well.  The A549 lung cancer epithelial cell line was used 
as a positive control for an IFN-β1response.  Total RNA was isolated from both non-
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infected and infected clones and A549 cells using Qiagen RNeasy Mini Kit (Qiagen, 
Valencia, CA). Purified RNA was quantified using an ND-1000 spectrophotometer 
(NanoDrop technologies, Wilmington, DE).  Reverse transcription was performed using 
total RNA isolated and Superscript II reverse transcriptase (Invitrogen) as per 
manufacturer’s instructions. PCR reactions were carried out using Brilliant SYBR Green 
QPCR Master Mix (Agilent Technologies/Stratagene) and a Stratagene Mx3000P machine 
with data exported to Microsoft Excel for analysis.  IFNβ1 and GAPDH primers were used 
and were previously described [40].  GAPDH served as an internal control for RNA input 
and quantification was performed using the ∆∆Ct method [41].   
Virus entry quantitation 
iOvCa147-F8 and iOvCa147- G4 cells were infected with MRBV at an MOI of 1 at 4ᵒC to 
allow virus infection of cells.  One hour after infection, supernatants containing uninfected 
virus was removed and titrated on vero cells. Virus titers were determined through limiting 
dilutions of virus.  Agarose overlay and plaque assay was performed to determine virus 
concentration.  A no cell infection was performed as a negative control to determine virus 
concentration at 0% infection.  
Immunoblotting 
Adherent and spheroid cells were washed once in cold phosphate-buffered saline (PBS), 
dissolved in lysis buffer (50 mM HEPES pH7.4, 150 mM NaCl, 10% glycerol, 1.5 mM 
MgCl2, 1 mM EGTA, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 10 
mM NaF, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 1x 
protease inhibitor cocktail (Roche, Laval, Quebec, Canada)), clarified by centrifugation 
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(20 min at 15,000g), and quantified by Bradford analysis (Bio-Rad Laboratories, 
Mississauga, Ontario, Canada). Western blotting of protein lysates was performed as 
described previously [3]. Antibodies against E-cadherin (#3195) and SNAIL (#3879) were 
purchased from Cell Signaling technologies (Danvers, MA).   LDLR antibody was 
purchased from Abcam (ab14056; Cambridge, MA). Anti- actin antibody (A2006) was 
purchased from Sigma (Mississauga, ON). Blots were washed using TBST and incubated 
with peroxidase-conjugated anti-chicken IgY (Ab97135) for 1 h at 1:10,000 dilution, 5% 
skim milk/TBST for the LDLR antibody, or peroxidase-conjugated anti-rabbit IgG 
1:10,000 dilution 5% BSA/TBST for actin, E-cadherin, and SNAIL at room temperature.  
Blots were washed again using TBST followed by incubation with Luminata Forte Western 
horseradish peroxidase substrate (Millipore, Etobicoke, ON) and visualized with the 
ChemiDoc MP System (BioRad, Mississauga, ON).   
SNAI1 knockdown  
Ascites-derived EOC cells were seeded at 500,000 cells/well of a 6-well dish.  After 16 h, 
cells were tranfected with siSNAIL SMARTPool RNA or siNT non-targeting control 
siRNA using DharmaFECT1 transfection reagent (Dharmacon). At 72 h post-transfection, 
cells were trypsinized and used to form spheroids at 50,000 cells/ well in 24-well ULA 
plates.  Virus infection and viability assays were performed as described above.  Protein 
was harvested from replicate wells at the time point when cell viability was assessed to 
verify Snail protein knockdown.   
Statistical Analysis 
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Statistical significance was determined by unpaired two-tailed Student’s t-test or one-way 
analysis of variance using GraphPad Prism 6 (GraphPad Software, San Diego, CA).  
Statistical Significance was set at p<0.05. 
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CHAPTER 5: General Discussion 
5.1 Summary of overall findings 
 Viral oncolytic therapy cannot be regarded as a universally efficacious treatment 
for cancer, but rather a broad strategic category of therapies that have vastly different 
impacts on the cells they infect, the tumor microenvironment, and the immune system 
which results in a spectrum of outcomes for patients.  The efficacy of oncolytic virotherapy 
is highly dependent on a number of dynamic variables which are differentially regulated 
during EOC metastasis and disease progression.  Thus, the efficacy of a virus is highly 
contextual and may not be universally effective across all disease stages or a broad patient 
population.  Within a single tumor, we observed variance in susceptibility to oncolysis 
which suggests that tumor cells could be selected for to give rise to cells resistant to viral 
therapy.  This implies that virus therapy faces the same challenges that most cancer 
therapies have to conquer: tumor heterogeneity and preventing treatment resistance.  
However, by defining the specific factors that regulate effective virus replication, oncolytic 
viruses are unlike conventional chemotherapies in that they can be genetically engineered 
and designed to improve their oncolysis in contexts which would normally limit their 
replication.  In characterizing both virus and host factors that influence MXYV, vvDD, and 
MRBV replication in an in vitro model of EOC, we found virus size, dynamic signaling 
processes during spheroid formation, dormancy, and both intercellular and temporal 
heterogeneity could impact virus infectivity, replication, and oncolysis.  These findings lay 
a foundation for the strategic design of future oncolytic viruses which can best circumvent 
conventional treatment barriers to effectively treat EOC. 
5.2 Oncolytic virus replication and tumor dormancy 
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Tumor dormancy in EOC is thought to allow the persistence of microscopic tumor 
lesions after front-line treatment with chemotherapeutic drugs.  In the context of metastatic 
ovarian cancer, the ability to target and kill dormant cancer cells is essential to eradicate 
disease recurrence, and decrease the high proportion of patients which experience relapse.  
Multi-cellular spheroids are not only a delivery mechanism to promote metastasis, but a 
reservoir for supporting tumor cell dormancy in EOC [1, 2].  In our assessment of oncolytic 
virus efficacy in dormant EOC spheroids, we observed significant reduction in the 
replication efficiency and induction of lysis from large poxviruses, including MYXV and 
vvDD.  However smaller viruses, like MRBV were able to efficiently replicate, albeit to a 
slightly reduced capacity in EOC spheroids made from cell lines [3].  Given that the 
oncolysis by MYXV and vvDD was induced immediately upon spheroid reattachment 
rather than requiring multiple days to complete replication as was observed in adherent cell 
infections, it is likely that viral replication is progressing within spheroids but is restricted 
at a late stage such that completion of oncolysis can only be observed upon reattachment.  
Similarly, expression of GFP by MYXV and vvDD in both adherent and spheroid EOC 
cells implies at least early gene expression of the viruses in both culture conditions as viral 
GFP expression is under the control of a synthetic early/late promoter.  Given that the first 
wave of poxvirus transcription is driven by RNA polymerases and transcription factors 
packaged with the virus, it is logical that virus replication in spheroids may be restricted in 
later stages that are more heavily dependent on host cell factors [4-8].  This would imply 
restriction possibly during intermediate or late stages of the viral life cycle perhaps during, 
morphogenesis, packaging, or egress in both MYXV and vvDD.   
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During morphogenesis, assembling virions require abundant lipid and protein 
within cytoplasmic viral factories to enclose the virus core components [9].  We have 
previously documented the role of autophagy in the degradation of many cellular 
components during quiescence in spheroids [10].  It is possible that the digestion of cellular 
organelles and proteins that are non-essential to cell survival through autophagy is 
sequestering vital components required for membrane wrapping of maturing virions.  
Similarly, intracellular acquisition of poxvirus envelopes requires trafficking through 
golgi-derived membranes.  However, golgi-derived membranes are commonly redirected 
for the formation of autophagosomes during autophagy and this may curtail viral envelope 
incorporation in spheroids [11].  Electron microscopy based studies of the intracellular 
components of spheroids is one future experiment which could be performed to determine 
the stage of poxvirus replication within spheroids.   
 Independent of the potential affect that autophagy may have on late stage viral 
replication in spheroids, it is possible that poxviruses do not represent an effective 
oncolytic therapy for the treatment of dormant cancer cells regardless of their morphology 
(adherent or spheroid).  It is likely that poxvirus replication is highly dependent on cell 
cycle progression [12, 13].  For instance, effective replication of MYXV requires the 
activation of mammalian p21-activated kinase 1 (PAK1) which is phosphorylated during 
mitosis and is important for cell cycle regulation [14].  Decreased phosphorylation of 
PAK1 does not impact virus entry or early virus gene expression but impedes MYXV 
before late gene expression and viral DNA replication, thus restricting the production of 
virus progeny [15].  Furthermore, a number of poxviruses have been shown to encode 
genes which act as viral mimetics of cellular anaphase-promoting protein complexes [13].  
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This regulates the progression of the host cell through mitosis and promotes poxvirus 
growth, thus emphasizing the significance of cellular replication for poxvirus replication.  
Dependence of MYXV on AKT signaling and vvDD on EGFR/ERK activation and 
abundant deoxynucleotide pools are unfavorable requirements for virus replication in 
dormant cells, particularly for viruses with sizeable genomes [16, 17].  Unfortunately, not 
only are these unfavorable conditions found in EOC spheroids but both AKT and ERK are 
among the most common signaling pathways to be suppressed in many dormant and 
resilient forms of pancreatic, colorectal, head and neck, and breast cancer metastases [18-
21].  Likewise, the expression of both host cell TK (on which vvDD is dependent) and 
ribonucleotide reductase, which is integral for the synthesis of dNTP, are nearly 
undetectable in resting G0 cells, and this represents as an important rate limiting step in the 
synthesis of the large DNA genomes of progeny virions [22, 23].  dNTP pools required for 
DNA synthesis are 20x lower in resting cells than those that are actively replicating [22].  
Thus, although there may be potential clinical therapeutic benefits of these larger 
poxviruses for highly proliferative cancer cells, they may be subject to the same limitations 
as chemotherapeutic drugs in indolent cancers.   
 Interestingly, MRBV oncolysis of spheroids was relatively resistant to tumor 
dormancy.  Thus far, no host cell factors have been identified for MRBV replication and 
its replication may be relatively independent of the host cell cycle.  Genome-wide siRNA 
screens to identify potential host factors necessary for VSV replication did not link any 
genes associated with cell cycle [24].  Furthermore, efficient replication of MRBV in 
dormant EOC ascites-derived spheroids suggests complete independence of MRBV from 
host cell replication.  The comparatively small genome size of MRBV implies a reduced 
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dependence on abundant ribonucleic acid pools for mRNA synthesis and genome 
replication for each progeny virion, potentially allowing for more virus progeny to be 
produced per round of infection, as we observed.  Thus, it is likely MRBV represents a 
more viable therapeutic option for the treatment of slow growing, indolent cancers which 
are associated with greater chemotherapeutic resistance. 
5.3 Primary cells vs. established cell lines for in vitro assays 
Comparative analysis of MRBV infected primary cells versus established cell lines 
reveals remarkable incongruencies in their overall response to infection.  Not only did we 
observe relative resistance of primary EOC ascites-derived cells to MRBV in adherent 
culture when compared to EOC cell lines, but there was also dramatic sensitization to 
MRBV-induced oncolysis of spheroids formed from ascites-derived cells, compared to 
EOC cell line spheroids.  These seemingly contradictory results raise many questions 
regarding the nature of cells that are used during in vitro assays which aim to recapitulate 
clinically relevant responses.   
Cell lines are enriched populations of immortalized cancer cells and therefore are a 
favorable model for understanding the behavior of tumor cells. However most have been 
long removed from patients and have transformed significantly over decades of in vitro 
culture.  In contrast, the nature of ascites-derived cells and other primary cell isolates is 
heterogeneous.  The cellular component of malignant ascites consists of variable 
proportions of tumor cells, mesothelial cells, fibroblasts, macrophages, white blood cells, 
and red blood cells which perhaps more accurately mimics the microenvironment of tumors 
[25].  It is evident that fibroblasts have significant contributions to the microenvironment 
of tumors and can alter behavior of cancer cells to promote increased metastasis and 
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aggressiveness.  Therefore, the absence of these cells from cell line models potentially 
limits our ability to understand the complex interaction between tumor stroma and 
malignant cells and therefore the context in which a treatment can function.  However, in 
heterogeneous ascites-derived cell populations it is unclear what proportion of cells are 
truly malignant thereby obscuring the interpretation of the results from molecular analyses.  
To accurately interpret our conflicting data between EOC cell lines and primary ascites 
infected with MRBV, further characterization of the ascites-derived cells is necessary.  
Given that ascites contains both malignant and non-malignant cellular components 
it is logical to expect greater death in transformed cell lines compared to ascites-derived 
cells from MRBV infection.  However, it is unclear why spheroid formation of ascites cells 
significantly increases susceptibility to MRBV-induced death over both adherent culture 
of ascites cells and even spheroids formed from cell lines.  In comparing TGFβ responses 
between adherent and spheroid EOC cell lines, we observed inconsistent changes in EMT 
markers across the lines and often only partial effects (unpublished data), whereas the 
induction of EMT in EOC ascites-derived cells was almost universal upon spheroid 
formation or TGFβ treatment [26].  This may be due to cellular defects in the TGFβ/SMAD 
signaling pathway in many EOC cell lines [27-30].  It is well established that cell line 
models fail to respond to TGFβ signalling or fully emulate the morphological and 
behavioral changes of EMT [31-36].  We speculated that this key difference between 
ascites-derived cells and EOC cell lines may be a mechanism governing differential MRBV 
responses.  
 TGFβ has dynamic functions in cancer and its behavior is highly contextual [37].  
In pre-malignancy, TGFβ functions as a tumor suppressor and induces apoptosis or 
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cytostasis in malignant cells.   However in malignant progression, cells can circumvent the 
tumor suppressive effects of TGFβ either through inactivation of core pathway 
components, such as TGFβ receptors, or through alterations downstream of TGFβ that 
disable only the tumor-suppressive arm of this pathway.  This latter mode of circumvention 
allows cancer cells to freely usurp the remaining TGFβ functions to acquire invasive 
properties (EMT), produce autocrine mitogens, and release pro-metastatic cytokines.  The 
induction of EMT through TGFβ signaling has essential functions in promoting metastasis, 
migration, chemo-resistance, and stem-like behavior in diverse cancers and many of its 
markers can act as predictive features for patient prognosis [26, 38-44].  For this reason, 
we used primary ascites-derived cells which consistently recapitulates this biologically 
relevant phenomenon to investigate the impact of TGFβ and EMT on MRBV replication.   
 It is likely that the sensitization to MRBV by TGFβ treatment or spheroid 
formation observed in ascites-derived cells may due to the oncolysis of non-cancerous that 
have undergone EMT rather than strictly tumor cells given that the non-cancerous cell 
population comprises up to 99% of the cellular component of ascites (although it is 
uncertain how generalizable this is across samples) [25].  However, it is unclear why non-
cancerous cells become sensitive to oncolytic death after adopting a mesenchymal 
phenotype.  Other groups that have described an association between virus infection and 
EMT have proposed increased receptor availability for virus binding after acquiring a 
mesenchymal phenotype.  However, we observed that neither LDLR expression nor virus 
entry are changed in TGFβ treated cells, so it remains unclear exactly what promotes 
sensitization of mesenchymal-like cells to MRBV.  Treatment of fibroblasts with TGFβ or 
FGF2 has been shown to induce desmoplasia (proliferation of reactive fibroblasts), a 
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hallmark of many epithelial tumors which promotes the transformation of normal 
fibroblasts into cancer-associated fibroblasts [45].  Cancer-associated fibroblasts 
demonstrate decreased IFNβ production and antiviral signaling compared to their normal 
counterparts.  Infection of normal fibroblasts with VSV demonstrates a robust induction of 
IFNβ and associated antiviral genes, while pre-treatment of the same fibroblasts with TGFβ 
show reduced antiviral responses [46].  However, while TGFβ pre-treatment can negatively 
impact IFNβ production, we demonstrated that the MRBV resistant ascites-derived cells 
grown in adherent culture lack an effective antiviral IFNβ response to MRBV infection 
without TGFβ pre-treatment.  Thus this explanation is still insufficient to explain the 
sensitization of ascites-derived cells to activated TGFβ signaling.  Moreover, it suggests a 
potentially unconventional mesenchymal-like phenotype of the cells we culture directly 
from the ascites.    
One study has illustrated an important function of TGFβ in inducing ER stress and 
the upregulation of a number of proteins associated in the unfolded protein response (UPR), 
XBP1, ATF6, and GRP-78 in lung fibroblasts [47].  ER stress induced by the accumulation 
of unfolded proteins from TGFβ treatment also causes EMT and pulmonary fibrosis [47, 
48].  Interestingly, inhibition of these same UPR pathways causes mild ER stress due to an 
accumulation of unfolded proteins similar to that observed during TGFβ treatment in lung 
fibroblasts [49].  Mild ER stress caused by unfolded protein accumulation prior to MRBV 
infection has been shown to rewire cancer cells to become sensitized to caspase-2 
dependent apoptosis upon MRBV infection [49].  This sensitization was independent of 
changes in antiviral cytokines such as IFNβ [49].  Further investigation into the 
mechanisms of TGFβ induced sensitization of ascites-derived cells to MRBV oncolysis 
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should include the characterization of ER stress and UPR responses after TGFβ treatment 
and spheroid formation to determine their functional relevance in mediating sensitivity to 
MRBV.   
5.4 Tumor heterogeneity and precision therapy in oncolytic virotherapy 
The development of personalized treatment regimens for individuals with cancer, 
including EOC, has been a major therapeutic directive in order to combat the 
heterogeneous nature of cancer across broad patient populations.  We selected SKOV3, 
OVCAR8, and HEY A8 based on their characterized genetic mutations and therefore 
predicted susceptibility to killing based on the known viral trophic factors for each virus.  
We predicted both OVCAR8 and SKOV3 cells with TP53 and PIK3CA mutations to be 
most susceptible to MYXV killing, while cells with mutations in KRAS, OVCAR8 and 
HEY A8, to be more susceptible to vvDD [50].  Interestingly, we found no correlation 
between known viral trophic factors in the EOC cell lines and susceptibility to virus killing.  
This was not surprising as intratumoral heterogeneity in EOC may be quite substantial and 
viral tropism is dependent on multiple factors and not tumor suppressor mutation/oncogene 
activation status alone.  This is clearly exhibited in our temporal and spatial heterogeneity 
models of EOC and the differential oncolytic efficacy of MRBV.   
Many in vitro models demonstrate diverse tumor cell heterogeneity which can give 
rise to differential treatment responses even in cell lines classified as being homogenous.  
For example, single nucleus genome sequencing of just 50 cells from the breast cancer cell 
line, SK-BR-3, which has previously been determined to be monoclonal and genomically 
stable[51, 52], reveals significant heterogeneity between cells with single nucleotide 
variants, copy number alterations, and structural variants.  Further characterization of these 
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variants revealed 409 non-synonymous variants and 1,452 structural variants, many of 
which occurred in cancer genes [53].  Additionally, unique barcoding of individual cells 
from the non-small cell lung cancer cell line HCC827 revealed a common mechanism for 
acquired resistance to erlotinib treatment.  HCC827 harbor an activating mutation in EGFR 
conferring sensitivity to the EGFR inhibitor erlotinib.  Of a total of approximately 1 million 
cells each with a distinct barcode, 462 barcodes were expanded and enriched after erlotinib 
treatment to give rise to erlotinib resistance.   If this resistance was driven mostly by de 
novo mutations, distinct barcodes would emerge as independent replicates.  Instead, this 
enrichment and expansion of a limited number of barcodes suggests the existence of 
resistant cell populations prior to treatment and extensive heterogeneity within the cell line 
[54].  Furthermore, the study shows that acquired tumor resistance to erlotinib treatment 
can arise from a starting subclonal population of cells which make up only 0.05% of the 
population.  These data suggest that the application of oncolytic viruses strictly as targeted 
therapies for the direct oncolysis of tumors with specific mutations or aberrant signaling 
pathways may be subject to similar Darwinian selective pressures and result in acquired 
resistance.  The possibility of acquired resistance through this mechanism would be more 
likely in genomically unstable cancers with high intratumoral heterogeneity such as EOC, 
where the probability of spontaneously developing a mutation to confer virus resistance 
would be greater [55].   
 Alternatively, we demonstrated that resistance to MRBV could be overcome by co-
culturing resistant EOC cells with sensitive cells.  Therefore, it is reasonable to believe that 
genomic instability may in fact benefit MRBV oncolysis as it increases the probability of 
having MRBV sensitive clones that can confer sensitivity to neighbouring resistant cells.  
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Under our co-culture conditions we demonstrated that as few as 25% of co-cultured cells 
need to be sensitive to confer MRBV sensitivity to resistant cells.  Likely, genomic 
instability will differentially impact patients depending on the random nature of tumor cell 
mutagenesis.  However, the acquisition of specific mutations which support tumor survival 
and metastasis, such as activating mutations in TGFβ [56], may be more common across 
many cancers and consequentially aid in mediating MRBV oncolysis.  Many breast, 
melanomas, and prostate cancers acquire mutations in the SMAD transcriptional 
complexes which alter cytostatic gene responses but maintain the core signaling 
components of the TGFβ pathway to enhance migration, invasion, and immune evasion.  
CD44+/CD24lo cells, which have been associated with cancer stemness and poorer 
metastasis-free survival, have been shown in human breast cancers to be driven by 
activations in the TGFβ pathway [57].  Therefore there is also reason to believe that 
heterogeneity could increase tumor cell susceptibility to MRBV infection.  Future studies 
investigating the dynamics of TGFβ signaling across heterogeneous EOC cells and 
mediating MRBV sensitization should be considered and perhaps assessed via co-culture 
viability assays of MRBV-sensitive TGFβ-responsive cells and MRBV-resistant TGFβ-
unresponsive cells. 
Although we showed that MYXV had variable success in EOC cells, it may be 
possible to apply the virus as an adjuvant to promote greater MRBV infection and 
replication in a combination therapeutic approach similar to AdMA3 and MRBV [58].  
Subverting the challenges of tumor heterogeneity in MRBV replication through 
modulating cancer cell gene expression with an initial infection with MXYV may 
theoretically be feasible.  Though MYXV demonstrated the least potent oncolytic activity, 
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it may alternatively function as a potent gene delivery vehicle [59-61].  In the three EOC 
cell lines cultured as both adherent and spheroids, MYXV demonstrated the highest degree 
of infection in of all three viruses tested.  We broadly observed MYXV infection of 
approximately 40% of EOC cells and GFP expression indicative of early gene expression.  
This suggests the differential oncolytic efficacy of MYXV for EOC may be a result of 
restriction later in the virus lifecycle and that MYXV entry and early gene expression may 
not be as strongly impacted by tumor heterogeneity or cell morphology.  By comparison, 
EOC spheroids formed from cell lines and clones which were resistant to MRBV oncolysis 
had as little as 5% of cells permissive to infection.  Identification of both LDLR expression 
and TGFβ activation as trophic factors which impact MRBV replication could support the 
concept of engineering either an LDLR or TGFβ type I activated receptor expressing 
MYXV under the control of an early/late promoter [62].  Given the large cloning capacity 
of poxviruses, both constructs would be feasible to engineer.  This strategy may broaden 
tumor cell tropism for a subsequent MRBV infection.  The expression of LDLR or TGFβ 
type I activated receptor after MYXV infection and early gene expression could support 
greater replication and oncolysis by a subsequent MRBV infection in the absence of 
MYXV oncolysis.  Given that we have demonstrated complete oncolysis of heterogeneous 
tumor populations with as little as 25% of cells being permissive to MRBV, a pre-treatment 
of tumor cells with MYXV-LDLR or MYXV-TGFβ type I activate receptor could 
proportionally increase the number of cells permissive to MRBV infection and induce 
complete oncolysis in heterogeneous tumors or even across patients largely resistant to 
MRBV.  In theory, this strategy could induce oncolysis of tumor cells regardless of the cell 
cycle stage so long as MYXV production of LDLR or TGFβ type I receptor is under the 
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control of the early/late promoter [62].  Furthermore, a dual virus administration strategy 
may enhance immune responses to both viruses and tumor cells.  Investigation on the 
feasibility of this conceptual treatment regimen would have to be explored in future studies.   
5.5 Antitumor immunity and oncolytic viruses 
The growing field of oncolytic therapy is increasingly recognizing the importance 
of immune stimulation in promoting cancer cell death [63].  The majority of newly 
developed applications of viral therapies incorporate some form of immune stimulation by 
the virus.  Thus, the host-pathogen interaction is an important limiting factor in our ability 
to fully assess the potential therapeutic benefit of the viruses we have evaluated in EOC 
cells in vitro.  Although we have identified important viral trophic factors impacting 
MRBV oncolysis and the impact intratumoral heterogeneity may have on virus killing, the 
biological significance of tumor heterogeneity in MRBV killing would need to be assessed 
in the context of an active immune response.  Perhaps MRBV-induced oncolysis of a 
subpopulation of tumor cells may promote robust antitumor immunity which may be 
sufficient to overcome the cellular complexity in tumor heterogeneity.  Assessing this may 
be particularly difficult in pre-clinical models of cancer as mouse xenograft models of EOC 
using heterogeneous primary human cancer cells use immunocompromised animals.  
Syngeneic models using murine cancer cell lines are little better as the tumors are much 
less heterogeneous.  In immune competent syngeneic murine melanoma models using B16-
F10 cells, Pol et al. show relatively poor induction of both cytotoxic and helper T cell 
activation after infection with armed MRBV-hDCT (melanoma associated antigen, 
dopachrome tautomerase).  This is likely due to an intact type I IFN response in B16 cells, 
which limits productive viral replication in vivo and restricts robust activation of the 
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adaptive immune system against the tumor [64].  Antitumor immune stimulation in 
heterogeneous tumor models in which a mixed population of virus-sensitive and virus-
resistant cells would be more informative in comprehending MRBV induction of antitumor 
immunity.  Transgenic mouse models of EOC may be one of the few pre-clinical models 
to fully evaluate the potential impact of tumor heterogeneity on MRBV in the context of 
an active immune system.  However, few if any, biologically relevant HGSOC transgenic 
mouse models have been characterized in terms of their ability to recapitulate tumor 
heterogeneity or stimulate immune function [65, 66].  Alternatively, humanized mouse 
models with xenografted human immune systems and tumor tissues may be another model 
to assess MRBV oncolysis in a heterogeneous tumor model in the context of a competent 
immune system [67, 68].   However, mismatching human leukocyte antigen (HLA) from 
tumors and hematopoetic cells and stem cells (used to recapitulate human immune system) 
is known to cause severe graft vs. host disease or lack of response [69].  Therefore, either 
matching HLA is required or co-transplantation of human tumors and human peripheral 
blood mononucleocytes into immunodeficient mice are required for the analysis of the 
immune response to tumor [70].  Thus, assessing the impact of tumor heterogeneity on 
MRBV oncolysis in the context of a fully competent immune system is exceedingly 
challenging given the systems that currently exist to model EOC.  
Though the oncolytic activity for both MYXV and vvDD may not be particularly 
potent in tumor dormancy, their ability to induce early gene transcription and large cloning 
capacity permits the application of poxviruses in diverse contexts aside from direct cancer 
cell infection and oncolysis.  Poxviruses could be used as vectors armed with tumor-
associated antigens to aid in tumor cell recognition by the immune system even in the 
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absence of virus amplification and oncolysis [71-73].  For EOC patients, increased anti-
tumor immunity as measured by tumor infiltrating lymphocytes is a robust prognostic 
indicator of outcome [74]. Furthermore, their restricted replication within the cytoplasm 
eliminates the risk of viral gene integration into the host genome and potential oncogenesis 
of host cells.  Recombinant MYXV armed with an IL15Rα-IL15 fusion protein, which 
functions as an immunostimulatory cytokine, demonstrates potent stimulation of both 
innate and adaptive immune responses. Through cytotoxic lymphocyte proliferation and 
significantly greater NK cell tumor infiltration in a murine melanoma model, a cessation 
of tumor growth and prolonged survival was achieved [61].   
Prime-boost administration of sequential infections with armed poxviruses has 
been evaluated in clinical trials with promising results.  Infection of EOC and melanoma 
patients with vaccinia virus armed with the tumor-associated antigen NY-ESO1, followed 
by a booster vaccination with fowl pox virus armed with the same antigen, elicited 
enhanced cytotoxic and helper T cell responses against tumors in 20/22 patients in a phase 
II clinical trial.  Patients who developed T cell responses in the presence or absence of 
neutralizing antibodies demonstrated improved overall survival compared to those who did 
not develop T cell responses (52.4 months vs. 14.5 months).  T cells extracted from 
responsive patients demonstrated immune recognition and cytotoxicity of NY-ESO1 
expressing tumors in ex vivo models providing evidence for the efficacy of poxvirus based 
immunotherapeutic vaccines against EOC [75].   
5.6 Conclusions 
This work highlights the aspects of cancer which continue to plague the 
development of effective therapies and perhaps limited the therapeutic benefit of early 
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clinical trials with oncolytic viruses.  The use of oncolytic viruses in in vitro models of 
EOC which aim to recapitulate the most common hurdles for effective therapy emphasize 
ongoing challenges but also new opportunities for improved treatment.  Although both 
metastasis and tumor heterogeneity remain major obstacles, characterization of viral 
trophic factors and their kinetics within EOC cells reveal new contexts in which viruses 
can be applied to combat these treatment barriers and hopefully improve outcomes. New 
insights into the syngeneic relationship between viruses and the immune system provide 
novel avenues to develop virus therapy to help overcome these longstanding impediments.  
The expanding repertoire of oncolytic viruses and their application in combination with 
each other provides a growing arsenal of agents to diversify the current options for cancer 
therapy and stimulate anti-tumor immunity in ways that standard chemotherapy and 
surgery fail to confront.  The challenges and opportunities presented here for oncolytic 
virus use in EOC reveal a new framework for designing viruses to surmount the complexity 
of EOC tumors and heterogeneity.   
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